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Abstract
There are an estimated 350 million people chronically infected with Hepatitis B Virus (HBV), of which
approximately 600 000 die each year from HBV complications including cirrhosis and liver cancer.
The X protein from HBV (HBx) has been implicated in the progression of chronic HBV to liver cancer
and has been reported to manipulate several critical cellular pathways. These include the cell cycle,
the tumour suppressor protein p53, protein degradation and signal transduction pathways. The role
of these interactions in HBV replication and the viral lifecycle is currently unknown. The lack of
animal models and infectable cell lines together with solubility and stability issues related to the
HBx protein have made progress difficult. The reliance on approximate cellular and animal models
has yielded many discordant studies that have confounded our interpretations of the role of HBx.
There have been no novel approaches attempting to express HBx at a quantity and quality sufficient
for high resolution X-ray and nuclear magnetic resonance structural determination. Additionally no
bioinformatic analyses have been applied to HBx, and thus distinctive features of HBx that may be
responsible for these challenges have not been reported.
This thesis describes the detailed experimentation to express and purify HBx in a functional, sol-
uble and stable form. The study focussed on Saccharomyces cerevisiae and Semliki Forest Virus
(SFV) expression systems, together with the use of a solubility-enhancing Maltose Binding Protein
protein tag (MBP). The S. cerevisiae-based pYES2 and YEp and mammalian expression vectors
showed production of HBx protein. However HBx that had been expressed using S. cerevisiae and
human cells could not be reliably detected in Western blots using antibodies raised against E. coli-
expressed HBx. This result was despite the positive visualisation of HBx using the same antibodies
and immunofluorescence microscopy. This validated previous reports describing the variable anti-
genicity of HBx. Furthermore these findings supported the decision to develop eukaryotic-based
HBx expression vectors as results suggested structural differences between eukaryote and prokary-
ote expressed protein. HBx was subsequently detected and purified in a soluble and active form
using an MBP tag as well as a SFV expression vector. All of these options provide an excellent point
from which further work at optimising HBx expression and structural elucidation can occur.
Bioinformatic analysis of HBx suggested the presence of protein disorder and protease sensitive
sites within the negative regulatory domain of HBx. Literature descriptions of the molecular promis-
iii
cuity that protein disorder allows, offers an explanation for the presence of the discordant findings on
HBx interactions and functions. It is generally accepted that proteins containing disorder are tightly
regulated and thus experimental systems employing overexpression methodologies may encourage
cellular toxicity and non-specific interactions through the use of short linear motifs. Evolutionary
analysis of HBx sequences revealed that the eight HBV genotypes (A-H) showed concordance re-
garding synonymous and non-synonymous substitutions at the overlapping and non-overlapping
domains of hbx. Substitutions in hbx were most common at positions where a synonymous substi-
tution occurred in the overlapping partner gene. The presence of sites under positive, neutral and
negative selection were identified across the length of HBx. The different genotypes showed positive
selection indicating selective pressures unique to each, thus offering a contributing explanation for
the variable disease severity observed between the subtypes.
Overall, this thesis has provided novel methods to express and purify HBx in S. cerevisiae and
mammalian cells. These methods, together with an increased understanding of the nature of HBx
sequences through bioinformatic analysis, pave the way to conduct both structural studies and bio-
logical assays to elucidate the genuine roles of HBx in the HBV lifecycle and its contribution to the
progression to liver cancer.
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Chapter 1
Introduction
In 1947 the British doctor, F. O. MacCallum suggested that a virus was the aetiological agent of a
disease called homologous serum hepatitis (1). Following a series of observations on soldiers who
received a Yellow Fever vaccine, MacCallum coined the term Hepatitis A and B for the forms of the
disease spread primarily through contaminated food and blood respectively. It was only in 1962 that
Baruch Blumberg and Harvey Alter discovered antigenic evidence of Hepatitis B whilst trying to de-
velop screens to determine genetic differences in human populations (2). This antigen, initially called
the Australia antigen was associated with clinical hepatitis (3), and was later discovered to be the
surface antigen of the Hepatitis B Virus (HBV). Electron microscopy studies subsequently revealed
the presence of spherical particles (42nm in diameter particles), now known as Dane particles which
are the infectious HBV virions (4).
There are two outcomes to HBV infection, either an acute infection where the disease is resolved
within 6 months of infection, or a chronic infection where the HBV virus persists indefinitely after
infection. There is a strong correlation between chronic infection and the risk of developing either
cirrhosis and/or hepatocellular carcinoma (HCC) (5). HCC is amongst the most prevalent tumours
in the world’s populous regions and has a mortality rate equal to its annual incidence. HCC has a
very rapid progression and poor outcomes. The surface antigen of HBV (HBs) serves as a diagnostic
marker for HBV infection but is not a marker for HCC development. Currently serum alphafetoprotein
(AFP) levels serve as a predictive marker for HCC as persistently elevated AFP levels (>200 ng/mL)
are a strong predictor of HCC presence (6). The sensitivity of AFP is however only 60 %, meaning that
elevated levels are only observed in 60 % of patients. Thus there is a need for specific markers to
diagnose HBV-related HCC and it may be possible to utilise another protein from HBV as a surrogate.
It is of primary importance to understand the role of HBV virulence factors in HCC development and
a diagnostic based on one or more of these factors would be very helpful. One such protein is the X
protein (HBx) which has been suggested in a multitude of studies to be involved in the progression of
chronic HBV infection to HCC. However studies have not proved unequivocally that HBx is involved
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in disease progression and there are many conflicting reports. The structural determination of HBx
would assist in ours understanding of the role of HBx, however studies thus far have focussed
exclusively on expressing HBx in Escherichia coli. As HBx is an unstable, poorly immunogenic
and insoluble protein when expressed in E. coli, the description of evolutionary, bioinformatic and
expression data in eukaryotic cells could help achieve this goal.
In this thesis the applicability of expressing HBx in Saccharomyces cerevisiae and mammalian
cells was assessed together with the elucidation of distinguishing sequence characteristics through a
bioinformatic approach. A variety of plasmid vectors were constructed and tested for the production
of HBx. Furthermore several predictive bioinformatic models and algorithms were applied to the
HBx sequence to aid in the interpretation of interaction and protein expression data.
1.1 HBV Epidemiology
Approximately 40 % of the world’s population has either come into contact with, or are carriers of
HBV. In 2005 this amounted to some 350 million chronic infections, despite 85 % of countries having
instituted universal childhood vaccination policies (7). In 2000 it was estimated that 620 000 deaths
occurred per year as a result of complications related to chronic HBV infection including HCC and/or
cirrhosis (8). Furthermore, countries which have not implemented vaccination policies continue to
have high prevalence rates and significant disease burdens.
Worldwide, there is a large difference in HBV prevalence rates, ranging between 0.1 % and
20 %. Typically, low prevalence areas lie in the developed economies of the West (Europe, North
America and Australasia), whereas the high prevalence areas are in South-East Asia, China and
sub-Saharan Africa. In the latter, most infections occur at a young age (<5 years) and the chance of
progressing to a chronic infection is inversely proportional to the age at infection. Perinatal infection
carries a chance of chronicity of almost 90 % (9), whereas adult infections only carry a 5 % chance (10).
Together with HIV, TB and malaria, HBV contributes to the excessive disease burden in sub-Saharan
African countries and places significant strain on public health infrastructure.
1.1.1 Infection with HBV and Pathogenesis
Upon infection with the virus, the site for replication and persistence is in the liver. This liver tropism
is a commonality between all the members of the hepadnavirus family although the exact mech-
anism and receptor(s) used to gain entry into hepatocytes is not known. As illustrated in Fig 1.1,
upon entry the partially double stranded HBV genome is delivered to the nucleus and converted
by host enzymes into an episomal covalently closed circular DNA (cccDNA) intermediate for viral
replication. The cccDNA serves as a template for the transcription of the four viral open reading
frames (ORFs): the 0.9 kb RNA serves as a template for HBx translation, the 2.1 kb RNA as tem-
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plate for the pre-S2 (M) and S proteins whilst the 2.4 kb RNA is a template for the pre-S1 protein
(L). The pregenomic RNA (pgRNA) has a greater-than-genome length and serves as a template
for core (HBc) and polymerase (HBp) translation and for progeny viral genomes. HBV expression
seems to be largely regulated by liver specific transcription factors as many have binding sites within
the HBV genome (reviewed in (11)). The HBc and HBp proteins and the pgRNA associate with each
other and form immature nucleocapsids in the cytoplasm of the infected cell. The nucleocapsids are
shuttled through the endoplasmic reticulum (ER) where they associate with high concentrations of
HBs proteins. The nascent viruses then bud from the ER membrane and are secreted from the cell.
This is only a brief overview of the HBV lifecycle and further details can be found in the following
reviews (12,13).
HBV typically incubates for an average of 90 days (range of 60 - 150 days) before symptoms
start to present as illustrated in Fig 1.2-Panel A. The HBs protein is normally detected at on average
at 4 weeks post infection (range of 1 - 9 weeks). However HBs may not be detected if a person is
newly infected, or if the host immune system mounts a successful response to HBs. In such cases,
the detection of host antibodies against HBc are used as a diagnostic marker and may provide the
only evidence of disease. Following the appearance of the HBs antigen is HBe. The exact function
of this protein is unknown, but it is suspected to play a role in immune system suppression.
Following immune clearance of HBs, and the emergence of antibodies against HBe, there is
typically a dramatic decrease in viral replication. In a classic acute infection, the infected person
will clear the HBs to undetectable levels, and antibodies will arise against HBc and HBs proteins.
However, in some individuals, the HBs is not successfully cleared, and after six months the individual
becomes a chronic HBV carrier (14). A classic example of progression to chronic infection is shown
in Fig 1.2-Panel B.
Although it is known that cytotoxic T cell and natural killer cell responses are needed to clear
an HBV infection completely (16–18), the reasons why an acute infection becomes chronic are still
not known. It is most likely that those individuals who are immuno-compromised or have a poorly
developed immune system (e.g. young children) fail to mount a strong innate response and thus do
not eliminate the infection (19). Such individuals are thereafter at an elevated risk of progressing to
HCC later on in life.
1.2 HBV and Hepatocellular Carcinoma
Epidemiological evidence has established a strong connection between chronic HBV infection and
HCC (20,21), with a lifetime risk of developing liver cancer ranging from 5 % to 20 %. After the dis-
covery of HBV genomic material in DNA isolated from HCC samples (22) and cell lines (23) it was
suggested that HBV acts as a proto-oncogene activator due to insertional mutagenesis.
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Figure 1.1: Illustration of the lifecycle of HBV from infection of a hepatocyte to the secretion of
progeny viruses. 1) The virus docks with an unknown receptor and enters the cell after which it is
uncoated. 2) The viral genome is transported into the nucleus and converted to cccDNA by host
enzymes. 3) Transcription of the four ORFs occurs from the cccDNA template. These include hbx,
preS2, and preS1/S mRNAs as well as pgRNA. The viral transcripts are exported from the nucleus,
and 4) translation of the respective proteins occurs in the cytoplasm. 5) Together with the pgRNA,
the polymerase (HBp) and core (HBc) proteins form immature, RNA packaged nucleocapsids. The
pgRNA is converted by HBp to DNA via reverse transcription. 6) The nucleocapsids then associate
with surface proteins (HBs) in the ER and Golgi bodies and are enveloped after budding from the
ER. The virions are secreted from the cell.
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Figure 1.2: Representative timecourses of acute (Panel A) and chronic (Panel B) HBV infections
showing viral antigen and DNA levels (15). Both acute and chronic infections proceed in a similar
manner, with a rapid rise in the levels of detected HBV DNA (green line), HBs (red line) and serum
Alanine transaminase levels (ALT) (yellow line) during the first three months of infection. The ALT is
a measurement of liver function. Thereafter acute infections are generally resolved within a further
3 months as measured by a drop in HBV DNA, HBs and ALT levels. In contrast chronic infections
continue to show elevated levels of HBs and HBV DNA although ALT levels may be reduced. The
dotted orange line represents an arbitrary limit of detection in both panels.
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The woodchuck hepatitis virus (WHV) was the first mammalian and avian hepatitis virus de-
scribed after HBV. Woodchucks chronically infected with WHV proceed to severe hepatitis and HCC
in the first 2 - 4 years of life. Furthermore the presentation of woodchuck HCC is very similar to
HBV-related HCC, making this a useful animal model for the study of HBV. Assessing the pattern
of insertional mutagenesis in woodchuck HCC revealed that nearly all WHV genomic insertions are
present near either the N-myc2 (24), c-myc (24) or N-myc1 loci (25), resulting in their activation. Unfor-
tunately, the same has not been observed for HBV and random integration sites were observed for
HBV tumours, with only a few cases of integration occurring near an oncogene (26).
As the search for predictable integration sites of HBV remains unsuccessful, there are two other
proposed models to help explain HBV-related HCC. The first model involves tumour suppressor
genes in the development of HCC and is discussed below, whereas the second model proposes the
presence of an oncogene within HBV and is discussed in Section 1.2.2.
The first model is based on HCC being a multistep disease process similar to that described
for colon cancer (see Fig 1.3). This was reasoned because a variety of lesions were visible in
people with HCC, including dysplastic nodules, altered hepatic foci and sites of HCC displaying
different degrees of cellular differentiation (5). Unlike colon cancer, the molecular characterisation of
liver cancer is still being determined but a major focus has been on the tumour suppressor protein
p53. This focus developed when two reports detailed that approximately half the HBV related HCC
samples obtained from patients in Qidong China (27) and Southern Africa (28) contained mutations
within this gene. In most of the cases described, a G to T transversion was present at codon 249.
Such substitutions are characteristic of exposure to chemical carcinogens such as aflatoxin B1 which
are common in these geographical regions (28,29). Liver cirrhosis is an additional risk factor for the
development of HCC and occurs when hepatocytes are replaced by scar tissue. This may be caused
by chronic HBV infection, Hepatitis C infection as well as alcohol abuse and fatty liver disease. In
cirrhosis, liver function is impaired, is generally irreversible and individuals with this disease are at
risk of dying from liver failure or progressing to HCC.
Subsequent findings have revealed that the frequency of p53 mutations in HCCs (12 - 30 % (31))
are lower than other human cancers (approximately 50 % (32)). It seems therefore that p53 mutations
are not an early event that leads to HCC, but rather a late event, similar to colon and other human
cancers (33). The second model of HBV-related HCC involves an oncogene encoded within the virus.
To further understand this, a brief overview of the HBV genome organisation is described below.
1.2.1 HBV Genome Organisation
As depicted in Fig 1.4, the DNA genome of HBV (and other hepadnaviruses), is partially double-
stranded and ranges in size from 3.1 - 3.3 kb, depending on the genotype or isolate (34). All of the
genes overlap to some degree with at least one other HBV gene. The four open reading frames are
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Figure 1.3: A model of the progression of chronic HBV infection to HCC as proposed by Merle
and Trepo (30). In the model, several types of liver cells could support the accumulation of genetic
alterations, leading to senescence and ultimately to HCC. When the cell cycle checkpoints are over-
ridden the cell is able to re-enter the cell cycle and telomerase activation causes DNA hypermethyla-
tion and genetic instability. The cell accumulates the changes necessary to achieve tumourigenicity
and cancer stem cell capabilities.
all encoded by the DNA minus strand (35), and the three sub-genomic transcripts (2.4, 2.1 and 0.9 kb)
as well as the single greater-than-genome length pgRNA, are produced during infection. The large
HBs protein is translated from the 2.4 kb transcript whereas the middle and major HBs proteins are
both translated from the 2.1 kb transcript. The HBx protein is translated from the 0.9 kb transcript.
The pgRNA serves as the template for HBc and HBp protein translation as well as template for HBV
progeny genomes. The pgRNA also contains a secondary structure (E) signal that is present on
both the 5′ and 3′ ends. The 5′ end is the one recognised by the HBV HBp and acts as the initial
packaging signal (36).
1.2.1.1 Core Protein
The core ORF is divided into two in-frame sections, a pre-core and core domain (see Fig 1.4).
Translation from the upstream pre-core codon results in the E antigen (HBe). This antigen contains
a signal peptide, is proteolytically cleaved on the amino and carboxy termini, and secreted from the
cell (37). The detection of this protein is indicative of active viral replication. Translation from the
downstrean core start codon results in HBc proteins which then dimerise and assemble to form viral
icosahedral capsids.
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1.2.1.2 Surface Proteins
During viral replication, the outer envelopes of the infectious Dane particles are added to the virus
by budding from the membrane of the endoplasmic reticulum (38). There are three viral proteins
in the envelope namely S, M and L proteins. S is the smallest protein (residues 175 - 400) and
defines the S domain common to all the HBs proteins. The M domain has an added pre-S2 domain
(residues 120 - 174), whilst the L domain has both the pre-S1 (residue 1 - 108 or 1 - 119) and pre-S2
domains (35). The exact size of these proteins depends on the HBV genotype. The HBs proteins are
co-translated in the ER due to the presence of several transmembrane sequences. Regions in the
ER which are high in the S but not M or L proteins may aggregate in the Golgi complex, bud into
the lumen of the ER, and then be secreted from the cell as 22 nm particles. The pre-S1 domain,
displayed on the outside of the S antigen, can elicit virus-neutralising antibodies and is thought to
be partly involved in the viral receptor responsible for infection (39). The function of the M domain is
not understood and the protein is not essential for the replication of HBV in hepatocyte cultures (40).
1.2.1.3 Polymerase Protein
The ORF containing polymerase encodes the HBp protein, which possesses both RNA- and DNA-
dependent polymerase activity required during viral replication. HBp is divided into three main do-
mains, the primase domain on the N-terminus, the polymerase domain in the middle and the RNase
H-like domain on the C-terminus (41). The primase domain primes minus strand synthesis and is
eventually covalently linked to the 5′ end of the DNA minus strand (42). It is also important for the
packaging of pgRNA as well as acting as a primer for reverse transcription (43). The middle domain
gives the protein its name and is responsible for the RNA- and DNA-dependent polymerase activity
of the protein. The RNase H domain is responsible for degrading the pgRNA from the RNA-DNA
intermediate created during reverse transcription (44). As the HBc, HBs and HBp proteins were of
less importance in this current body of work, only a brief description of these proteins has been
provided. A more detailed description of these proteins may be found in (15).
1.2.2 HBV X Protein
The second oncogenic model described above predicts that expression of one of more of the pro-
teins of HBV may induce a malignant transformation in tissue culture cells or animal models of HBV.
Suspicion of oncogenic potential initially fell on HBx in 1988 when its mRNA transcripts were de-
tected in the livers of infected Woodchucks (45) and human patients (46). The detection of HBx protein
in HCC liver biopsy samples from human patients has been variable, ranging between 0 % (47) and
86 % (48). This low level of concordance between studies could be as a result of antibody detection
problems because HBx is known to have a low immunogenicity. However there could be an interplay
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Figure 1.4: The HBV genome is a partially double stranded DNA genome with 4 open readings
frames. It encodes four main genes, polymerase, surface, core and hbx. The preS1 and preS2
and surface segments are in frame with each other, and depending at which AUG codon translation
occurs from, the large (S1/S2/S), middle(S2/S) and major(S) HBs proteins are produced. The pre-
core segment is in frame with core and translation from this AUG results in the e antigen pre-
core/core precursor. The core gene encodes the HBc protein which makes up the viral nucleocapsid.
The hbx gene encodes the HBx protein which displays transactivation function.
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between virus genotype, patient ethnicity, age of infection and HBx expression which has not been
fully explored.
Numerous studies have used mouse models to examine the hepatocyte transformative capa-
bilities of the HBx protein. The overexpression of HBx in CD-1 mice, which are susceptible to
spontaneous hepatoma generation, showed a 10-fold increase in liver tumour frequency compared
to control mice of the same strain. Changes to the liver included preneoplastic liver foci, which
consisted of hepatocytes with cytoplasmic vacuolations (49). However using mice expressing HBx
at a physiologically relevant level, there was no change in the prevalence of liver tumour develop-
ment (50). Still more mouse models, observed over a period of two years, showed that at a level of
HBx expression lower than that used in the CD-1 mouse study, HBx protein alone did not cause
serious liver damage nor HCC (51). These studies highlight that prudence should be shown when
considering the results generated with animal models as, like the WHV-HCC progression studies
discussed in section 1.2, the differences between model systems and HBV-human biology is often
contrasting.
The manipulation of cell cycle and cell proliferation pathways is a major mechanism by which sev-
eral tumorigenic viruses transform infected cells (e.g. SV40, HPV-16, EBV). These viruses encode
non-structural proteins that can stimulate quiescent cells to enter the S phase of the cell cycle (52).
Similarly such cell cycle manipulation has been described for HBV (53). It has been observed that
serum starved cells in an arrested growth phase proceeded to the G1 phase but not S phase when
exposed to HBx (54). Bouchard et al conducted a study to determine what effect HBx had on the
cell cycle, both by itself and in the context of other HBV genes. Using primary rat hepatocytes, they
determined that upon infection with HBV, normally quiescent hepatocytes were induced by HBx to
move from the G0 to the G1 phase of the cell cycle (55). The authors suggested that due to the free
pool of dNTPs in quiescent hepatocytes being low, HBV (through the actions of HBx) causes the
cell to move into the G1 phase thus increasing access to dNTPs needed for viral production (56). It
has been suggested that the cell cycle is manipulated as a result of membrane depolarisation of
mitochondria (57), as shown in Fig 1.5. Depolarisation results in the release of free Ca2+ which not
only interacts with the Pyk2/FAK and SRC kinase families but is important in inducing quiescent
cells to re-enter the cell cycle (58). Of note is the stalling of the cell in the G1 phase which may be
advantageous for the virus as it then does not compete with host replication machinery, and likely
prevents the initiation of apoptotic pathways brought on by premature cellular DNA synthesis and
replication (55). Furthermore as this study was conducted using physiologically relevant cells and
viral levels, the data are highly suggestive of a natural function of HBx.
Most experimental evidence generated thus far suggests that HBx is not by itself directly respon-
sible for the progression of chronic HBV to HCC. Many of the described interactions may have been
a result of an inadvertent amplification of HBx protein’s inherent ability to be involved in multiple
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Figure 1.5: A model of the interactions of HBx with cellular targets and mitochondria (adapted from
Bouchard and Schneider (59) and Katsuro and Koike (60)). Several signal transduction pathways have
been shown to interact with HBx including RAS/MAPK, JNK, NF-κB, and Src (blue ovals). The most
prominent interaction is with the mitochondria permeability transition pore, which results in depo-
larisation of the membrane potential and an increase in the cytosolic levels of Ca2+ (57). This Ca2+
increase is involved in many cellular pathways, the most notable of which is cell cycle control. Active
versions of the relevant proteins are phosphorylated as shown by a yellow circle. ROS (reactive
oxygen species).
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functions and interactions. It is notable that despite the increased risk of liver cancer in a chronic
infection, there is little evidence to suggest that HBV is cytotoxic to liver cells under physiological
conditions in an experimental setting (61–63).
It has also been common practise for HBx research to involve animal models and cell lines
that do not adequately reflect human liver physiology. Studies attempting to replicate findings from
other research groups have often generated different conclusions, probably as a result of differ-
ent experimental conditions rather than true discrepancies. It is also possible that the use of HBx
overexpression and poor non-hepatic cellular models have unintentionally ”forced” interactions be-
tween HBx and various cellular targets. It has therefore become very difficult to distil genuine versus
artefactual interactions. To remedy this, greater emphasis needs to be placed on model systems
that are physiologically relevant including the use of HBx in context with other HBV proteins, and at
concentration of proteins observed in an infection setting.
Taken together these results and discrepancies suggest that the progression to HCC could be an
interplay between HBV’s manipulation of the cell cycle to enable virus production, and the immune
system attempting to counter virus production through immune-mediated cell death. The ability of
HBx to manipulate the cell cycle may thus set the stage for the proliferation of cells containing DNA
damage leading to carcinoma formation over time. Solid data relating to the functions of HBx remain
isolated and thus concrete facts about HBx functioning remain few. Continued robust explorations
to uncover the true functions of HBx in HCC as well as the viral life cycle are needed, especially as
the majority of studies to date have been conducted using prokaryote expressed HBV proteins.
1.3 Systems of Protein Expression
The study of proteins is often hampered by the low levels at which their genes are naturally ex-
pressed. To facilitate studies, two main protein expression systems are normally used, Escherichia
coli and baculovirus-mediated insect cell expression. Derivations of these systems were developed
many years ago, and their capabilities are increasingly insufficient for demands in producing poorly
characterised proteins such as HBx.
E. coli is normally the first expression system used when generating a heterologous protein.
This is facilitated by the bacteria’s rapid growth cycle and dependence on inexpensive substrates.
Furthermore E. coli genetics are well known and there are a variety of cloning vectors and mutants
that one may choose from. There is however no guarantee that the chosen system will produce a
correctly folded, active protein. Certainly in the case of HBx, expression with additional tags results
in mostly insoluble protein located in inclusion bodies (64). Furthermore denaturation and refolding
are required to allow pure functional protein to be purified. Similarly work previously conducted in
the Arbuthnot laboratory found HBx expressed from Sf9 insect cells was also insoluble and required
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extensive manipulation to generate a soluble form (65). Thus there is a significant need for additional
systems of expression that can generate soluble eukaryote expressed HBV proteins.
It has long been appreciated that yeasts, and specifically Saccharomyces cerevisiae, are a good
system for the expression of heterologous proteins (for a detailed review see (66)). Yeast are clas-
sified as a Generally Regarded as Safe (GRAS) food organism, and are acceptable hosts for the
expression of pharmaceutical proteins. In contrast E. coli may contain cell wall endotoxins and
mammalian cells are often contaminated with exogenous viruses, so products from these hosts un-
dergo thorough testing before use. Like bacteria, yeasts can be grown on inexpensive media and
they can be genetically manipulated almost as readily as E. coli. As yeasts are also eukaryotes,
any proteins they produce are often identical to (or at least similar to) those produced in mammalian
cells, whereas prokaryote produced proteins (from E. coli) are not. Importantly yeasts are amenable
to high-level secretion of expressed proteins as well as cytosolic accumulation of soluble proteins
and thus could be the ideal host to express HBV proteins and in particular HBx.
Bioinformatic analysis of HBx sequences may yield insights into the behaviour and structure of
the protein and may be useful in designing an expression system. An analysis of structural disorder,
the presence of protease-sensitive sites and instability may suggest reasons for the difficulty in
expressing and purifying HBx.
1.4 Bioinformatic Analysis of HBx
The HBV HBp lacks 3′ - 5′ proofreading exonuclease activity resulting in an estimated misincorpo-
ration rate of 10-4 nucleotides (67). Together with a replication rate capable of producing 1013 viral
particles per day (68), the viral population accumulates an estimated 109 mutations per day over the
3.2 kb HBV genome (69). The rate is unlikely to be uniform over the length of the genome, as overlap-
ping segments of HBV genes place evolutionary constraints on the overlapped partner gene. Thus
large sequence variation accumulates in the viral population and is a source of selection for mutants
that are able to resist the host immune response and to escape treatment (70).
There are eight genotypes of HBV (A-H) each differing from each other by at least 8 % (71).
Genotypes are still largely geographically separated which might allow for HBV to follow different
evolutionary paths (see Fig 1.6). This is illustrated by the differences in severity, course and likeli-
hood of developing HBV-related complications (72). Genotypes also differ in their requirment for HBe
seroconversion and the response to treatment for chronic infection (73,74). Considering the sequence,
geographic location and pathogenesis differences of the genotypes, analysis should be performed
on each genotype separately to make certain that notable differences in evolutionary mechanisms
are not lost due to averaging of data.
Considering the purported role of HBx in the development of HCC, and because hbx overlaps
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Figure 1.6: Geographic distribution of the 8 declared genotypes of HBV (75). Genotype A is largely
situated in sub-Saharan and Western Africa, India and Western Europe. Genotype B is concentrated
in South-East Asia and Japan. Genotype C is present in Eastern Asia, Australasia and some Pacific
islands. Genotpe D is located in North Africa, Southern Europe, the Middle East, Russia and its
satellite states. Genotype E is largely in central and Western Africa. Genotype F is concentrated
mainly in central and South America. Genotypes G and H are also situated in central America.
with pre-core and polymerase genes, it is important to pursue studies examining the mechanism of
evolution on HBx. This might offer insight into the interactions between HBx and cellular targets as
well as the immune system.
Molecular evolution is part of the evolutionary process, but focussing on the DNA, RNA or pro-
tein changes that underlie organism differences cannot be inferred from morphological features. The
analysis of the molecular evolution of species helps investigate the forces and mechanisms of the
evolutionary process (76). This is studied by estimating rates of nucleotide and amino acid substitu-
tions, and then applying computational models of mutation and selection using sequence data (76).
A database of sequences serves as a collection of the evolutionary history of sequences and allows
comparisons to be made that could not be done using morphological characteristics. The analysis
of the molecular evolution of sequences relies on large datasets and is often very computationally
intensive. To date, while HBV sequences lie within a single repository these have not been com-
piled nor sufficiently annotated. This would be a prerequisite for any evolutionary analysis and was
conducted as part of the current body of work.
1.5 Aims of Research
Research into the functions of HBx has been mired in an ever-expanding list of interacting host cell
proteins. As such there is no consensus on the exact function of this protein in the HBV lifecy-
cle, and importantly the specific role this protein plays in the development of HBV-related HCC. E.
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coli based expression systems lack the appropriate mechanisms for carrying out post-translational
modifications such as disulphide bond formation, glycosylation, and phosphorylation to name a
few. Therefore eukaryote based expression systems were chosen so that expressed proteins would
closely resemble HBx found in infected hepatocytes. Concurrent to this, bioinformatic and evolution-
ary analysis of HBx was undertaken to understand HBx proteins more closely.
Previous attempts at expressing HBx in E. coli suggested that the expression and purification
of HBx using eukaryotic cells would be technically very challenging due to the biochemical nature
of HBx. However it was felt that progress could only be made on the expression, function and
structure of HBx through the use of technically more difficult methodologies. The results from this
work significantly improved the understanding of the nature of HBx protein, provided new avenues
for the production and purification of eukaryotic HBx, and uncovered vital considerations for the
design and execution of HBx studies. This thesis included the following aims:
1. Exploration into the suitability of S. cerevisiae and mammalian cells for the large-scale ex-
pression and purification of HBx.
2. An analysis of the HBx amino acid sequence to determine whether there were any predictors
which could help explain the technical difficulties in working with this protein. This included
protease sensitivity and stability.
3. A computational evaluation of regions of structural disorder within the HBx protein. This could
supplement any findings of protease sensitivity, but also provide information regarding the
nature of interactions between HBx and cellular targets.
4. The use of solubility-enhancing tags in combination with mammalian Semliki Forest Virus
expression systems was evaluated for their combined suitability in producing large quantities
of HBx in eukaryotic cells.
5. A study of the recent evolution of HBx was conducted to determine what types of substitutions
are prevalent in HBx, and how these relate to the overlapping reading frames of polymerase
and pre-core. Additionally, the presence of adaptive and negative evolution was assessed at
sites within HBx and along the length of HBx.
6. Determination of whether there is independent evolution in HBx. This would be suggestive of
differences in evolutionary pressures between the genotypes of HBV.
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Chapter 2
Exposition on the Expression,
Purification and Detection of
Recombinant HBx
2.1 Introduction
Despite 30 years since the discovery of HBx, elucidation of potential functions of this protein re-
main controversial (reviewed in (59,77)). Major discrepancies in HBx related literature are common
(reviewed in (78)), and are largely due to poor availability in methodologies e.g. the lack of HBV
infectable cell lines, and reliance on overexpression systems to identify HBx function. This has cre-
ated a fabric of data that is not biologically relevant and is riddled with artefactual findings. Some of
the data are discussed briefly below to illustrate the gaping need for undertaking technically difficult
experimentation to uncover the physiological functions of HBx.
1) Discrepancies arose in attempts to describe the presence of enhancer elements in HBV. En-
hancer elements are typically required to increase basal levels of transcription by coordinating DNA-
protein interactions in cis or in trans on upstream and downstream ORFs. The enhancer 1 (EnhI)
element of HBV lies upstream of the X ORF and is itself overlapped by several cis-elements includ-
ing enhancer 2 (Enh II) (79). Di et al (80) were unable to identify a functional enhancer element in WHV
homologous to EnhI in HBV, but they did confirm the presence of an enhancer analogous to EnhII.
Opposing data was generated by Murakami and colleagues who found the predicted enhancer se-
quences were able to form DNA-protein complexes of several synthetic DNAs (81) suggesting that the
predicted enhancer elements were functional. It is not clear why these differences were observed.
2) Sub-cellular localisation of HBx also remains controversial, with separate studies showing
perinuclear localisation (82), nuclear localisation (83), and a combination of cytoplasmic and nuclear
localisation by Doria et al (84) and separately by Nomura et al (85). Specifically, Nomura showed that
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FLAG-tagged HBx was found in either the cytoplasm, the nucleus or both cellular compartments.
These discordant results were shown more recently to be a result of the strength of the promoter
used in HBx expression localisation experiments. At low levels, HBx is largely nuclear whereas at
higher expression levels it shows largely cytoplasmic localisation( (86,87)).
3) A variety of data on the effect of HBx on cell death and apoptosis has been reported by sev-
eral groups. These reports range from the prevention of p53-dependent apoptosis by the microin-
jection of HBx into primary fibroblasts (88), to the induction of p53-dependent apoptosis in NIH3T3
cells transiently expressing HBx after DNA damage with low dosages of topoisomerase II inhibitor
etoposide (89). Indeed a third finding by Su et al (90) did not observe apoptosis in Chang liver cells
expressing HBx, but found the cells were instead sensitised to programmed cell death by low levels
of TNFα.
Taken together these data illustrate the inconsistencies common to HBx related ”functions” and
highlight the wide range of cell culture models and methodologies that have contributed to the poor
concordance between these datasets. Despite these inconsistencies, HBx is important for viral
replication in woodchucks (91,92) and mammalian cells (55,93,94) and critically, it has been implicated
in the progression of liver carcinogenesis in individuals chronically infected with HBV. As a result
of the importance of HBx in the HBV lifecycle and potential involvement in the health outcomes of
chronically infected individuals, it is vital that experimentally difficult aspects of HBx are researched
so that its true mechanisms of action, function and structure are identified.
The importance of isolating preparative quantities of HBx for structural determination has been
hampered by the solubility and instability problems that HBx exhibits. To date, HBx has eluded
high resolution X-ray crystallography and nuclear magnetic resonance studies (59) and as a result
researchers know very little about the structure of HBx. Attempts to express this protein in E. coli
have until recently led to 99% of the expressed protein being deposited in inclusion bodies (95,96),
even with the addition of solubility tags such as Glutathione-S-transferase (97). Clearly alternative
systems that do not involve bacterial or insect expression (65,98) are required to generate HBx protein
and this forms the basis of the results presented in the current chapter. Specifically we wanted to
express HBx in eukaryotic cells to ensure correct post-translational modifications and importantly,
improved solubility. In this chapter, initial efforts were directed towards expressing HBx in different S.
cerevisiae vectors and different mammalian expression vectors. S. cerevisiae has to our knowledge
only been used with HBx in yeast two-hybrid experiments (99,100). S. cerevisiae offers distinct ad-
vantages over prokaryotic cells including eukaryotic post-translational modifications and the relative
ease of manipulation and cost of culturing conditions compared to mammalian systems. Different
mammalian expression vectors were evaluated for the ability to express HIS tagged intracellular
HBx, codon optimised HBx and GFP fusion constructs. We intended for these expression systems
to produce quantities of HBx that would allow future work to focus on the structural analysis of HBx.
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2.2 Materials and Methods
Each of the constructs used in this work is described in detail below, but an overview is described
here. Initially, the E. coli pET-ELPI (Elastin like protein and Intein) was used as the ELP permitted
rapid isolation of HBx fusion protein. The eukaryotic plasmids were then constructed, with the
HBx sequence being inserted into the S. cerevisiae pYES plasmid, with and without a 6xHIS tag.
This was repeated for the S. cerevisiae YEp vectors. The mammalian pCI-Neo vector followed,
with one plasmid containing untagged wildtype HBx, and another a codon-optimised 6xHIS tagged
HBx. Lastly, a GFP-Intein-HBx fusion sequence was sub-cloned into each of the vectors mentioned,
including the mammalian pCEP4 vector.
2.2.1 Bacterial Expression Vector Construction
2.2.1.1 pET Vectors
pET-ELP-I-HBx HBx was sub-cloned into the pET-ELP-Intein system developed by Banki et al. (101).
The elastin-like-protein (ELP) possesses reversible solubility characteristics that are determined by
temperature, salt and protein concentration. Above a certain transition temperature (Tt) and salt
concentration the fusion protein becomes insoluble and hence precipitates out of solution whereas
below Tt and with reduced salt concentration, the protein resolubilises. This allows the rapid par-
titioning of the fusion protein from contaminating cellular proteins. In addition, the Intein portion of
the fusion allows the target protein, i.e. HBx, to be cleaved from the ELP-Intein fusion without the
requirements for additional proteases such as Factor Xa. The effect of this system on expression
and HBx solubility had not been determined and so its suitability for HBx expression was further
evaluated here.
A two step approach was used to generate the vectors with oligonucleotide primers purchased
from Integrated DNA Technologies (IA, USA). First, HBx was PCR amplified with a forward primer
containing a Bsp1407 I site (5′ -GATC TGTACA CAACAT GGCTGC TAGGTT GTACT-3′, the Bsp1407 I
site is underlined) and a reverse primer (5′-GATCCC TAGGTT AGGCAG AGGTGA AAAA-3′ ) with
pCR-HBVA1 1.3x as template (102). The PCR fragment was cloned into pTZ57R/T (Appendix B.3.1)
and sequenced using standard M13 primers.
Positive clones were bulk prepared as described in Appendix B.2 and HBx fragments were ex-
cised from pTZ using Bsp1407 I and Hind III restriction enzymes incubated in Tango buffer (Fermen-
tas, WI, USA) at 37 ◦C. The fragments were ligated in the pET-ELP-I vector that had been cut with
the same enzymes (Appendix B.3).
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2.2.2 Codon Optimisation
To test whether codon optimisation of HBx would make a difference to protein expression levels, we
purchased codon optimised HBx sequences from GeneArt R© (Regensburg, Germany). The algo-
rithm used to optimise the sequence minimised the occurrence of cryptic poly-A sites and reduced
any calculated mRNA secondary structure that could inhibit translation. The occurrence of codons
with the HBx sequence was altered to reflect similar codon useage of human proteins showing high
expression levels. The same modifications were made for a HBx sequence optimised for expression
within S cerevisiae.
2.2.3 Yeast Expression Vector Construction
2.2.3.1 pYES2 Expression Vectors
pYES2 (a gift from Professor Koos Albertyn, University of the Free State, Bloemfontein, South Africa)
was the initial choice in attempts to express HBx. Protein expression in this vector is strongly con-
trolled by the GAL1 promoter, which is repressed in the presence of glucose, but induced in the
presence of galactose. This fine control of expression is ideal for potentially cytotoxic proteins as the
cells are allowed to reach a logarithmic stage of growth before being induced. A Kozak translation
initiation sequence was inserted before each gene to ensure the correct initiation of translation (103).
Briefly, HBx was PCR amplified from a replication competent plasmid vector of the A1 subgeno-
type of HBV that had been constructed in our laboratory. The HBV sequence of this vector starts
upstream of the HBV basic core promoter and ends downstream of the HBV polyadenylation site (102)
thus encompassing 1.3-times-the-length of the HBV genome (Fig 1.4). A forward primer (5′-GATC
AAGCTT ACCACC ATGGCT GCTAGG TTGTACT-3′, Hind III underlined) and reverse primer (5′-
GATC GAATTC AGATCT AGAGAT GATTAG GCAGAGG-3′, EcoRI underlined, Bgl II italicised) were
used to PCR amplify HBx using standard conditions (see 2.2.5). The PCR product was cloned into
pTZ57R/T (Appendix B.3.1) and positive clones were verified by sequencing. The positive pTZ clone
and the pYES2 backbone (Invitrogen, CA, USA) were digested with EcoRI and Hind III in Buffer Red
(Fermentas, WI, USA), and the HBx fragment was ligated into the pYES2 backbone (Appendix B.3).
2.2.3.2 YEp Expression Vectors
The YEpHF secretory vector (a gift from Professor Sally Twining of Medical College of Wisconsin,
USA) was chosen as an alternative to the pYES2 vector because protein expression is driven by a
yeast ADH2 promoter in the former. This promoter is regulated by glucose repression and therefore
requires no inducers. Additionally the presence of the α-factor leader sequence would hopefully
allow HBx secretion from the cell, and hence purification from the growth medium, resulting in a
rapid and cleaner preparation of recombinant HBx.
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The HBx gene was PCR amplified from pCR-HBVA1 1.3x (102) using a forward primer (5′-GATC
GGTACC TTTGGA TAAAAGA CACCACCACCACCACCAC ATGGCT GCTAGG TTGTACT-3′, KpnI
underlined, 6xHIS is in italics) and reverse primer (5′-ATTACT CGAGAG GCCTAT TAGGCA GAG-
GTG AAAAA-3′). The PCR product was cloned into pTZ57R/T (Appendix B.3.1) and positive clones
were verified by sequencing. The pTZ clone and the YEp backbone were digested with KpnI and
BamHI in BamHI Buffer (Fermentas, WI, USA), gel purified (Appendix B.2.4), and ligated using
standard cloning procedures (Appendix B.3).
YEp-GFP-I-HBx To visualise the presence of HBx within induced S. cerevisiae cells, a fusion pro-
tein consisting of yeast codon optimised GFP ( (104) purchased from EUROSCARF), the intein frag-
ment from the pET-ELP-I vectors (section 2.2.1.1) and 6xHIS tagged HBx from pCR-HBVA1 1.3x (102)
was constructed. Initially, the YEp vector was altered by removing 6xHIS and FLAG tag by PCR am-
plifying the 188 bp region upstream of the HIS-FLAG tag and α mating factor with the forward primer
(5′-GTATA GCATGC CTATCA CATATA AATAG-3′) containing an SphI site and reverse primer (5′-G
GAATTC TCGAGC TTGGTG TATTAC GA-3′) containing an EcoRI site. This PCR fragment was
cloned into pTZ (Appendix B.3.1) and sequenced (Appendix B.2.7). Both the YepHF and pTZ plas-
mid were digested with SphI and EcoRI to remove the intervening 483 bp sequence from YepHF
and replaced with the new 188 bp sequence from pTZ.
The GFP-Intein-HBx fusion protein was cloned into the new YEp vector using a two step process
(Appendix B.3). Codon-optimised GFP was PCR amplified using forward primer (5′-AG GGATCC
ACCACC ATGTCT AAAGGT GAAGAA TT-3′) with BamHI (underlined) and a Kozak sequence (itali-
cised) (103) before the primary ATG, and a reverse primer (5′-AG GAATTC TTTGTA CAATTC ATCCAT
AC-3′) containing an EcoRI site (underlined). The PCR amplicon was cloned into pTZ57R/T (Ap-
pendix B.3.1) and verified by sequencing. The 1024 bp Intein-HBx segment from the pET-ELP-I-HBx
vector was excised using EcoRI and Not I. Concurrently, the GFP fragment from the pTZ plasmid
was excised using BamHI and EcoRI and the backbone YEp plasmid was digested with BamHI
and Not I. The fragments were ligated together in a 3-way ligation reaction using a 3:1 molar ratio
of insert to backbone (YEp) and a 1:1 molar ratio of insert to insert as mentioned (Appendix B.3).
Positive clones were confirmed using restriction digest analysis.
pYES-GFP-I-HBx The restriction sites for the generation of YEp-GFP-I- pYES2-GFP-I-HBx vector
was generated as described in section 2.2.3.2.
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2.2.4 Mammalian HBx Expression Vector Construction
2.2.4.1 pCI-Neo
The plasmid containing the human codon optimised HBx was PCR amplified using a forward primer
containing a BamHI site (bold), Kozak sequence (underlined) and 6xHIS tag (italicised), 5′-AG
GGATCC ACCACC ATGGAG CACCACCATCACCACCAC GCCGCC AGGCTG TACTGC-3′ and a
reverse primer containing a SpeI site (italicised) 5′-AG ACTAGT GCTCAT CAGGCG GAGGTG-3′.
The PCR product was cloned into pTZ57R/T (Appendix B.3.1), and positive clones were sequenced.
HBx was sub-cloned out of pTZ using EcoRI and Sal I restriction enzymes in Buffer Orange (Fer-
mentas, WI, USA) and into pCI-Neo using the same restriction sites.
2.2.4.2 pCEP4 Expression Vector
The pCEP4 vector (Invitrogen, CA, USA) was chosen as it contains the Epstein-Barr Virus repli-
cation origin and nuclear antigen (encoded by the EBNA-1 gene) which permits extrachromosomal
replication in human cells. Additionally the vector also encodes the hygromycin B resistance gene
for the stable selection of transfected mammalian cells.
The GFP-Intein-HBx fusion protein was cloned (Appendix B.3) into the mammalian expression
cassette pCEP4 (Invitrogen, CA, USA) using a 2 step process. GFP was PCR-amplified from
pCI-Neo-GFP using a forward primer (5′-AG GGATCC GTCGAC ACCACC ATGGTG AGCAAG
GGCGAGG-3′) containing a BamHI site (underlined) and a Kozak sequence (italicised) (103) before
the primary ATG, and a reverse primer (5′ -AG GAATTC CTTGTA CAGCTC GTCCATG-3′) contain-
ing an EcoRI site (underlined). The GFP PCR product was first cloned into pTZ57R/T (Appendix
B.3.1) and sequenced before proceeding. The Intein-HBx fragment was sub-cloned from pET-ELPI-
HBx (section 2.2.1.1) using EcoRI and Hind III restriction sites. The pCEP4 backbone was cleaved
using BamHI and Hind III and the 3 products were ligated together at a 3:1 molar ratio of insert to
backbone and 1:1 molar ratio of insert to insert (Appendix B.3). Positive clones were confirmed by
restriction digest analysis.
2.2.5 PCR Conditions
All PCRs were carried out using Expand HiFiPLUS PCR System reagents (Roche, Basel, Switzerland)
on a Mastercycler (BioRad, CA, USA). PCR mixtures included 0.4 µM of each of the respective
forward and reverse primers, 10 ng of template, 1.5 mM MgCl2, 1 µL dNTP mix (10mM), 2.5 U of
Expand HiFiPLUS Taq polymerase and 1 x final volume Expand HiFiPLUS Reaction Buffer (proprietary
information) in a final volume of 25 µL.
PCR conditions comprised an initial denaturation step of 3 minutes at 95 ◦C followed by 30 am-
plification cycles, where each cycle had a denaturation step at 95 ◦C for 30 seconds, 58 ◦C annealing
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step for 30 seconds and a 72 ◦C elongation step of 1 minute per kilobase, followed by a 10 minute
final elongation at 72 ◦C.
2.2.6 Protein Induction, Purification and Detection
2.2.6.1 Expression of HBx in E. coli pET15b and pET-ELP Vectors
pET15B-HBx This vector was previously constructed in our laboratory, and all protocols used to
express and purify HBx protein from this vector were performed as described by Capovilla et al (105).
pET-ELP-Intein-HBx HBx expressed from the pET-ELP-Intein-HBx construct was purified as de-
scribed in (106,107) and as illustrated in Figure 2.1. Briefly, cells were pelleted by centrifugation at
10 000 x g and 4 ◦C, resuspended at 10 mL per 1 g wet cell paste in 10 mM Tris pH 8.5, 2 mM
EDTA and 0.1 mg/mL lysozyme and frozen at −20 ◦C overnight. The following day the pellets were
thawed and subjected to 4 rounds of sonication, each round being 30 seconds at 75 % power. The
solution was centrifuged at 37 500 x g for 30 minutes to clarify the lysate. An equal volume of 0.8M
(NH4)2SO4 was added and the sample was incubated in a waterbath at 37 ◦C for 10 minutes. The
sample was centrifuged at 10 000 x g for 10 minutes. The pellet was resuspended in cold buffer,
and the salting out procedure was repeated until the pellet resuspended without precipitates cloud-
ing the sample. To encourage cleavage of HBx from the intein fusion, the pellet was resuspended in
cold PBS cleavage supplemented with 40 mM Bis-Tris pH 6.2, 2 mM EDTA and incubated at room
temperature overnight. The following day the ELP-Intein protein was salted out as described above
and the supernatant was dialysed to remove the (NH4)2SO4. HBx was applied to a G-25 Sephadex
column (1.0 cm diameter, 8cm length) as a final cleanup and buffer exchange into the original lysis
buffer. Fraction samples containing protein were quantified using a BCA assay, concentrated using
a 5 kDa MWCO Amicon ultrafiltrator to at least 1 mg/mL, and snap frozen for storage at −70 ◦C.
2.2.6.2 Expression of HBx in S. cerevisiae pYES2 and YEp Vectors
For pYES2 vectors, discrete colonies of transformed (Appendix B.1.4) YVH10 S. cerevisiae were
picked from SCM-URA selective plates, inoculated into SCM-URA liquid media and grown at 300
rpm at 30 ◦C until an OD600 near to 0.8 was reached. An aliquot of this culture was inoculated into
YP media plus 2% galactose to a final OD600 of 0.4 and incubated at 300 rpm overnight at 30 ◦C.
Cultures were pelleted at 1500 x g for 5 minutes and 4 ◦C and either stored at −70 ◦C or resus-
pended in Y-PER (Pierce Chemical, Rockford, IL) and processed according to the manufacturers
instructions.
For YEp vectors, discrete colonies of transformed YVH10 S. cerevisiae were picked off SCM-TRP
selective plates and inoculated into SCM-TRP liquid media, grown at 300 rpm at 30 ◦C for 48 hours,
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Figure 2.1: A - Basic description of the functioning of ELP tags adapted from (101) whereby the
transition temperature (Tt) is the temperature above which the ELP fusion becomes insoluble, and
below which remains is soluble. This is dependent on salt concentration e.g. (NH4)2SO4 or NaCl,
temperature and concentration of ELP protein. B - The solubility phase shift allows rapid separation
of ELP-tagged proteins from contaminating cellular proteins, as a removal of salt and reduction in
temperature causes the ELP tagged protein to resolubilise. Progress to the cleavage reaction can
proceed in less than one hour under optimal conditions.
23
until a saturated culture was reached. A 1:20 dilution of saturated culture was diluted into fresh
YPD + 3% glycerol and grown at 300 rpm, at 30 ◦C for 48 hours. Following induction, cultures were
pelleted at 1500 x g for 5 minutes and 4 ◦C and either stored at −70 ◦C or resuspended in Y-PER
(Pierce Chemical, Rockford, IL) and processed according to the manufacturer’s instructions. The
supernatants of the YEp vector were also stored or tested for HBx presence (see 2.2.6.4).
2.2.6.3 Expression of HBx in Mammalian Vectors
Forty eight hours after Lipofectamine
TM
2000-based transfection (Appendix B.4.1), adherent HEK293
mammalian cells were resuspended using 1xPBS with 1mM EDTA. Cells were pelleted by centrifu-
gation at 800 rpm for 3 minutes. The cell pellet was resuspended in radio immunoprecipitation assay
(RIPA) buffer (50mM Tris-cl pH 7.4, 150mM NaCl, 1% NP40, 0.25% Na-deoxycholate, 1mM PMSF)
and incubated at 4 ◦C for 5 minutes. The solution was sonicated at the lowest power setting to ensure
cell lysis and to reduce viscosity. The solution was centrifuged at maximum speed and processed
as needed.
2.2.6.4 Protein Concentration from Growth Medium Supernatant
Protein from supernatant was precipitated by adding one volume of 100 % trichloroacetic acid to
four volumes of cell free supernatant. This was mixed by vortexing for 5 seconds and incubated
for 10 minutes at 4 ◦C. The sample was centrifuged for 10 minutes at 16 000 x g. The pellet was
washed twice with cold acetone and left to air dry. The dried protein pellet was resuspended in a
solubilisation buffer (3 % SDS, 100 mM Tris, pH 11, 3 mM dithiothreitol) (108) at room temperature
with gentle mixing overnight .
2.2.6.5 6xHIS tagged proteins
6xHIS tagged protein samples with volumes of <2 mL were purified using Ni2+ charged magnetic
beads purchased from Genscript (NJ, USA) according to manufacturer’s instructions. Larger sam-
ple volumes were batch purified with Ni2+ charged, cross-linked sepharose 6B (Sigma-Aldrich,
MO , USA). The resin was washed once with Buffer A (20 mM Na-phosphate, pH 7.5, 2 mM β-
mercaptoethanol, 10 mM Imidazole), twice with Buffer B (same as Buffer A but with 60 mM Imida-
zole) and finally eluted with Buffer C (same as Buffer B but with 500 mM Imidazole). The resin was
washed with gentle agitation in a glass beaker and collected using vacuum filtration on a porous
sintered glass funnel.
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2.2.6.6 Western blotting
SDS-PAGE and Western blotting was performed as described in Appendix B.5.2 with the following
modifications: a variety of blotting conditions were tested to allow detection of HBx during Western
blotting; different blotting membranes were used including Nitrocellulose, 0.22 µm (used for proteins
smaller than 20 kDa) and 0.45 µm PVDF; the protein component of blocking solutions was alter-
nated between BSA and milk powder, as it is known that some antibodies react adversely to one
blocking agent but not the other (109); incubation of the primary antibody was altered between room
temperature for 1 hour and overnight incubation at 4 ◦C, as this is known affect non-specific binding
of primary antibodies (110).
2.2.6.7 Mass Spectrometry Protein Identification
As an alternative to antibody detection of HBx protein, samples for mass spectrometric analysis
were prepared as follows: HEK293T cells were lipid transfected with the pCEP4-GFP-I-HBx-6xHIS
using Lipofectamine
TM
2000 under standard conditions (Appendix B.4.1). After 48 hours, the cells
were gently washed with cold PBS, resuspended, and placed into a 15 mL centrifuge tube. Follow-
ing centrifugation at 129 x g for 3 minutes, the cells were resuspended in cold RIPA buffer. Cells
were aspirated multiple times to shear DNA, and were subjected to the lowest sonication possible.
The lysed cells were centrifuged at maximum 16 000 x g for 5 minutes, and the supernatant was
transferred to a new tube for purification as described in section 2.2.6.5.
Following purification, the entire eluted sample was loaded and run on a freshly prepared 5 -
20% gradient SDS-PAGE gel. Electrophoresis was terminated when the 15 kDa MW marker was 2
cm from the bottom of the gel. The gel was then processed for aldehyde-free silver-ammonia stain-
ing (111). Bands of interest were excised from the gel and processed for mass spectrometry using
the Trypsin Profile IGD Kit (Sigma-Aldrich, MO , USA). Prepared gel band samples were processed
using oMALDI-QTOF facilities at the Council for Scientific and Industrial Research, Pretoria, South
Africa.
2.2.7 Immunofluorescence Microscopy Imaging
2.2.7.1 Immunofluorescence Sample Preparation
To visually detect HBx expression in mammalian cells that had been transiently transfected with
the CMV promoter-containing expression constructs described above, immunofluorescence slides
where set up as follows: briefly, HEK293T cells were seeded at 250 000 cells per well in a 12 well
plate containing sterile glass coverslips (12mm diameter). Twenty four hours later, each well was
transfected with 2 µg of HBx-expressing plasmid and 15 ng of pCI-eGFP (used to determine trans-
fection efficiency). Forty eight hours later the media was gently aspirated, and the cells were gently
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washed twice with 1x PBS, fixed for 30 minutes in freshly prepared, filtered, 4 % paraformaldehyde
in PBS. Cells were washed twice in 250 µL of 1x PBS for 5 minutes each. Fixed slides were stored
at 4 ◦C. S. cerevisiae cells were prepared according to Atkin (112).
2.2.7.2 Antibody Staining of Fixed Cells
The development of multiple monoclonal antibodies that recognise different antigenic sites on HBx
has proved difficult as the protein has notoriously low immunogenicity (78). As a consequence, sub-
stantial efforts have been applied in our laboratory to develop hybridomas which produce monoclonal
antibodies recognising different antigenic sites on HBx. Currently, we have access to four different
HBx antibodies, three of which bind unique antigenic sites (S1, S2 and S3), and a fourth which
partially overlaps with the previous three (6.1). The HBx antibodies had been partially purified using
6xHIS tagged, urea denatured, E. coli HBx, attached to Ni2+ affinity resin. They were resuspended
at 0.5 mg/mL in PBS and stored at −20 ◦C (see section2.2.6.5). A working stock of these antibod-
ies was prepared at a dilution of 1:100 in PBS with 2% BSA. One anti-HIS tag antibody (THE
TM
HIS Tag Antibody, Genscript, NJ, USA) was used to detect protein expressed from pCI-HHBx and
GFP-Intein-HBx constructs. A 1:500 working stock of this antibody was prepared in PBS with 2%
BSA. Secondary antibodies included a rabbit anti-mouse conjugated to Cy3 using a Lightning Link
Kit (Innova Biosciences, Cambridge, UK) and Cy3 AffiniPure Rabbit Anti-Mouse IgG (H+L) (min X
Hu Sr Prot Jackson Immunoresearch Laboratories Inc. PA, USA). A working stock of the secondary
antibodies was prepared at 1:200 in PBS with 2% BSA. Three washes with PBS + 0.2% BSA, of 1
minute each were performed in between antibody incubations. The final wash was done in PBS + 1x
DAPI to stain the nuclei. Cells were then mounted with FluorSave
TM
(Merck, Damrastadt, Germany)
and stored at −20 ◦C until processed using the microscopy facilities at the Gene Expression and
Biophysics Group, CSIR Biosciences, Pretoria South Africa.
2.2.8 HBx mRNA detection using RT-PCR
Total mRNA was extracted as described in Appendix B.2.5 and B.2.6 and precipitated as follows:
mRNA stored in formamide was precipitated by reducing the formamide to 30 % with RNase free
dH2O, adding 1:10 v/v of 3M sodium acetate and 2.5 volumes of 100 % ethanol (113). Samples were
placed on ice for 30 minutes, after which they were centrifuged for 30 minutes at 16 000 x g. Pellets
were washed with 70 % ethanol and left to air dry. Samples were resuspended in dH2O and adjusted
to 1 µg/µl.
Reverse transcription was performed as follows: a mixture of 1 µg mRNA, 2 µl of 10 µM oligo-dT
primers, 4 µl of 10 mM dNTP mix made up to 16 µl with RNase free dH2O was heated to 70 ◦C
for 5 minutes. The sample was briefly centrifuged, and placed on ice. To each tube, a mixture
26
of the following was added: 2 µl of 10x RT buffer, 0.5 µl RNase inhibitor, 1 µl M-MuLV reverse
transcriptase (New England Biolabs R© Inc, MA, USA). The samples were then incubated at 42 ◦C for
1 hour. Samples were inactivated by heating to 80 ◦C for 5 minutes, after which the sample volume
was adjusted to 50 µl dH2O. Negative control reactions contained no M-MuLV enzyme, and were
otherwise identically treated.
PCR conditions are described in section 2.2.5. For each PCR, 5 µl of RT sample was used to-
gether with GAPDH forward (5′-AGGGGT CATTGA TGGCAA CAATAT CCA-3′) and reverse primers
(5′-TTTACC AGAGTT AAAAGC AGCCCT GGTG-3′) for mammalian samples, and PDA1 forward (5′-
GGTCAG GAGGCC ATTGCT GT-3′) and reverse primers (5′-GACCAG CAATTG GATCGT TCTTGG-
3′) for yeast samples. Primers used for the amplification of HBx were the same as those used in the
construction of the expression vectors.
2.2.9 Protein Disorder and Protease Susceptibility Prediction
Prediction of protein disorder was carried out by analysing the amino acid sequence of HBx obtained
from pCR-HBVA1 1.3x (102) using the GLOBPLOT (114), RONN (115), IUPRED (116), PRDOS (117) pre-
dictive algorithms. Websites for these algorithms can be found on the DISPROT website (118). Pro-
tease sensitive sites were predicted using PESTFIND (119) and D-BOX Finder (120).
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2.3 Results
The results described below offer a logical account of the experiments performed to express HBx in
the yeast and mammalian cells. Initial expression experiments focussed on S. cerevisiae expression
vectors. Despite the use of varied conditions for both the expression and detection of HBx, protein
was not detected using Western blot analysis. This problem could be as a result of issues in the
transcription of HBx DNA or translation of resultant HBx mRNA. The presence of full length HBx
mRNA was confirmed in induced cells and in all assayed vectors, thus indicating that the problem
lay with the translation of HBx mRNA or subsequent detection steps, rather than the transcription
of the HBx DNA. A GFP fusion protein was thus constructed so that HBx could be visualised using
fluorescence microscopy and thus determine if the problem lay with translation of HBx mRNA. The
positive visualisation of fluorescent, intracellular GFP-Intein-HBx fusion protein offered evidence
that HBx was being translated into protein in both S. cerevisiae and mammalian cells and thus the
detection problem was a result of either HBx purification or antibody detection. This same protein
was purified using the 6xHIS tag on the C-terminus and analysed using mass spectrometry (MS).
Only peptides from the GFP portion of the fusion protein were identified. This result nonetheless
indicated the presence of HBx due to the use of a 6xHIS tag. The MS results suggested that
the antibodies used for HBx detection where not binding their respective antigenic sites under the
conditions tested in Western blots.
To determine whether the antibodies used could bind to HBx before any purification or detection
steps mentioned thus far, immunofluorescence microscopy was performed on induced S. cerevisiae
and mammalian cells using the four in-house anti-HBx antibodies and a commercial anti-HIS anti-
body that had been used on Western blots. Results strongly suggested that all the antibodies did
indeed bind to HBx under the conditions tested.
Detailed consideration of all results indicated that the monoclonal antibodies used for Western
blots did not bind eukaryotic HBx when exposed to the denaturation steps during Western blotting,
whereas E. coli expressed HBx was not affected by those same denaturation steps. A detailed
description of the results obtained in this work are presented below.
2.3.1 pET-ELPI-HBx protein purification
Although measurable quantities of HBx were purified from the pET-ELPI-HBx system (Fig 2.2-C), this
vector was not used further due to reproducibility problems and significant protein losses during the
salting-out steps. Specific problems included inconsistent cleavage of HBx from the ELPI backbone,
loss of HBx when applied to a G-75 column and difficulties in re-solubilising the ELPI-HBx protein
pellet after salting out. The ELPI system, like other tags, does not offer a purification panacea for all
proteins. The behaviour of the tag has not been perfected, and any difficile biophysical properties of
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the attached protein (i.e. HBx) are not nullified by the presence of the ELPI tag.
2.3.2 Evaluation of S. cerevisiae Expression Vectors
2.3.2.1 pYES2 vectors
As summarised in Table 2.1, numerous expression conditions and plasmid vectors were used in an
attempt to express HBx in eukaryotic cells. Initially, the galactose-driven pYES2 system was used,
and in spite of variations to the expression conditions such as expression temperature (25 ◦C to
37 ◦C), induction time (4-24 hours), growth media (defined and complex media), different S. cere-
visiae protease deficient strains (YVH10, BJ3505 and CEN.PK2) and induction ODs (0.1-0.6), the
presence of the HBx was never detected by Western blotting using the anti-HBx antibodies devel-
oped in-house, or the commercial anti-HIS (Genscript, NJ, USA) and anti-HBx (Acris Antibodies,
Germany) antibodies. This is shown clearly in Figure 2.2-A. The non-detection was surprising con-
sidering that GAL promoters are the most tightly regulated and powerful promoters in the GAL gene
family (reviewed in (121)). Typically, induction with galactose causes a 1000 fold increase in mRNA
transcription (122). The possibility of HBx being present in the insoluble fraction was also tested, but
again no HBx was detected by Western blot (data not shown). Attempts to concentrate any HBx that
may have been expressed were also tried using HIS purification and TCA precipitation methods, but
this also did not yield any positive results possibly due to HBx instability and non-binding of primary
antibodies to HBx.
2.3.2.2 YEp vectors
In an attempt to make the purification of HBx protein easier, the protein was cloned upstream and
inframe of a secretory α-mating factor. The YEp vector is driven by the ADH2 promoter, which is
repressed 100 fold by glucose (123), making it useful in the expression of toxic proteins, such as may
be the case with HBx (124). Similar conditions tested for the pYES2 vectors were tested for the YEp
vectors including a greater range of induction times (48-96 hours). Protein samples analysed by
Western blot yielded the same results as for the pYES2 vectors, except that a supernatant fraction
was included to test for secretion. Protein expression was not detected by Western blot under any of
the conditions tested (Fig 2.2-A). Attempts to concentrate any HBx that might have been present in
the supernatant using batch HIS purification and Amicon ultrafiltration (Millipore, USA, 5kDA MWCO)
methods also did not yield any detectable protein.
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Figure 2.2: Representative compilation of the Western blots obtained using the anti-HBx antibodies.
A - Western blot of pYES2 protein samples, including lysate and supernatant with anti-HBx 6.1
antibody. No HBx was detected in any of the samples. B - Western blot of YEp as in A. C - Western
blot of pCI-Neo proteins samples as in A and B. D - Western blot of E coli 6xHIS-HBx protein
samples using various anti-HBx antibodies. HBx was detected in all samples. E - Coomassie stain
and Western blot of E. coli pET-ELPI-HBx protein using anti-HBx 6.1 antibody. HBx was detected
using both methods.
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Table 2.1: Summary of different HBx expressing clones, experimental conditions used and results obtained.
Construct Cell line Tag Induction time Media Temperature WB1 mRNA Purification
pET15B-HBx E. coli BL21 HIS 4 hours LB 37 ◦C YES NA Urea-HIS
pET-ELPI-HBx E. coli BLR-DE3 Elastin 48 hrs TB 25 ◦C NO NA1 Salt
pYES2-HBx S. cerevisiae YVH10 None 12 hours YPG1 30 ◦C NO YES None
pYES2-HHBx S. cerevisiae YVH10 HIS 12 hours YPG 30 ◦C NO YES HIS
pYES2-GFP-I-X S. cerevisiae YVH10 GFP, HIS 12 hours YPG 30 ◦C NO YES HIS
YEp-HBx S. cerevisiae YVH10 HIS 48-72 hours YPD1 30 ◦C NO YES None
YEp-HHBx S. cerevisiae YVH10 HIS 48-72 hours YPD 30 ◦C NO YES HIS
YEp-GFP-I-HBx S. cerevisiae YVH10 GFP, HIS 48-72 hours YPD 30 ◦C NO YES HIS
pCI-Neo-HBx HEK293T None 48 hours DMEM 37 ◦C NO YES None
pCI-Neo-HBxco HEK293T HIS 48 hours DMEM 37 ◦C NO YES HIS
pCEP4-GFP-I-HBx-6xHIS HEK293T GFP, HIS 48 hours DMEM 37 ◦C NO YES HIS
1WB - Western blot, YPD - Yeast Extract Peptone and Glucose, YPG - Yeast Extract Peptone Galactose, TB - Terrific Broth, co - codon-optimised, NA - Not Applicable
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2.3.3 Western blot Analysis
The presence of HBx in each of the expression vectors was tested under different expression con-
ditions. Results repeatedly showed no detection of HBx protein in any of the samples taken from
the eukaryotic cells (Fig 2.2 A). The positive controls of E. coli expressed 6xHIS-HBx, HBx protein
purified from pET-ELP-I-HBx vectors (Fig 2.2 B and C) and the generic size standard (EasyWestern,
Genscript, NJ, USA) were easily detected. A variety of blotting conditions (Nitrocellulose, 0.2 µm
and 0.45 µm PVDF, BSA, milk powder, overnight incubation at 4 ◦C) yielded no detection in signal
from any of the samples.
2.3.4 Detection of HBx mRNA in induced cultures and cell lines
To determine whether the problem of non-detection of HBx lay with transcription of HBx DNA or
translation of HBx mRNA, the presence of full-length mRNA from the various constructs was deter-
mined (Fig 2.3). In all cases, full-length mRNA of HBx was detected, and this should have resulted
in translation of the mRNA. This assay was not a quantitative measurement of mRNA, but rather a
qualitative indication that HBx mRNA was present, which indirectly indicated the presence of HBx
protein. The pCEP4-GFP-I-HBx vector full-length 1700 bp mRNA sample could not be amplified,
although the HBx and GFP portions could be separately amplified (Fig 2.3-C).
Figure 2.3: Negative exposure of RT-PCR products run on 1% agarose gels. A - pYES2 based
constructs, B - YEp based contructs, and C - pCEP4 and pCI-Neo based constructs. Bands indicate
the presence of full-length mRNA (Sizes of amplicons are as follows PDA1 - 672 bp, GAPDH - 100bp,
HBx - 465bp, GFP - 723 bp, GFP-I-HBX - 1722 bp). RT-PCR controls included amplification of a
housekeeping gene (PDA1 for S. cerevisiae and GAPDH for mammalian cells) plus an RT- reaction
to control for plasmid DNA contamination.
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2.3.4.1 GFP-Intein fusion vectors
To exclude the possibility that HBx was not being translated from mRNA or that the detection
methodology was misleading, a GFP fusion protein with HBx was constructed to directly visualise
expression using fluorescence microscopy. The data were promising, as the fluorescence level of
GFP in all the constructs was high as shown in Figs 2.9, 2.12, 2.13. This indicated that induction
was occurring and at least part of the fusion protein was being translated. However, attempts to
detect the fusion protein using Western blot failed, even after protein was purified using the HIS tag
on the C-terminus of the HBx segment of the fusion. This indicated either antibody binding or HBx
purification problems.
2.3.5 Mass Spectrometry
To determine if the non-detection of HBx was an antibody binding problem, a purification issue, or
whether the entire GFP-I-HBx fusion protein was being translated, protein that had been isolated
from the mammalian pCEP4-GFP-I-HBx-6xHIS expression vector was run on an SDS-PAGE gel.
After aldehyde-free silver staining, protein bands were excised, processed and analysed by MS. Of
the 10 protein bands submitted, only fragments identified from the GFP section of the fusion peptide
were detected (Fig 2.4). As the purification of the fusion peptide used a C-terminus 6xHIS tag,
this indicated that HBx was present during the purification process and that the fusion protein was
intact, but losses during cleavage of intein motif, proteolysis or autolytic cleavage during processing,
resulted in an HBx concentration lower than the nanogram limit of silver staining detection. This
indicated that there were antibody binding problems and/or HBx purification problems.
Figure 2.4: Peptides identified with greater than 90% certainty after mass spectrometry. There were
no positive hits from protein bands identified from the Intein or HBx segments of the fusion protein.
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2.3.6 Immunofluorescence detection of HBx protein in induced yeast cultures and
mammalian cell lines
Immunofluorescence (IF) microscopy was performed to determine whether the denaturation condi-
tions used in IF were more suited for the antibodies to bind to HBx compared to those used with
Western blotting (i.e. paraformaldehyde versus SDS, heat and methanol). If IF was successful, it
would show that non-fusion vectors were producing HBx protein and thus indicate that aberrant an-
tibody binding and HBx purification problems were chiefly responsible for non-detection of HBx by
Western blot.
pYES2 and YEp constructs Both the pYES2 (Fig 2.6) and YEp (Fig 2.8) vectors showed a strong
signal for HBx binding with all the anti-HBx and anti-HIS antibodies tested. As expected, HBx was
detected throughout the yeast cell with the pYES2 vectors, and the YEp vectors showed a strong
localisation of HBx to the periphery of the cell suggesting that the α mating factor secretion mecha-
nism was functional.
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Figure 2.5: Immunofluorescence microscopy images of HBx staining in S. cerevisiae cells expressing the pYES2-HBx vector. Antibodies specific to each figure
are shown in the top left corner. Blue indicates DAPI staining and red indicates anti-HBx antibodies bound to a Cy3 conjugated secondary antibody. Cy3
fluorescence was not detected in samples containing primary or secondary antibody alone. Samples containing both primary and secondary antibodies showed
significant Cy3 fluorescence. Magnification is 100x and scale bar = 5µm.
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Figure 2.6: Immunofluorescence microscopy image compilation of the S. cerevisiae non-secreted, 6xHIS tagged, pYES2-HHBx vector. Antibodies specific to
each figure are shown in the top left corner. Blue indicates DAPI staining and red indicates anti-HBx/HIS antibodies bound to a Cy3 conjugated secondary
antibody. There was minimal Cy3 fluorescence in samples only containing primary or secondary antibody alone. All samples of this vector showed significant
Cy3 fluorescence by the secondary antibody bound to the anti-HBx and anti-HIS antibodies. Magnification is 100x and scale bar = 5µm.
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Figure 2.7: Immunofluorescence microscopy image compilation of the yeast secretory YEp-HBx vector. Antibodies specific for each figure are shown in the top
left corner. Blue indicates DAPI staining and red indicates anti-HBx/HIS antibodies bound to a Cy3 conjugated secondary antibody. The Cy3 signal is lower in
the samples containing both primary and secondary antibodies compared to the other yeast vectors. Interestingly, the Cy3 fluorescence was localised to the cell
periphery. Magnification is 100x and scale bar = 5µm.
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Figure 2.8: Immunofluorescence microscopy image compilation of the yeast, secreting, HIS tagged YEp-HHBx vector. Antibodies specific for each figure are
shown in the top left corner. Blue indicates DAPI staining and red indicates anti-HBx/HIS antibodies bound to a Cy3 conjugated secondary antibody. There is
minimal Cy3 fluorescence in samples containing only primary or secondary antibody. Samples containing both antibodies show a strong Cy3 fluorescence. Cy3
was not localised to the cell periphery to the same degree as Fig 2.7, but Cy3 signal was strong with all the antibodies used. Magnification is 100x and scale bar
= 5µm.
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Mammalian pCI-Neo and GFP-Intein constructs Co-localisation of the GFP (green) and HBx
(Cy3, red) channels of GFP-Intein constructs are shown in yellow (S2, S3 and 6.1 + Secondary in
Fig 2.9). Interestingly, the anti-HBx S1 antibody did not show Cy3 fluorescence, indicating that the
antibody did not bind to HBx, possibly due to site availability. In the pCI-Neo constructs, the S2, S3
and 6.1 anti-HBx antibodies for the wildtype pCI-Neo-HBx showed very weak Cy3 fluorescence with
samples containing both primary and secondary antibodies (Fig 2.10).
The only antibody indicating HBx presence in Fig 2.10 was S1. Interestingly, although the codon
optimised pCI-Neo-6xHIS-HBx (Fig 2.11) did not indicate Cy3 fluorescence to the levels of Fig 2.9,
it nonetheless showed an increase Cy3 fluorescence over the wildtype (Fig 2.10) as indicated by
fluorescence intensity.
Figure 2.9: Maximum intensity projections (MIP) from Z-stacked immunofluorescence microscopy
images of HEK293T cells expressing the pCEP4-GFP-I-HBx-6xHIS fusion vector. Antibodies spe-
cific to each image are shown in the top left corner. Blue indicates DAPI staining and red indicates
anti-HBx/HIS antibodies bound to a Cy3 conjugated secondary antibody. Antibodies 6.1, S2 and S3
show good co-localisation of GFP and Cy3 fluorescence whereas S1 plus secondary shows no Cy3
fluorescence at all. Non-specific Cy3 fluorescence is low as shown by the primary, secondary and
non-antibody controls. Magnification is 100x for the two left panels, and 60x for the right panel, the
scale bar = 10µm.
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Figure 2.10: Maximum intensity projections (MIP) from Z-stacked immunofluorescence microscopy
images of HEK293T cells expressing the wildtype pCI-HBx vector. Antibodies specific to each image
are shown in the top left corner. Blue indicates DAPI staining and red indicates anti-HBx/HIS anti-
bodies bound to a Cy3 conjugated secondary antibody. Cy3 fluorescence is low in the S1, S2, S3
and 6.1 plus secondary antibody samples. Only the S1 antibody shows notable Cy3 fluorescence.
Magnification is 60x and scale bar = 10µm.
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Figure 2.11: Maximum intensity projections (MIP) from Z-stacked immunofluorescence microscopy images of HEK293 cells expressing the codon optimised
pCI-6xHIS-HBx. Antibodies specific to each image are shown in the top left corner. Blue indicates DAPI staining and red indicates anti-HBx/HIS antibodies
bound to a Cy3 conjugated secondary antibody. The anti-HIS, S1 and 6.1 plus secondary antibodies showed high Cy3 fluorescence, whereas the S2 and S3
antibodies plus secondary antibody showed weak Cy3 fluorescence. Magnification is 60x and scale bar = 10µm.
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Yeast GFP-Intein constructs The YEp-GFP-I-HBx vector showed a strong Cy3 fluorescence for
all of the antibodies tested (Fig 2.12). The pYES2-GFP-I-HBx showed a high Cy3 fluorescence,
with saturation of the 6.1 and anti-HIS antibodies. The S1, S2 and S3 antibodies showed less
fluorescence intensity upon binding. Overlapping fluorescence intensities indicated co-localisation
suggesting either the presence of GFP and HBx in the same region of the cell, or the presence of
complete GFP-I-HBx fusion protein.
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Figure 2.12: Immunofluorescence microscopy image compilation of S. cerevisiae expressing the YEp-GFP-I-HBx-6xHIS vector. Antibodies specific to each
image are shown in the top left corner. Blue indicates DAPI staining whereas red indicates anti-HBx/HIS antibodies bound to a Cy3 conjugated secondary
antibody. A merge of the Cy3 and GFP channels indicates co-localisation of HBx and GFP (yellow/orange). Cells showed strong GFP fluorescence, and co-
localisation of Cy3 in most cells containing a primary and secondary antibody. Certain cells showed only GFP or Cy3 with no co-localisation. Magnification is
100x and scale bar = 5µm.
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Figure 2.13: Immunofluorescence microscopy image compilation of S. cerevisiae cells expressing the pYES2-GFP-I-HBx-6xHIS vector. Antibodies specific to
each image are shown in the top left corner. Blue indicates DAPI staining whereas red indicates anti-HBx/HIS antibodies bound to a Cy3 conjugated secondary
antibody. A merge of the Cy3 and GFP channels indicates co-localisation of HBx and GFP (yellow/orange). Antibodies S1-S3 showed weak Cy3 fluorescence
and co-localisation, whereas 6.1 and anti-HIS antibodies showed very strong Cy3 fluorescence. Magnification is 100x, the scale bar = 5µm.
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2.3.7 Protease Sensitivity and Disorder Prediction
A variety of prediction parameters can be used to evaluate the likelihood of disordered structure of
amino acid combinations in a protein. Four separate algorithms were used in the evaluation of HBx,
and the results were similar with all four.
The GLOBPLOT (Fig 2.14-A) algorithm is the simplest of the four algorithms and is based on
a running sum of the propensity for amino acids to be in a globular or non-globular state (114). The
algorithm predicted a disordered region (blue regions) between amino acids 25 to 52 of HBx, and a
globular domain (green regions) from amino acids 58 to 145.
The RONN algorithm (Fig 2.14-B) is claimed by the authors to be the most accurate algo-
rithm (115). RONN (regional order neural network) compares unknown sequences with a series of
sequences that have known folding states (ordered, disordered or a mixture of both). Alignment
scores against these known sequences are then used to classify the disorder of each unknown
sequence by using a suitably trained neural network. This algorithm predicted a disordered region
between amino acids 20 and 60 of HBx.
IUPRED (Fig 2.14-C) has the underlying assumption that globular proteins are composed of
amino acids which have the potential to form a large number of favourable interactions, whereas this
does not occur in disordered proteins because their amino acid sequence does not allow favourable
interactions to occur (116). This algorithm shows a weaker prediction for disorder between amino
acids 25 and 55 of HBx compared to the other tests.
The fourth algorithm used (Fig 2.14-D), PRDOS, utilises two predictors: the first is implemented
using a support vector machine algorithm which is then combined with the second predictor which
assumes the conservation of the intrinsic disorder of protein families and is an implementation of
PSI-BLAST (Position-Specific Iterated BLAST). The developers of the algorithm noted that this algo-
rithm is especially suited for the prediction of short disordered regions (117). This algorithm predicted
a disordered region between amino acids 25 and 45 of HBx.
The algorithms described above consistently predicted that amino acids between 20 and 50 rep-
resent a potentially disordered region. A prediction of HBx protease sensitivity was also performed to
determine whether proteolysis could be a contributing factor in the non-detection of HBx on Western
blots. HBx was computationally tested for PEST and D-BOX motifs. PEST regions are rich in proline
(P), glutamic acid (E), serine (S), and threonine (T) and are associated with a short intracellular half-
life (125,126). D-BOX is a sequence recognised by the Anaphase Promoting Complex (APC/C) that
in turn brings together the E2 ubiquitin-conjugating enzyme and the D-BOX. This results in protein
ubiquitination and degradation. A D-BOX is characterised by amino acid sequences comprised of
RLXXXXN, where R is arginine, X is any amino acid, L is Leucine, and N is asparagine.
Interestingly, analysis of HBx showed that the 20-50 bp region is predicted to have protease
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Figure 2.14: Protein sequence disorder predictions from four different algorithms A - GLOBPLOT.
Russel-Linding (black line) plots the occurrence of coils with high temperature factors, raw data is
plotted as a red line, disordered regions are shown as blue blocks, and globular domains (Globdom)
are shown as green blocks, B - RONN - probability disorder is plotted as a blue line and the threshold
for disorder is set at 0.5, C - IUPRED - probability disorder is shown in blue, with the threshold (black)
set at 0.5. D - PRDOS - probability disorder is plotted as a dotted black line with disordered residues
show in red above the threshold of 0.5.
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sensitivity sites (PEST and D-BOX sites, Fig 2.15). Even though the scores of the predicted sites
for PEST (4.17 and -12.57) and D-BOX regions were not high, it is nonetheless an indication that
this region of HBx is sensitive to proteolysis. Additionally, an Instability Index (a measure of the
summation of the weight values of dipeptide instability normalised over the length of the protein),
shows HBx to have a measure of 59.10, classifying the protein as unstable (>40), compared to a
stable protein with a value of <40 (127).
Figure 2.15: Predicted PEST and D-BOX regions in the protein HBx. HBx has two poorly predicted
PEST sites (shown in red), between amino acids 33-49 (score = 4.17), and 98-111 (score = -12.57).
Both sites are poorly predicted as they are below the 5.0 threshold. A D-BOX sequence (shown as
vertical lines in green) is predicted to occur between amino acids 32-36, but the alignment E-value
has a low score of 0.16. These sites would need to be validated experimentally to determine if they
do occur.
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Figure 2.16: A far-UV CD-spectrograph of purified HBx from Liu et al (128). The spectrograph indi-
cates β-sheet structure(s) shown as a positive peak at 194 nm (A) and a negative shoulder at 218
nm. The two negative troughs (207 and 222nm, shown as B) are characteristic of α-helical struc-
ture(s). The weak positive peak between 220-230 nm (C) is characteristic of a disordered protein
structure.
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2.4 Discussion
The expression and purification of soluble and pure eukaryotic proteins is a critical point in the de-
termination of their secondary structures. There has been little success in expressing soluble HBx
protein, and there have been no published studies on the recombinant expression and purification
of HBx using eukaryotic cells. HBx has unsurprisingly also evaded high resolution X-ray crystallo-
graphic and NMR structural determination. To address this in the current body of work, HBx was
expressed in two different S. cerevisiae expression systems, with one permitting secretion of HBx.
Expression was also performed in mammalian cells using either a wildtype, a codon optimised HBx
or a GFP-Intein-HBx fusion protein sequence.
Despite the use of several expression systems, cell types and protease deficient S. cerevisiae
mutants, it was a challenge to determine why neither intracellular, secreted, 6xHIS tagged nor un-
tagged HBx protein could be detected using Western blotting (Fig 2.2-A). The use of numerous
expression and detection conditions together with the positive detection of E. coli denatured HBx
(Fig 2.2-B and C) raised concerns that transcription of HBx mRNA or the translation of HBx pro-
tein was not occurring. The premature termination of HBx transcription resulting from the presence
of cryptic poly-A sites or other terminating sequence determinants were thus the first possibilities
tested. RT-PCR of total RNA extractions from induced cells indicated that full length HBx mRNA
was indeed present within the induced cells and thus available for translation into HBx protein (Fig
2.3). The absence of a full length mRNA for the pCEP4-GFP-I-HBx vector can be explained by am-
plification problems, as the individual HBx and GFP portions of the mRNA could be amplified (Fig
2.3-C). Taken together, these results suggested that aberrant transcription was not the reason for
non-detection on Western blots. Whilst this experiment was not done quantitatively, it is not certain
that Q-PCR would have yielded informative data as several research groups have demonstrated in
both E .coli and S. cerevisiae (129) that mRNA and protein levels do not generally correlate (130,131).
As full length transcripts were detected for all of the expression plasmids, we decided to eliminate
any problematic structural motifs and rare codons within the HBx sequence that could negatively
affect translation. We obtained codon optimised HBx sequences for human and yeast cells. Nu-
merous examples regarding the positive effect codon optimisation has had on recombinant protein
production have been recorded for E. coli (132), S. cerevisiae (133), Pichia pastoris (134) and human
cells (135). Disappointingly, the benefit that codon optimisation might allow for HBx expression was
nullified as the codon optimised constructs showed no improvement in detection over the wildtype
HBx sequences using Western blots (Fig 2.2-A). These results suggested that the non-detection of
HBx was either a result of the lack of experimental rigour, the non-translation of HBx due to unde-
termined factors, or problems with the methods and reagents used in the detection of HBx protein.
To eliminate the possibility of experimental rigour being at fault, two separate researchers in
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different laboratories, using different reagents and equipment were tasked with expressing HBx in
mammalian systems and trying to detect HBx using Western blot. In both of these instances, positive
controls, which were either HBx purified from pET15B-HBx (Table 2.1) for the anti-HBx antibodies
or the HIS protein ladder from Qiagen for the anti-HIS antibodies, were detected. None of the
samples containing denatured eukaryotic HBx could be detected on the Western blots (data not
shown, personal communication with Kubendran Naidoo and Naazneen Moolla).
The combination of (1) negative Western blots using eukaryote expressed HBx, (2) positive
detection of prokaryote expressed HBx and (3) positive mRNA detection from eukaryotic vectors,
raised the possibility that HBx was either not being translated from its cognate mRNA or that anti-
body detection was problematic. To test the first hypothesis, immunofluorescence microscopy was
performed on cells transformed with the expression vectors listed in Table 2.1 using suitable nega-
tive controls to discount non-specific antibody interactions (Fig A.1 to A.6). Interestingly, the pYES2
(Figs 2.5, 2.6, 2.13), YEp (Fig 2.7, 2.8, 2.12) and pCEP4 (Fig 2.9) constructs showed a strong signal
for HBx-antibody binding. This indicates quite convincingly that the translation of HBx was indeed
occurring, and that the problems experienced with its detection occurred post cell lysis. To confirm
these results, mass spectrometric analysis of pCEP4-GFP-Intein-HBx-6x-HIS purified protein (Fig
2.4) showed that at a minimum, the GFP portion of the protein could be detected. The non-detection
of HBx using MS was unsurprising considering the previous technical difficulties in visualising HBx
using silver stained SDS-PAGE gels and Western blots. As the purification of GFP depended on the
presence of HBx due to the 6xHIS tag on the C-terminus of the protein, the presence of GFP could
be construed as indirect confirmation of HBx presence.
These interesting results and the confounding positive HBx detection obtained from the E. coli
pET-ELPI-HBx and pET15B-HBx plasmids provided important points for consideration. Was the
native structure of eukaryotic HBx prone to aggregation and proteolysis? Alternatively, was non-
detection a result of post-translational modifications to HBx such that purification and or detection
attempts were thwarted? Additionally, were experimental conditions altering the antigenic sites that
the anti-HBx (6.1, S1, S2 and S3) and anti-HIS antibodies recognised, thus preventing recognition?
Lastly, were the screening conditions under which the anti-HBx antibodies selected inappropriate for
Western blot assays of eukaryotic HBx?
To consider the first point, that HBx is possibly prone to aggregation and proteolysis, work done
by Liu et al (128) and recently extended by Basu et al (136) indicated that HBx has disordered re-
gion(s) within its secondary structure, particularly between amino acids 25 to 52. This important
finding was deduced from the weak positive peaks between 220-230 nm using far-UV CD-spectra
of soluble HBx (Fig 2.16). It is now well established that the proportion of disordered proteins in the
genomes of Eukarya range from 35-51% (137) and is thus not an uncommon occurrence. Sequence
constraints (e.g. small overlapping viral genomes such as HBV) mean that having disordered re-
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gions within proteins allows a greater range of interactions (e.g. protein-mediated regulation and
cell control, signal transduction and transcription regulation) as compared to proteins with more rigid
structures. Greater ranges of interactions are obviously incompatible with rigid and static tertiary
structures (138,139). Certainly, disorder seems to be a characteristic of many viral proteins (140) and
HBx is a good example if one considers the numerous interactions ascribed to it. Intrinsically dis-
ordered or unstructured proteins (IDP/IUP) are able to adopt secondary structures depending on
stimuli or interactions with a binding partner. This structural plasticity allows an exceptionally diverse
range of interactions depending on the state of the cell, and is termed binding promiscuity (141) or
”one to many” signalling (142).
Importantly for this work, there are technical problems for recombinant protein production involv-
ing proteins with disordered regions as they are known for their proteolytic susceptibility (143). Even
so, disordered motifs may avoid degradation through several mechanisms such as the protection
of disordered sites by steric factors, the lack of protease sensitive residues within disordered se-
quences and the possibility that disordered regions may exist only transiently, as proteins move from
one binding event to another (144). This has been demonstrated with calmodulin which becomes
sensitive to proteases when Ca2+ levels drop thus leaving its enzymatic partners to bind with pro-
teins containing IQ motifs instead (145,146). However proteasomes can degrade disordered proteins
directly, without prior ubiquitination, (147–149) and an unstructured initiation site is required even for
degradation of tightly folded but ubiquitinated proteins. Even though a ubiquitin tag by itself it not
sufficient for proteasome degradation (150), it would be interesting to see if the co-expression of a de-
scribed binding partner would reduce the chance of HBx being ubiquitinated (151) and thus degraded
or whether a binding partner could prevent direct proteolysis by direct action of the proteasome. Ad-
ditionally proteasome deficient mutants could be used to determine the protective effects of binding
partners.
The half life of proteins is determined by a number of interacting factors not just disorder or pro-
tease sensitivity. Bioinformatic analysis of HBx weakly predicted the presence of two signal peptides
that could increase HBx degradation. These include D-BOX and PEST sequences (Fig 2.15), and
all predicted sites overlap with the predicted disordered region described above. D-BOX patterns
tend to fall within locally disordered regions (152) and PEST sequences are known to correlate with
protein disorder (153) and to be a partial determinant of protein turnover (125,126,154). These predicted
sites (amino acids 25 to 60) are within the negative regulatory domain (amino acids 1 to 50) and are
next to the start of the trans-activation domain (amino acids 51 to 154) (155). It is unclear how this
disordered region is involved in either negative regulation mechanisms or if it is involved in trans-
activation and/or co-activation (156) without further studies. However it is an important observation
regarding the structure and function of HBx. Protein disorder may be a major determinant of protein
degradation, but is by no means the only factor, even though disorder has been demonstrated to
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play a bigger role than motifs like the D-BOX or PEST sequences. Protein degradation is ultimately
determined by multiple factors which may carry different weighting depending on the protein (144).
From the data, it seemed however that the structural and biophysical peculiarities of HBx, whilst
helping explain the inherent difficulties in working with this protein, were not an adequate explanation
for its non-detection. Certainly the points discussed above may be compounding factors in the non-
detection of HBx, but the shear lack of signal from Western blots suggested that the explanation
had more to do with antibody detection and secondary structure modifications, rather than problems
with the expression of HBx protein which would have shown a faint or degraded signal rather than
no signal at all.
The issue of antibodies and antigenic sites has been in the fore recently, with projects like the
Human Protein Atlas rigorously validating commercially available antibodies and finding that only
35% work under the conditions tested (157). Although reasons for these antibody failures were not
stated, it seems reasonable that careful characterisation has not taken place for many commercially
available antibodies and that their detection abilities are thus overstated by companies and over-
estimated by researchers. This under-characterisation of antibodies almost certainly occurs with
in-house antibodies as well. The selection of antibodies is a very sensitive procedure, and care
should be taken when preparing the target protein for selection. As the anti-HBx antibodies used
in this project were raised against urea-denatured, E. coli expressed HBx, it can be reasonably
assumed that antibodies that were selected would either fail to bind to the eukaryote derived HBx
entirely, or would share some antigenic determinants and conformational features between the eu-
karyotic and prokaryotic HBx. The denatured E. coli HBx used for antibody selection may also have
undergone further denaturation when combined with Freund’s adjuvent, or undergone proteolysis
when injected into mice, thus further complicating selection conditions. This could promote the se-
lection of antibodies that recognise unfolded or degraded protein, and if subsequent assays did not
test for authentic recognition of eukaryotic HBx, it is likely that antibodies were selected that recog-
nise HBx only under certain circumstances. It follows that multiple selection methods of antibodies
(i.e ELISA and/or Western blot against E. coli denatured and native eukaryote derived HBx) are im-
portant in determining whether antibodies work in different immunoassays. It is vital to keep in mind
that studies have shown that rapidly binding monoclonal antibodies recognise epitopes on the native
protein, whereas antibodies that react slowly in solution bind preferentially to the denatured form of
the protein (158,159). As experienced in this work, the anti-HBx antibodies probably recognised E. coli
denatured HBx epitopes better than the eukaryotic native or denatured epitopes. This has been
shown to occurr with other proteins such as the β2-subunit of E. coli tryptophan synthase (160). The
antibodies used must have bound antigenic determinants which revealed themselves upon partial
or total unfolding of denatured E. coli derived HBx (160), which is known to occur when a protein is
immobilised on a solid phase support such as an ELISA plate. Furthermore, antigen conformation
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on a solid phase may frequently be different to the conformation found in solution and that screening
by ELISA, in which the antigen is attached to a solid phase, can be misleading in determining useful
monoclonal antibodies (161). Overall et al suggested that the presentation of epitopes to antibodies
should ideally occur in solution, although if this is not possible due to protein solubility problems,
then screening methods should extend to other solid supports such as Western blot (162). Indeed
indications are that this is not the first study to experience problems with antibody specificity against
HBx (78). Thus it seems that immunogenic determinants are shared between eukaryotic HBx protein
and denatured E. coli HBx. These epitopes are easily recognised by ELISAs using denatured E.
coli derived HBx, and immunofluorescence detection of eukaryotic HBx, but not denaturing Western
blots of eukaryotic HBx. The non-detection of denatured eukaryotic HBx by Western blot seems to
suggest that the problem concerns not only the antibodies used, but also the structure of the epi-
topes the various antibodies bind to, the antibody selection procedures used, and effects of various
denaturation procedures on eukaryotic HBx structure. For clarification, during SDS-PAGE, eukary-
ote native HBx is heat-denatured with SDS at 95 ◦C, which causes a certain denatured structure,
whereafter the transfer of HBx to PVDF membrane involving a 20 % methanol Towbin transfer buffer
adds another level of denaturation. These successive denaturation steps could result in cumulative
alterations to the HBx secondary structure, such that the antigenic sites are no longer present or
recognised. This altering of epitopes of native HBx, including 6xHIS, is the most likely explanation
for the non-detection of eukaryotic HBx in Western blots with the antibodies used. It is likely that
the recognised epitopes of eukaryotic HBx are discontinuous (i.e. an epitope where the amino acids
are in close proximity in the folded protein, but distant when unfolded). These discontinuous epi-
topes are most likely hidden or destroyed when certain denaturing conditions are experienced by
HBx under Western blots. Overall, these results illustrate the importance of determining whether an
antigen recognised by an antibody is present in both native and denatured forms of the protein (160).
Despite the technical problems regarding antibody recognition of HBx, the protein was successfully
expressed in both S. cerevisisae and mammalian cells. Future work will need to focus on improving
expression levels through additional HBx sequence optimisation and the use of other detection tags
such as FLAG or c-myc that might allow detection via Western blot. This work also illustrates inter-
ventions and experiments to consider when trying to produce proteins that are difficult to work with
due to solubility, stability, antigenicity, proteolytic or detection problems. Considering the stability,
solubility and antigenic challenges encountered with trying to express HBx using the systems de-
scribed in this chapter, work aimed at improving these was conducted and is described in Chapter
3.
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Chapter 3
Expression and Purification of HBx
Protein using a combination of Maltose
Binding Protein Tag and Semliki Forest
Virus
3.1 Introduction
The difficulty in expressing and detecting native HBx protein in eukaryotic cells detailed in Chapter 2
prompted the evaluation of alternative antibody targets for HBx detection as well as alternative sys-
tems of expression. Large fusion tags that can be detected using antibodies should ideally increase
solubility and permit the rapid and simple purification of proteins such as HBx. In addition, fusion
tag expression systems should be easily scaled and have been reported to show good expression
for a variety of proteins.
Transient expression systems combined with solubility enhancing tags (e.g. thioredoxin, GST
and NusA) allow the researcher to express and purify recombinant proteins with improved solubility,
stability and rapidity. A popular solubility tag is Maltose Binding Protein (MBP) which is a native
E. coli expressed protein that is effective in promoting the solubility and native folding of proteins
fused to it (163). MBP displays the best solubility enhancing properties compared to glutathione-S-
transferase and thioredoxin when tested with a passenger group of aggregation prone proteins (163).
It is unclear whether this enhanced ability is due to chaperone-like properties (164–166) or merely
passivity (167). Nonetheless, Liu et al recently used this tag to express and purify soluble HBx in
E. coli (128). This system presented a good starting point from which to produce soluble HBx in a
mammalian expression vector.
Semliki Forest Virus (SFV), is one such vector which has been used to express a wide range of
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proteins, including those that are membrane bound, G-protein-coupled receptors and ligand-gated
ion channels (168–170). Importantly for HBx, SFV has been used to express the structural proteins of
HBV (171), as well as the polymerase (172).
SFV-derived vectors are amongst the most studied Alphavirus vectors used for recombinant pro-
tein expression due to a number of advantages. The virus has a broad host range, and so a variety
of cellular backgrounds may be used to express proteins. These vectors may be used to express
protein either in vitro or in vivo. Expression typically occurs when a heterologous gene sequence
replaces a viral structural protein that is required for the encapsidation of viral RNA. Current versions
of the SFV vector are based on helper RNAs, and in some cases two helper RNAs (173), where the
viral capsid and spike proteins have been cloned into separate vectors. Co-transfection of all the
plasmids into cells results in the generation of packaged replicons which can infect cells, but can-
not replicate themselves. The vectors are thus safe to work with. This approach is able to rapidly
generate high titer virus stocks and the efficient replication of the viral mRNA replicon opens the
possibility of infecting large numbers of cells very quickly, and thus producing substantial quantities
of recombinant protein.
Considering the difficulties in detecting eukaryotic HBx described in Chapter 2, and the previ-
ous difficulties encountered in the same laboratory with prokaryotic HBx expression, we decided to
utilise a solubility enhancing fusion system based on MBP. This rationale was based on the solubil-
isation and stabilisation of the formidable BRCA2 protein using a double MBP fusion tag (174). In a
separate study HBx was tagged with MBP (128) and expressed in E. coli. This differed significantly
from previous work conducted in our laboratory, where prokaryotic HBx was only expressed in an
insoluble form.
In this chapter, HBx was expressed as part of a MBP fusion protein in both E. coli and mam-
malian cells. The initial expression in E. coli was used to optimise purification of the MBP-HBx fusion
protein and was based on the work by Liu et al (128). This system was sub-cloned into different SFV
expression constructs to determine the suitability of combining MBP and SFV to express soluble
HBx in eukaryotic cells.
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3.2 Materials and Methods
3.2.1 pMAL-HBx Vector Construction
The pMAL-c2 (New England Biolabs R© Inc, MA, USA) vector which encodes the MBP tag and per-
mits cytoplasmic accumulation of the fusion protein, was used to express HBx. The purification and
characterisation of this procedure was recently described (128). Briefly, to facilitate the blunt cloning
of HBx into the pMAL-c2 vector, HBx was PCR amplified with a forward primer (5′-ATGGCT GC-
TAGG TTGTAC TGC-3′) and a reverse primer with SmaI (5′-CCCGGG CTATTA GGCAGA GGTGAA
AAAGTT GC-3′) using pHBV-1.3x as template (102). The PCR amplicon was cloned directly into
pMAL-c2 that had been blunt digested with XmnI in Buffer Tango (Fermentas, WI, USA), using a 1:5
insert to backbone molar ratio (Appendix B.3). pMAL-HBx clones with the correct orientation were
sequenced using standard pMAL-c2 sequencing primers.
3.2.2 Semliki Forest Virus Expression Vectors
3.2.2.1 pSFV-b12a vector
The pSFV-b12A vector was a kind gift from Professor Cristian Smerdou (CIMA, Pamplona, Spain)
and has been described elsewhere (169). The enhancer boosts protein expression levels and is
encoded by the first 34 amino acids of the SFV capsid (175). The enhancer is fused to the amino
terminal of the Foot and Mouth Disease virus (FMDV) 2A autoprotease, which permits autocatalytic
cleavage of the enhancer-2A from the recombinant protein.
A schematic of the cloning procedure used to generate pSFV-b12a-MBP-HBx vector is illus-
trated in Figure 3.1. As the pSFV-b12a vector contains a single ApaI site for cloning, subcloning
was initially completed in the pGEM vector (Promega, WI, USA) as follows: the secretory leader
sequences contained a NdeI site, thus the NdeI site present in pGEM was deleted by incubating
pGEM, linearised with NdeI, with high fidelity DNA polymerase (GeneAmpTM High Fidelity PCR
System, Applied Biosystems, CA, USA) and 1 µL dNTP mix at 57 ◦C for 15 minutes. The pGEM
backbone was then purified using phenol:chloroform and re-ligated (Appendix B.3). Positive clones
(pGEM∆NdeI) were selected based on the inability of NdeI to cut the pGEM backbone.
Secretory leader sequences were included to aid in the purification of HBx from pSFV-b12A-
MBP-HBx. Secretory leaders PPT, BM40 (derived from osteonectin) and CD5 were included in
the cloning procedure. Initially sequences were cloned into pTZ57R/T as follows: 0.1 µM of 2
partially complementary oligonucleotides spanning the length of BM40 (5′-AG GGGCCC ATGGGC
GCCTGG ATCTTT TTCCTG CTGTGC GCCGGC AGAG-3′, ApaI underlined) and (5′-AG GTCGAC
AA CATATG GCCCTG GGCCAG TGCTCT GCCGGC GCACAG CAGG-3′, Sal I underlined, NdeI
italicised) or CD5 (5′-AG GGGCCC ATGGGC ATGGGA AGCCTG CAGCCT CTGGCC ACACTG
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TACCTG CTGG-3′, ApaI underlined) and (5′-AG GTCGAC AA CATATG GGCCAG CACGCT GGC-
CAC CAGCAT GCCCAG CAGGTA CAGTGT GGCCA-3′, Sal I underlined and NdeI italicised) were
extended to their full length using the GeneAmpTMHigh Fidelity PCR System (Applied Biosystems,
CA, USA) by repeating 3 amplification cycles, each at 95 ◦C denaturation for 30 seconds, 58 ◦C an-
nealing for 30 seconds and 72 ◦C elongation for 10 minutes (Appendix B.3.1). Presumptive clones
were sequence verified (Appendix B.2.7). The PPT leader sequence was short enough to be in-
cluded in the primers used to amplify MBP-HBx for cloning into vectors.
Restriction digests of the pTZ-CD5 and pTZ-BM40 plasmids were performed using ApaI and
Sal I enzymes in BamHI buffer, at 37 ◦C overnight. The fragments were gel purified using standard
procedures but supplemented with glycogen (Fermentas, WI, USA) to a final concentration of 0.05
µg/µL to aid in the precipitation of the small DNA fragments (64 bp for BM40 and 82 bp for CD5)
(Appendix B.2.4). These fragments were ligated into pGEM∆NdeI and presumptive clones were
confirmed by restoration of the NdeI restriction site and subsequent sequencing.
The MBP-HBx fusion protein was cloned into pSFV-b12A as follows: MBP-HBx was PCR am-
plified using a forward primer (5′-AG GGGCCC CATATG AAAATC GAAGAA GGTAA-3′, ApaI un-
derlined, NdeI italicised) and a reverse primer (5′-GTCGAC GGGCCC CTATTA GGCAGA GGTGAA
AAAG-3′, ApaI underlined, Sal I italicised). The PCR amplicon was cloned into pTZ57R/T and pos-
itive clones were sequence verified (Appendix B.3.1). MBP-HBx was excised from pTZ using NdeI
and Sal I in Buffer Orange (Fermentas, WI, USA), gel purified (Appendix B.2.4), and cloned into
similarly digested pGEM∆NdeI-CD5 and pGEM∆NdeI-BM40 (Appendix B.3). Positive clones from
this step were digested out of pGEM∆NdeI backbone using ApaI and cloned into similarly digested
pSFV-b12A. Positive orientation of the MBP-HBx insert was confirmed by digesting pSFV-b12A-
MBP-HBx with SpeI and NruI in Buffer BamHI (1235 bp DNA fragment).
pSFV-S2-9-pac vector The pSFV-S2-9-pac vector is non-cytotoxic, and functions as a self-replicating
viral RNA whilst being maintained in the cell by puromycin selection. The pSFV-S2-9-pac vector is
similar to pSFV-b12A so the cloning strategy used to generate MBP-HBx was the same as for pSFV-
b12A. Further details can be found in Fig 3.1. Only the CD5-MBP-HBx DNA fragment vector could
be cloned into pSFV-S2-9-pac.
3.2.3 Protein Induction and Purification
3.2.3.1 pMAL-c2 Vectors
Briefly, one litre of LB, supplemented with glucose (2 g/L) and ampicillin was inoculated with 10 mL
of an overnight culture of BL21 E. coli cells containing the pMAL-HBx vector, and grown at 37 ◦C
until the OD600 reached 0.5. IPTG was added to a final concentration of 0.3 mM to induce MBP-
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Figure 3.1: Schematic describing the cloning of MBP-HBx fusion protein, including secretory leader
sequences, into the pSFV-b12a and pSFV-S2-9-pac vectors. Both CD5 and BM40 secretory leader
sequences (green) were generated using complementary, partially overlapping oligos (upper panel),
and cloned into a previously generated pGEM∆NdeI vector using ApaI and Sal I (upper). The middle
panel shows a detailed view of the MBP-HBx fusion protein (red/orange block). The ApaI and NdeI
sites are shown in red and are italicised where overlapping. The Factor Xa cleavage site is indicated
with an arrow. Asterisks indicate two stop codons within HBx.
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HBx protein expression. The induced culture was incubated at 37 ◦C for 2 hours until harvesting.
Following induction, the E. coli cells were pelleted at 10 000 x g and 4 ◦C, and were resuspended
at 10 mL per 1 g wet cell paste in 20 mM Tris-HCl pH 7.4, 200 mM NaCl, 1 mM EDTA and 0.1
mg/mL lysozyme and frozen at −20 ◦C overnight. The following day the pellets were thawed and
sonicated in 25 mL aliquots for 4 pulses of 30 seconds each at 75 % power. To this lysate, 0.1%
(w/v) polyethyleneimine, and 1% of streptomycin sulphate (w/v) were slowly added. The lysate
was stirred for 1 hour at 4 ◦C to allow for the precipitation of aggregates and DNA bound proteins.
The solution was then centrifuged at 37 500 x g to clarify the lysate. Protein concentration was
measured by BCA assay (Pierce, IL, USA) and adjusted to 2.5 mg/mL before loading onto a 2.2 cm
diameter amylose affinity resin column (New England Biolabs R© Inc, MA, USA). Following loading,
12 volumes of column buffer were passed through the column to remove non-specifically bound
proteins. The MBP fusion protein was eluted in 200 µL fractions, totalling 7 column volumes of
column buffer supplemented with 10 mM maltose into a Pharmacia 100 fraction collector. The
protein concentration of the fractions were quantified by BCA micro assay and fractions containing
protein were concentrated and dialysed against a 10mM Tris-HCl pH 8.0, 25 mM NaCl buffer using a
5 kDa MWCO Amicon ultrafiltrator to a maximum of 1 mL. The sample was loaded onto a 10 mL G-
75 Sepharose size exclusion column and washed with 5 column volumes of Tris buffer as mentioned
above. Fractions of 200 µL were again collected and tested using the BCA micro assay. Fractions
containing protein were pooled and concentrated with a 10 kDa MWCO Amicon ultrafiltrator to at
least 1 mg/mL. The concentrated protein was stabilised with 50% (v/v) sterile glycerol and snap
frozen in liquid N2 for storage at −70 ◦C or used in a cleavage reaction with Factor Xa.
3.2.3.2 Cleavage of MBP-HBx using Factor Xa
The cleavage of HBx from the fusion protein was achieved by incubating purified MBP-HBx with
Factor Xa (New England Biolabs, MA, USA) at a 50:1 (w/w) ratio. The optimal cleavage time required
was assessed by splitting the reaction into equal volumes and incubating at room temperature. After
24, 48, and 72 hours, SDS-PAGE sample buffer was added to a reaction to a 1x concentration and
the sample was boiled for 5 minutes at 95 ◦C. The samples were assessed using SDS-PAGE and
Western blot.
3.2.4 In Vitro Transcription (IVT) and Electroporation of SFV Vectors
Each recombinant expression vector, including the split-helper plasmid used to generated SFV viri-
ons, was in vitro transcribed as follows. Five µg of DNA was linearised with SpeI in a standard
reaction at 37 ◦C and confirmed on a 0.8 % agarose gel. Linearised DNA was purified using phe-
nol:chloroform (see Appendix B.2.2) and resuspended in RNase free dH2O at 1 µg/µl. A 50 µl IVT
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Table 3.1: Components of a standard IVT reaction for the generation of capped SFV mRNA.
Reagent Volume (µl) Final Concentration
SP6 Buffer 5 1x
rNTPs
4mM A/C/UTP
25 0.8mM GTP,
6.4mM G(5′)ppp(5′)G
Pyrophosphatase 2 0.004 units/µl
MgCl2 (500mM) 1.4 14 mM
linear DNA 2 2 µg
dH2O 12.6
Final Volume 50
reaction was set up for each of the plasmids as shown in Table 3.1 and incubated at 40 ◦C for 2
hours.
BHK-21 mammalian cells were were seeded to 80% confluency in a T75 flask less than 24 hours
before electroporation. The medium was removed and cells were washed with sterile PBS without
Ca2+ or Mg2+. Following this, 2 mL of 1x trypsin-PBS-EDTA solution was added, and cells were
incubated for 1-2 minutes until they started to detach. Ten mL of BHK-21 medium was added and
cells were resuspended to obtain a single cell suspension. The cells were transferred to a 15 mL
centrifuge tube, and pelleted by centrifugation at 129 x g for 3 minutes. The cells were washed with
15 mL sterile PBS, and re-centrifuged. This process was repeated twice. Cells were re-suspended
in PBS, counted using a haemocytometer and adjusted to 107 cells/mL with PBS. Fifty microlitres
(50 µl) of IVT mRNA was added either singly or premixed together with the 2 split helper mRNAs
into a 0.4 cm electroporation cuvette. The cuvette was pulsed twice with a 15 second interval, at
850 V and 25 µF at room temperature. Cells were immediately transferred into pre-warmed BHK-21
media and incubated in a humidified atmosphere with 5% CO2, at 33 ◦C for 40-48 hours to maximise
generation of virus.
3.2.5 Harvesting of Viral Particles
The medium was aspirated and centrifuged at 40 000 x g for 30 minutes to remove cells and cel-
lular debris. The supernatant was filtered through a 0.45 µm filter before being transferred to an
ultracentrifuge tube 25 x 89 mm (Beckman Coulter, CA USA, ). A 5 mL cushion of 20% sucrose
was gently pipetted to the bottom of the tube using a glass Pasteur pipette so as not to mix the two
layers. Tubes were then centrifuged for 90 minutes at 82 705 x g and 4 ◦C in a vacuum to pellet the
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virus. The supernatant was aspirated without touching the bottom of the tube. Five hundred µl of
TNE buffer was added to each tube, covered with parafilm and incubated at 37 ◦C to resuspend the
viral pellet. The concentrated stock was sterilised by filtration with a 0.22 µm filter, aliquoted and
stored at −70 ◦C.
3.2.6 Viral Titering by Immunofluorescence Microscopy Imaging
To titre SFV viral stocks, BHK-21 cells were grown to 80 % confluency in complete BHK-21 medium.
Cells were seeded into 6 well plates with sterile glass coverslips, at a cell density of 5 x 105 cells/ml.
Cells were left to grow at 37 ◦C for 8 to 16 hours. A dilution series of viral stocks was made between
10-2 to 10-5 in MEM (Gibco with 0.2 % (w/v) BSA, 2 mM L-glutamine, 20 mM HEPES). The cells
were washed twice with PBS, thereafter 500 µl of virus in minimal media was added to the cells.
The cells were incubated at 37 ◦C for 1 hour, and the flask was rocked every 10 minutes. The
virus-containing medium was removed and replaced with fresh medium, after which the cells were
incubated overnight at 37 ◦C.
Cells were fixed and labelled with antibody as described in section 2.2.7.1, with the exception
that the primary antibody was rabbit antiserum specific for SFV replicase, diluted to 1:400. The
secondary antibody was a Cy5 or FITC-conjugated goat anti-rabbit antibody.
3.2.7 HBx Activity Assay
To assay purified recombinant HBx for functional activity, the transactivation of the interleukin 8 (IL8)
promoter by HBx was tested (176) using a HeLa cell line stably expressing eGFP from an IL8 promoter
(kindly provided by Dr Musa Mhlanga CSIR, South Africa). HBx function was measured as a change
in eGFP expression within these cells.
Stable HeLa cells were seeded at 80% confluency onto glass coverslips before the addition of :
1) no protein (background control), 2) TNFα (positive control), 3) MBP (negative control), 4) MBP-
HBx (uncleaved), 5) MBP-HBx (cleaved). Purified proteins were added to a final concentration of
100 µ/g mL. Cells were fixed at 2 and 24 hours according to section 2.2.7.1 and were mounted with
VectaShield containing DAPI (Vector Laboratories, CA, USA) to stain the nuclei.
Following mounting, 10 images of each sample were acquired in both the DAPI and GFP chan-
nels by blind sampling i.e. image acquisition was acquired in the DAPI channel to prevent sampling
bias in the GFP channel. Mean fluorescence intensities of the GFP channel were analysed using Im-
ageJ image analysis software (177). Significant fluorescence intensity differences between samples
was determined by applying a Students-t test in the R statistical suite. The immunofluorescence mi-
croscopy facilities at the Gene Expression and Biophysics Group, CSIR Biosciences, Pretoria South
Africa, were used to acquire the images.
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3.3 Results
3.3.1 Expression of MBP-HBx fusion protein in E. coli
As shown in the elution profile of MBP-HBx from the maltose resin, (Fig 3.2), and the elution pro-
file from the G-75 size exclusion resin (Fig 3.3), a clean preparation of MBP-HBx was achieved.
The preparations of the fusion protein showed a certain degree of instability as indicated by the
degradation products on a Western blot (Fig 3.4-A).
Figure 3.2: Affinity elution profile of E. coli expressed MBP-HBx eluted with 10mM maltose, af-
ter washing for 20 column volumes. Fractions were 200 µl each and those containing protein as
measured by BCA assay were pooled for subsequent storage or cleavage. A standard curve was
generated against a 0-2000 µg/mL range of BSA. A single peak correlating with MBP-HBx protein
eluted in fractions 3 to 7 suggested a clean preparation was achieved.
3.3.2 Cleavage of MBP-HBx fusion with Factor Xa
Cleavage of HBx from the MBP tag was found to be more reproducible if performed directly after
purified and concentration protein. As reported by Liu and colleagues (128), cleavage of HBx off
MBP-HBx did not increase appreciably after 48 hours as shown in Fig 3.4-B. The cleaved products
were separated using G-75 size exclusion chromatography and fractions found to contain HBx were
concentrated and snap frozen with 50 % glycerol in liquid N2 and stored at −70 ◦C.
3.3.3 In vitro activity assay of HBx protein
Previous studies and work from our laboratory have shown that recombinant E. coli expressed
HBx, after denaturation and refolding, possesses biological activity (95,105). As HBx possesses no
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Figure 3.3: G-75 Sephadex size exclusion elution profile of E. coli expressed MBP-HBx after 48
hours of cleavage with Factor Xa. Fractions were 200 µl each and those containing protein as
measured by BCA assay were pooled for cold storage. A standard curve was generated against a
0-2000 µg/mL range of BSA. Three peaks correlating with HBx alone, MBP + Factor Xa and MBP-
HBx were observed. The separation of the three peaks permitted easy isolation of purified HBx.
Figure 3.4: Western blot and Coomassie stain of (A) MBP-HBx and (B) cleavage of HBx from MBP
(B). A - MBP-HBx and MBP preparations after affinity and size exclusion chromatography showed
a high degree of purity. Degradation products are indicated with arrows. B - Western blot using
the anti-HBx 6.1 antibody to detect HBx from a time cleavage assay of MBP-HBx using Factor Xa.
Samples were taken at 24, 48 and 72 hours. No increase in cleavage was seen after 48 hours.
63
enzymatic activity, its ability to transactivate promoters serves as a measure of biological activ-
ity. Typically assays that measure changes in Chloramphenicol acetyltransferase (CAT) levels are
used (64,178–180). CAT is expressed from the HIV LTR promoter and a doubling of protein in the pres-
ence of HBx can be expected. In this work, HeLa cells stably expressing eGFP off an IL8 promoter
were used to assay the transactivation activity of HBx. As shown in Fig 3.5, HBx can transacti-
vate IL8 leading to an increase in GFP expression. Interestingly, HBx seemed to retain its activity
whilst attached to MBP. Importantly the negative controls including MBP alone, and no added protein
showed no increase in GFP levels.
Figure 3.5: Notched box and whisker plots of comparative fluorescence intensities (n=10) of IL8-
GFP containing HeLa cells after exposure to either MBP, TNFα, MBP-HBx or HBx. The difference
between the fluorescence values of HBx versus MBP and HBx versus No Protein samples were
determined by applying a Students-t test with a 95% confidence level. The results show that MBP-
HBx and HBx alone caused an increase in eGFP fluorescence intensity similar to the TNFα positive
control. The notches on the box represent the confidence intervals for the medians. If notches of
two medians do not overlap the medians are significantly different at a 95 % confidence interval. A
key explaining a box and whisker plot is presented in Appendix A.7.
3.3.4 Expression of MBP-HBx using pSFV-b12a
The expression and partial secretion of the MBP-HBx fusion protein using the pSFV-b12a vector
was successful, showing that this is a promising construct for mammalian production of recombinant
HBx. The Western blot in Fig 3.6 indicates that the majority of the protein was located intracellularly
(Lane 3), although comparable amounts of protein was secreted into the growth medium (Lane
1). Further attempts at expanding the use of this vector through the generation of virions, were
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unsuccessful (data not shown). Conditions attempted included lowering the incubation temperature
to 33 ◦C, increasing the amount of mRNA electroporated into cells from the pSFV-b12a and two
helper plasmids, and optimising the timing of electroporation to less than 18 hours after splitting the
cells. Despite these attempts, titres of virus were never more than 104-5 infectious units (IU) per mL.
As several log increases to 108-9 IU were needed for large-scale infections, the use of this vector
was not pursued.
Figure 3.6: Western blot of protein samples taken from cells electroporated with pSFV-b12a-ppt-
MBP-HBx mRNA. MBP-HBx and degradation products (lower bands) were detected in all samples
analysed. Lane 1 shows beads used to purify MBP from supernatant (control for presence of MBP),
Lane 2 shows TCA plus supernatant (non-specific protein precipitation). Lane 3 shows beads used
to isolate MBP from cell lysate. Lane 4 shows cell lysate only.
3.3.5 Expression of MBP-HBx using pSFV-S2-9-pac2A-CD5-MBP-HBx
During infection with the pSFV-b12A vector, cellular processes are sequestered by the demands of
the SFV RNA during recombinant protein production (181). The cytotoxicity of this vector is such that
after 72 hours all infected cells are dead and the electroporation or infection needs to be repeated in
fresh cells. To allow for continuous protein expression and purification as opposed to the repeated
transient expression of pSFV-b12A vector, the use of the non-cytotoxic pSFV-S2-9-pac2A vector
was pursued. This vector circumvents the need to produce virions for infection, and instead relies
on the replication of the SFV mRNA within the cytoplasm of the electroporated cell. To maintain
mRNA presence, the replication of the viral mRNA is directly linked to a puromycin selection marker.
This vector allows positively selected cells to be grown to a large-scale. Three attempts at estab-
lishing pseudo-stable BHK-21 cells expressing MBP-HBx were unsuccessful. Western blots aimed
at detecting MBP or MBP-HBx in the supernatant of electroporated cells were negative (data not
shown). This was true for the SFV nsp2 protein, which is part of the SFV replicase and should be
detected in cells containing an SFV vector (Fig 3.7 Lane 1 and 2).
Nsp2 was however detected in the positive control derived from the pSFV-GFP vector (Fig 3.7
Lane 2). The BHK-21 cells with no vector showed an unusual tolerance for puromycin at the 5
µg/mL concentration reported to kill cells not expressing a puromycin resistance cassette. Although
the concentration of puromycin was increased from 5 to 7 µg/mL, this did not result in the selection
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of MBP-HBx expressing cells. Clumps or colonies of BHK-21 cells are known to be resistant to
puromycin and so care was taken to ensure that cells were split at a low confluency and were not
permitted to overgrow. It is possible that the BHK-21 cells used in these experiments had greater
than normal interferon activity which would cause the SFV vector to be rapidly expelled from the cell.
However, this was not determined.
Figure 3.7: Western blot of pSFV-S2-9-pac2A-CD5-MBP-HBx to screen for the presence of non-
structural protein 2 (nsp2) protein from pSFV-S2-9-pac2A-CD5-MBP-HBx containing cells. The nsp2
protein indicates the presence of an SFV vector (positive control) and serves as confirmation of the
presence of an SFV RNA replicon. Nsp2 protein was only detected in the positive control (pSFV-
b12A-GFP) sample.
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3.4 Discussion
The expression and purification of soluble and native HBx using a MBP fusion approach was a
major achievement in expressing a protein renowned for its insolubility and temperamental nature.
As researchers can now produce preparative scale quantities of this protein, at least in E. coli,
attempts at elucidating its structure, which for so long have been frustrated, are now more likely to
be met with progress.
The MBP system used in this work, whilst successfully producing soluble, functional HBx, could
be further improved to increase the final yield of HBx. A major concern is the considerable quantity of
degradation products from the MBP-HBx fusion protein that complicates the purification procedure
(Fig 3.4-A). The complication lies in that degradation products compete for binding on the maltose
resin, thus necessitating an additional separation step using G-75 size exclusion or Anion exchange
chromatography. Furthermore, and more importantly, the degradation products suggest that the
yield of HBx from the fusion protein is continually decreasing. The standard purification methodology
suggested by New England Biolabs and used in this work are column dimensions of 2.5 cm, which
dictates a maximal flow rate of 1 mL/minute [10 x (diameter of column in cm)2]. This flow rate holds
true for both the loading of the column and the washing and elution of any bound proteins. A further
limitation is that the maximum loading protein concentration must be approximately 2.5 mg/mL to
avoid losses, channelling and blocking of the column resin. To reduce the load of protein applied
to the column, affinity precipitation of MBP-HBx was attempted (182), although this was not included
here. Cationic starch (part of affinity precipitation) is not a standard, readily available, nor often used
laboratory chemical, and so differences in the cationic starch qualities to those described were likely
to be responsible for the negative results. Improvements to the protocol and reagent availability of
this initial affinity precipitation technique could greatly reduce the time and cost to purify MBP tagged
proteins.
Without the initial affinity precipitation, the MBP-HBx fusion protein is on the column for 14 hours
or more. Loading of the maltose column takes 4-5 hours depending on lysate volume and protein
concentration, and washing of the column occurs over an additional 10-14 hours. If the MBP tag
was altered to include a rapidly purifying 6xHIS tag as an initial step, the purification of the protein
could be greatly accelerated. The MBP affinity resin could then be used as a final polishing step as
opposed to its current use as an initial purification step.
Further increases in the stability of the MBP-HBx fusion could be achieved if an additional MBP
tag was attached, possibly in tandem, to the fusion protein. This had a positive impact on another dif-
ficult to express protein, BRCA2 (174), where two N-terminal MBP tags were attached. The downside
of this is that increased stability of the fusion protein is counteracted by an increase in the proportion
of MBP in the fusion, and a subsequent decrease in the final yield of the protein of interest (e.g. a 2
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N-terminal MBP-MBP-HBx protein would decrease the final yield of HBx from 28% to 17%). It would
be important to determine whether an increase in stability as a result of additional MBP tags results
in a real increase in the protein of interest.
Alternatively, other solubility enhancing tags like NusA (E. coli transcription termination anti-
termination factor) or SUMO (Small Ubiquitin-like Modifier) could also be tested, either alone or in
combination with each other (183). Both of these tags have been shown to have similar solubility
promoting effects on their fusion partners. Further attempts should focus on keeping the fusion
cleavage position site as close to the beginning or end of HBx as possible to ensure that there are
no modifications to the target protein sequence or structure. Additionally, other secretory leaders
(prepro-trypsin or BM40) that resisted subcloning from the pGEM∆NdeI plasmid (data not shown)
could be tested for improved secretory performance.
The MBP-HBx fusion protein was sub-cloned into the SFV protein expression system as these
vectors can be used for large scale expression of proteins (184). Notably, reports of infections of 1-
10 litres of suspension cells, producing around 1-20 mg/L of protein, make this system useful for
proteins amenable to this mode of production. The system does have several shortcomings which
have been addressed comprehensively over the years. Transient infections of cells by either the
viral mRNA or viral particles results in a complete hijacking of the cellular machinery, so much so
that infected cells are dead by 72 hours. This has been ameliorated by the creation of SFV vectors
with lowered cytotoxicity (185), and more recently a non-cytotoxic, self replicating SFV vector, used
in the experiments here (pSFV-S2-9-pac vector) (170,186). Additional concerns, although admittedly
beneficial for experimental purposes, are the ability of alphavirus vectors to infect a wide variety of
cells and hosts (e.g. avian, insect and mammalian cells). This represents a significant biosafety
problem which numerous researchers have addressed. Early use of SFV showed the production
of replication-proficient viruses (RPVs) which presented a danger of infecting the experimenter or
other lab personnel. This has largely been overcome by separating the viral helper and vector RNA,
preventing a productive infection. Recent enhanced biosafety modifications include the split-helper
system whereby the capsid and spike helper regions are split into two independent RNAs (173). An
additional mutation abolishing capsid self-cleaving activity increases the biosafety of this system
even further (187,188).
Despite the expression improvements and biosafety modifications made to the SFV system,
the generation of substantial quantities of MBP-HBx was still not successful. Difficulties in in vitro
transcription and electroporation of single or multiple 12 kb mRNAs were largely overcome, but
generating high titres of viral particles and/or increasing packaging efficiency was not improved. The
selection of pseudo-stable cells using the pSFV-S2-9-pac2A-CD5-MBP-HBx was also not successful
despite multiple attempts at selection. The BHK-21 cells used showed a remarkable resistance to
puromycin, that did not prevent SFV mRNA negative cells from expanding.
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The absence of SFV mRNA in the cells was deduced from the absence nsp2 proteins in Western
blots, as compared to the controls (Fig 3.7 Lane 1 and 2). It was not determined exactly why the
generation of high viral titres and the selection of stable cells was not successful, but it is possible
that the BHK-21 cells used produced elevated levels of interferon which induced an antiviral state in
the cells thus expelling the SFV RNA (189).
Despite the shortcomings and technical difficulties of working with SFV based systems, SFV
was successfully used to express MBP-HBx protein as well as permitting its secretion from infected
BHK-21 cells. The MBP-SFV expression system presented in this chapter, represents a significant
milestone in HBx research and is an excellent point from which to pursue preparative scale produc-
tion of soluble, eukaryotic HBx. The system demonstrated that with additional modifications to the
SFV expression construct and closer collaboration with researchers actively developing these SFV
vectors, significant progress could be made in the large scale expression and structural determi-
nation of HBx. This will ensure that structural data can be gleaned and will assist researchers in
elucidating the genuine biological role of HBx in hepatocarcinogenesis.
Due to a lack of structural studies related to the unavailability of eukaryote expressed HBx, the
genuine biological role of HBx in hepatocellular carcinogenesis, as well as its roles in the lifecycle
in HBV remain controversial. Thus eukaryotic expression of HBx using the systems presented here
would be highly beneficial. In addition, studies on the overlapping genes of the HBV genome would
provide interesting insights into HBx. Evolutionary analysis of HBV sequences, would provide in-
teresting insights into the evolutionary pressures experienced by overlapping and non-overlapping
regions. Importantly, this analysis could reveal information on regions of biological importance which
could assist future structural studies. Additionally the elucidation of sites that are prone to mutation
could assist future antiviral therapies by directing researchers away from unsuitable regions. Fur-
thermore, as HBV subtypes are still largely separated geographically, analysis of selection on the
subtypes could reveal information on the evolution of HBV in different geographic regions. The
evolutionary analysis of HBx is dealt with in Chapter 4.
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Chapter 4
Evolutionary Analysis of Hepatitis B
Virus HBx Protein
4.1 Introduction
Overlapping genes are created as a result of substitutions occurring within an upstream codon in an
adjacent gene. This substitution results either in the addition of an initiation codon or the removal
of a termination codon. The reading frame of the downstream gene is thus extended proportion-
ally. This mechanism is known as over-printing (190). Overlapping sequences are constrained in their
ability to adapt and this effect may imprint on the remainder of the gene. Despite this constraint,
it is proposed that overlapping genes offer a fitness advantage to viruses as the assemblage of
proteins is increased without increasing the genome size (191,192) as this in turn is constrained by
packaging capacity of the capsid (193). Additionally, several analytical models have shown that over-
lapping sequences may palliate the effects of detrimental substitutions, especially when mutation
rates are high (194,195). This may be the case with HBV, although a weak host immune response re-
sults in the viral genome being relatively stable (196). Overlapping genes reduce redundancy (called
antiredundancy) in genomes and this seems to be a characteristic of large populations such as
viruses. Antiredundancy serves to remove mutants, thereby improving the robustness of wildtype
genomes (197).
When an overlap is created, the newly added sequence that was previously non-coding has not
undergone functional adaptation and thus mutations will typically have no fitness cost. This ensures
these mutations are maintained within the population. In general, when an overlap is created, the
additional protein sequence is disordered and is taxonomically restricted (198).
Hepatitis B Virus is characterised by uni-directional overlapping of all of its genes such that the
3′ end of one gene, overlaps with the 5′ end of another gene (Fig 4.1). The hbx and core genes
occupy a 123:312 phase with respect to the polymerase gene such that the first codon base in the
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hBx or core gene corresponds to the degenerate third position of polymerase, whereas the surface
protein occupies a 123:231 phase with respect to polymerase. The degree of overlap within the
HBV genome is considerable. The genome size is 3.2 kb and can encode 180 kDa of protein,
as opposed to a theoretical maximum of 120 kDa for a non-overlapping 3.2 kb genome (199). HBV
regulation relies on the interactions of several trans-acting factors, and their cis motifs in overlapping
regions adds further evidence to the efficient organisation of the HBV genome (reviewed in (11)).
Figure 4.1: Representation of the overlapping genome of HBV and the reading frames associ-
ated with each overlap. Both linear and circular representations of core (yellow), polymerase
(blue),surface (green) and hbx (red) are shown with each of the reading frames labelled as 1,2
or 3. (A-D) the first nucleotide position of polymerase corresponds to the third nucleotide position
of surface (p1/s3), the second nucleotide position of core (p1/c2), the second nucleotide position of
hbx (p1/x2), whereas the third nucleotide position of hbx corresponds to the first position of core
(x1/c2).
In Chapter 2 (see Fig 2.14) it was suggested that HBx possesses disorder, additionally it is
known to be restricted to the genera orthohepadnaviruses which only infect mammals. This indicates
that hbx evolved de novo via the over-printing mechanism mentioned above. This is also true of
unspliced RNA viruses (e.g. tymovirus and luteovirus) where overlapping genes have been shown to
code for proteins that are either partly or wholly disordered, have an unusual sequence composition
and play a role in viral pathogenicity or spread (192,198).
At a sequence level, hbx can be divided into 3 distinct segments (Fig 4.1). The first segment
overlaps with polymerase on its N-terminus (54 % of hbx length), a non-overlapping segment in the
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middle of hbx (40 % of hbx), and a short C-terminus segment that overlaps with the pre-core gene
(3.9 % of hbx). The evolutionary pressures on these three sections of hbx are hypothesized to be
different from each other, since the position of a nucleotide substitution strongly influences whether
that substitution will be synonymous in the other reading frames or not. A mutation in: 1) the first
codon position causes a non-synonymous mutation in 60 out of 64 cases (93 %), 2) the second
position affects 63 out of 64 cases (98 %) and 3) the third position affects only 16 out of 64 cases
(25 %, amino acid redundancy). Therefore a substitution in the first position of hbx will probably
cause an amino acid change in pre-core (position 1 of hbx is position 2 of pre-core, x1/c2 - compare
hbx in red to pre-core in yellow in Fig 4.1). Furthermore, a substitution in the first position of hbx will
probably result in an amino acid change in HBx, but not in Polymerase, x1/p3 (compare hbx in red
to polymerase in blue in Fig 4.1).
Despite the fact that 1) hbx overlaps with pre-core and polymerase in the HBV genome; 2) hbx
contains a disordered region and 3) hbx may be involved in the pathogenicity of the virus, no studies
have been published to determine the types of selection within hbx. Thus selection within the HBV
genome and within hbx in particular was assessed here. It was hypothesized that the evolution of
hbx may mirror the research done by Zaaijer et al (200) where the evolution of the HBV surface and
polymerase genes occurred at s2/p3 and p1/s3 respectively, meaning that substitutions at s2 and
p1 (non-synonymous) probably did not result in an amino acid change at p3 and s3 respectively.
Additionally, we hypothesized that the negative regulatory domain, with its predicted disordered
segment (see Fig 2.14), would be under different selection compared to the transactivation domain.
Considering that HBx has been reported to play a role in the progression of chronic HBV infec-
tion to liver cancer, this work also aimed to provide direction with regards to the development of
chemotherapeutics or inhibitory small molecules through the application of phylogenomics.
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4.2 Methods and Materials
4.2.1 Sequence Extraction and Analysis
To determine the evolutionary patterns of the 4 main genes of HBV (hbx, surface, core, polymerase),
the variation in the codons and amino acids of the 8 genotypes were gathered as follows: the
complete list of 2475 separate HBV genomic sequences was downloaded from Genbank and re-
genotyped using the Oxford HBV Subtyping Tool (201,202). This was to ensure that sequences had
been correctly annotated. The type sequences within each genotype were duplicated by concatena-
tion to facilitate correct sequence alignment, and then used to extract the 4 genes from the database
of sequences using the Waterman alignment in the EMBOSS suite of tools (203). Gene sequences
containing insertions or deletions greater than 10 nucleotides were removed from the datasets as
this affected the computations. All identical sequences were removed as this affects the conver-
gence of the evolutionary models. All stop codons were removed, as well as sequences containing
premature stop codons as these are not tolerated by the analysis software. This was in line with the
requirements for downstream analysis.
Overall, the dataset of sequences covering all eight genotypes was too large to be computed
in a reasonable time. Thus, a random sampling of a maximum of 75 polymerase sequences per
genotype was analysed (due to the sequence length). Approximately 200 sequences for each of the
hbx, surface and core genes were sampled. All sequences were extracted using Python code as
described in Appendix C.
The extracted gene sequences were translated and aligned using MUSCLE (204). Initial phylo-
genetic trees were calculated using the BioNJ function (205) of SeaView software (206) with a Jukes-
Cantor correction and 500 bootstraps. Protein sequence alignment was included simply to ensure
an inframe alignment. All subsequent analyses were performed on the gene sequences only, unless
specified otherwise.
The CODEML module of PAML 4.4d (207,208) was applied to the codons to estimate the relative
rates of synonymous and non-synonymous nucleotide substitutions. The hbx, core polymerase and
surface genes were analysed by maximum likelihood (ML) approximation separately but concur-
rently. The nested site models (0, 1 and 2, 7 and 8) of PAML were run on the cluster supported
by Wits Bioinformatics running Scientific Linux 5.4. Computations of datasets amounted to several
thousand hours in total for all four genes.
In cases where the nested site models were not converging as expected, an initial input phy-
logenetic tree from model 1 was used to overcome parameter trapping and increase the speed
of analysis. Likelihood-ratio tests (LRT) and Bayes Empirical Bayes (BEB) statistics (209–211) were
applied as described in the PAML manual (http://abacus.gene.ucl.ac.uk/software/paml.html).
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4.2.2 Calculation of Codon Position Substitutions using Entropy
The calculation of entropy reflects the amount of variability through a column in an alignment and is
a measure of the lack of “information content” at each position in the alignment. In other words, it is
a measure of the lack of predictability at a particular position in the alignment. Entropy calculations
for each of the three codon positions of hbx were performed using the Entropy function of BioEdit
software version 7.0.5.3. (http://www.mbio.ncsu.edu/bioedit/bioedit.html) (212). Calculations for the
three reading frames tested (x1/p3, x2/p1, x3/p2) were performed by removing one nucleotide and
recalculating the entropy for the reading frame.
4.2.3 Branched Site Models
To determine the selective pressures occurring in hbx in the different genotypes of HBV, all hbx
sequences were combined and aligned using MUSCLE. The CODEML module of PAML 4.4d was
again used and Model 2, NSsites 2, Method 1 and Model 2, NSsites 3, Method 1 were applied to
the data set. An initial phylogenetic tree was generated using BioNJ with a bootstrap of 100 (205). All
branches within each genotype were labelled as a clade using ”$1”. The branched site models were
applied to each genotype consecutively.
4.2.4 Ka/Ks estimations
The ratio of non-synonymous substitutions per non-synonymous site to the number of synonymous
substitutions per synonymous site is represented as Ka/Ks. The ratios were calculated using SWAAP
1.03 (213) with the Nei-Gojobori distance estimation method (sliding window length = 15 nt; window
step = 3 nt) (214). Sequences of each hbx genotype were subdivided into segments of 99 sequences
each and analysed separately (due to a limitation on number of sequences that could be entered
into SWAAP). Results were combined, giving a total of 1666 comparisons.
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4.3 Results
4.3.1 Entropy Calculations for hbx Reading Frames
The hbx gene can be divided into three sections based on the overlap with polymerase and pre-core
(Fig 4.1). The entropy for each of these sections (overlap with polymerase, overlap with pre-core
and non-overlapping region) was calculated, in three different reading frames. The results shown
in Fig 4.2 indicate that where hbx overlaps with polymerase (amino acids 1-83), the variability in
hbx is primarily non-synonymous and occur at x1/p3, while the same mutations are synonymous in
polymerase. The non-overlapping section of hbx shows a high proportion of evolution occurring by
non-synonymous substitutions in the x1 reading frame, and similarly in the x2 reading frame. This
suggests that the lack of overlap with additional sequences permits evolution in this hbx section to
be mainly non-synonymous. Regulatory elements like the basic core promoter which modulates the
precise initiation of both the pre-core and pregenomic RNA are present in this section. There are
also sequence motifs located upstream and within the basic core promoter which have been shown
to interact with several liver-specific transcription factors. Thus the evolution in this section of hbx
is not only directed to the hbx sequence, but the regulatory sequences contained therein. Whether
this represents a constraint or not was not determined.
The section of hbx that overlaps with pre-core translates to only eight amino acids and thus there
is less data for entropy analysis. Nonetheless, the data suggested that where substitutions occur
in the x2/c3 and x3/c1 reading frames, the alternate gene is more likely to undergo a synonymous
mutation.
4.3.2 Ka/Ks Estimates of Positive Selection
To determine whether the negative enhancer and trans-activation domains of HBx are under positive
selection, the use of a sliding window over the whole of HBx was used to calculate Ka/Ks ratios for
each amino acid site. A value less than one indicates negative selection, a value equal to one
indicates neutral selection and a value greater than one indicates positive selection at a particular
site.
In Fig 4.3 the Ka/Ks ratio for each sliding window is compared between all genotypes (e.g. sliding
window one which corresponds to the first 15 amino acids of genotype A is compared to the same
amino acids in all the other genotypes, and similarly for the remaining sliding windows).
The majority of data points for genotypes A-E in Fig 4.3 cluster between zero and one which
is indicative of negative selection. However, there are several values substantially higher than one,
indicating positive selection at certain sites within HBx. Only genotype E showed a lower clustering
of Ka/Ks ratios , thus indicating fewer sites under positive selection and higher negative selection.
The Ka/Ks ratios of genotypes A-F were also plotted over the length of the gene to give an
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Figure 4.2: Split bar matrix chart representation of the cumulative entropy determined for HBx, in all
genotypes, and for all three codon positions of hbx. The graph is divided up into 3 sections: Panel
A, corresponds to the overlap of hbx with polymerase (amino acids 1-83), Panel B corresponds to
that portion of hbx not overlapping with HBV genes (amino acids 84-146), and Panel C, where hbx
overlaps with pre-core of the Core protein (amino acids 147-153). In all panels, the x1 position is
shown in yellow, the x2 position in red, and the x3 position in blue. Entropy values are provided at
the end of each line. Results in panel A, show that the majority of substitutions occur at x1 (non-
synonmous), which coincides with p3 (synonymous). Panel B shows an increase in x2 substitutions
as there is no constraint from any overlapping gene. Panel C shows almost identical levels of
substitutions at x2/c3 (non-synonymous) and x3/c1 (synonymous). Comparisons are only made
across a panel and not between panels.
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indication of which regions are under positive selection across the different genotypes (Fig 4.4).
Overall there are clusters of positive selection (indicated by Ka/Ks ratios higher than 1), with two
spikes in the negative regulation domain (nucleotides 0-200) at positions 0-40 and 80-160. The
transactivation domain (nucleotides 200-450) shows 3 spikes around nucleotides 300, 375 and 440.
Overall these results suggest that the negative regulation domain of hbx in under positive selection
across all genotypes.
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Figure 4.3: Matrix plot comparison of Ka/Ks ratios of HBx between genotypes A-F. Ka/Ks values were calculated using a sliding window of 15 nucleotides and
a step of 3. The axes have a maximum arbitrary value of 10 and plots on opposite sides of the grey boxes mirror each other. A value less than one indicates
negative selection, a value equal to one indicates neutral selection and a value greater than one indicates positive selection at a particular site.
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Figure 4.4: Ka/Ks values calculated over the length of HBx plotted against nucleotide position for
genotypes A-F. The axes have a maximum arbitrary value of 10. Genotypes are represented by
colour as follows: A - light blue, B - dark blue, C - orange, D - yellow, E - green, F - purple. A 4x
moving average of Ka/Ks was calculated and plotted to assist with the interpretation of the overall
trend (black line).
4.3.3 Sites Under Positive Selection
To identify sites within HBx subjected to positive selection (also known as diversifying or adaptive
selection) several site-specific models within the PAML software were applied (215,216) to determine
which model fitted the data. (1) Model 0 assumes a constant rate among all nucleotide sites and
branches within the dataset. Genotypes A-E showed very similar dN/dS ratios (ω, ratio of non-
synonymous over synonymous substitutions) with a mean of 0.673. Transition transversion (ts/tv)
ratios were also similar with a mean of 2.546 (Table 4.1). (2) Model 1 suggests that HBx genotypes
A-E are under negative selection (purifying or stabilising) such that the removal of these sites are
deleterious (ω <0.15).
(3) Model 2 differs from Model 1 by incorporating an extra parameter for sites with an ω >1.
Using this model, 64 % of HBx sequences in genotypes A-E are under negative selection, while 5-9
% are under positive selection. All PAML models are based on maximum log likelihood estimates
(lnL) and a comparison of these values using a Likelihood ratio test (LRT) between Models 1 and 2
provide additional support for the data described above (Table 4.2). Furthermore, Model 2 provided
a better fit of the data as compared to Model 1 (P>0.0001).
The nested site Models 7 and 8 employ 10 and 11 class site parameters respectively for the
accumulation of ω values at sites along the gene. Model 8, parameter 11 shows dN/dS and LRT
values similar to those presented in Model 2 for genotypes A and C-E (ω >1). Using this model
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genotype B had a dN/dS ratio half that predicted by Models 1 and 2.
Models 7 and 8 also describe the shape of the β-distribution (dN/dS ratio as a function of the
proportion of sites with a certain ratio). These are given as parameters p and q and extreme values
indicate that either the proportion of sites are highly conserved or nearly neutral. Genotypes A-E
and G have similar p and q values indicating that their β-distributions are U-shaped (see Table 4.1).
Genotypes F and H have unimodal β-distributions for Model 8 as the p and q values were both above
1.
The results for genotype F, G and H were included in Tables 4.1 and 4.3 and Fig 4.5, but the low
number of sequences analysed led to insufficient diversity within the dataset and thus these results
were not discussed.
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Table 4.1: Summary of Log-likelihood values (lnL) and parameter estimates for models applied to HBx across all genotypes of HBV using PAML Models 0, 1, 2,
7 and 8. Transition-transversion (ts/tv) ratios are represented for Model 0 only. dN/dS(pn) represents the proportion of data with a certain ω value. p and q denote
the shape of the β-distribution of Models 7 and 8 only. For example, genotype A Model 1, dN/dS(p0) shows that (0.617) or 61.7 % of the data has an ω of 0.052.
genotype A genotype B genotype C genotype D genotype E genotype F genotype G genotype H
Model 0
ts/tv 2.241 2.459 2.686 2.708 2.637 2.895 1.425 3.175
lnL -2735.253 -3990.912 -3914.499 -3905.945 -1925.287 -1541.530 -876.802 -911.453
dN/dS 0.611 0.699 0.726 0.601 0.729 0.976 0.857 0.523
Model 1
lnL -2659.660 -3894.022 -3827.891 -3790.433 -1880.208 -1526.890 -876.727 -910.611
dN/dS(p0) 0.052 (0.663) 0.100(0.636) 0.142(0.700) 0.101(0.730) 0.052(0.714) 0.000(0.490) 0.000(0.159) 0.088(0.554)
dN/dS(p1) 1.000 (0.337) 1.000(0.364) 1.000(0.290) 1.000(0.270) 1.000(0.286) 1.000(0.511) 1.000(0.841) 1.000(0.446)
Model 2
lnL -2629.314 -3841.504 -3755.892 -3742.459 -1840.239 -1513.184 -876.710 -910.108
dN/dS(p0) 0.052(0.617) 0.103(0.607) 0.162(0.647) 0.129(0.700) 0.062(0.650) 0.250(0.786) 0.000(0.239) 0.389(0.965)
dN/dS(p1) 1.000(0.292) 1.000(0.378) 1.000(0.318) 1.000(0.207) 1.000(0.293) 1.000(0.000) 1.000(0.000) 1.000(0.000)
dN/dS(p2) 4.304(0.091) 8.710(0.015) 6.820(0.035) 3.751(0.093) 7.539(0.058) 3.810(0.214) 1.150(0.760) 4.410(0.035)
Model 7
lnL -2660.299 -3900.615 -3839.132 -3806.842 -1882.259 -1526.487 -876.737 -910.628
p 0.017 0.228 0.329 0.202 0.013 0.005 0.063 0.022
q 0.021 0.296 0.459 0.361 0.025 0.005 0.012 0.020
Model 8
lnL -2629.599 -3849.545 -3761.387 -3744.251 -1840.348 -1513.191 -876.711 -910.110
p 0.173 0.276 0.400 0.402 0.098 33.194 0.005 63.198
q 0.384 0.371 0.489 0.976 0.181 99 0.008 99.000
p0 0.903 0.93 0.963 0.89789 0.942 0.786 0.392 0.035
dN/dS(p11) 4.013(0.097) 4.188(0.07) 6.727(0.037) 3.555(0.102) 7.511(0.058) 3.812(0.214) 1.179(0.610) 4.413(0.035)
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Figure 4.5: Sites within HBx under positive selection as determined by Model 8 of PAML software. All genes within HBV are shown in relation to each other as
yellow blocks. The sites under positive selection are indicated as vertical lines according to different colours for each genotype. Several sites within the sequence
of HBx are under positive selection both within the NRD and TD. There is a notable lack of sites under positive selection between the AD and NRE (seen as a
gap). AD - a determinant, NRD - negative regulation domain, TD - transactivation domain, BCP - basic core promoter.
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Table 4.2: Likelihood ratio tests (LRT) comparing the lnL values of PAML Models 1 versus 2 and
Models 7 versus 8. Genotypes A-F were evaluated at confidence levels of P = 0.001, whereas
genotypes G and H were evaluated at a confidence levels of P = 0.05 (as explained in the text). As
the LRT values were greater than the critical value, it was concluded that Models 2 and 8 showed
the best fit.
genotype A genotype B genotype C genotype D genotype E genotype F genotype G genotype H
LRT (2vs1) 60.692 105.036 143.998 95.948 79.938 27.412 0.034 1.006
LRT (8vs7) 61.400 102.140 155.490 125.182 83.822 26.592 0.052 1.036
Critical Value 13.815 13.815 13.815 13.815 13.815 13.815 5.991 5.991
P Value 0.001 0.001 0.001 0.001 0.001 0.001 0.05 0.05
Based on the LRT values (Table 4.2) Models 2 and 8 showed the best fits of the data and thus the
sites identified as being under positive selection by these models were subjected to Bayes Empirical
Bayes statistical analysis (BEB). The BEB output determines which amino acid sites were under
positive selection and are displayed graphically in Fig 4.5 (As Models 2 and 8 identified the same
amino acids, only one set of data was plotted). Sites under positive selection with HBx seemed to
cluster in two distinct regions. The region between amino acids 1-50 in HBx, (predicted in Chapter
2 to show structural disorder Fig 2.14), showed a strong localisation of positive or diversifying sites
under selection. The trans-activation domain (defined as amino acids 51-154) also showed numer-
ous sites under positive selection with a notable region (amino acids 50-70) showing an absence
of sites under positive selection. Taken together these data suggest that distinct regions within
HBx are under positive selection across all genotypes tested although the reasons for this remain
speculative.
Taken together these data suggest that distinct regions within HBx are under positive selection
across all genotypes tested although the reasons for this remain speculative.
4.3.4 Branched Sites Selection
To determine if there were genotype-specific sites under positive selection within HBx, two branched
site models (A and B) were applied. The data are represented in Table 4.3 and Fig 4.6. Model A
suggested that 63-78 % of sites within HBx across all lineages are under negative selection (ωˆ0
<1), whereas 17-23 % of sites are nearly neutral (ωˆ1 = 1). The number of sites under positive
selection varies widely between 0.07 % in genotype F and 11 % in genotype E. Genotype G shows
a large number of sites under selection (20 %), but could be a consequence of the low number of
sequences analysed and thus the result of a sequence bias. Genotypes B, D, F and H show a ωˆ2
= 999 which is the upper bound set for ωˆ2 and indicates infinity. This means that there are one or
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more non-synonymous substitutions and no synonymous substitutions in the branch.
An infinity value makes the data difficult to analyse and thus an LRT should ideally be performed
(using an lnL between branched site Model A and site Model 1, and branched site Model B and site
Model 3).
However the datasets between the branched sites models and the sites specific models were
different. The former required the use of close to 1000 sequences from different genotypes (217),
whereas the site-specific models were applied to HBx sequences of only one genotype at a time.
Nonetheless the data indicates that there are sites within each genotype of HBx that are experienc-
ing positive selection.
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Figure 4.6: Phylogenetic tree of HBx sequences that were used to determine sites under positive
selection. Sequences within each genotype are clustered in different branches based on sequence
relatedness. The tree was constructed using BioNJ with 100 bootstraps. Each genotype is repre-
sented in a different colour. Specific amino acids are indicated with their probabilities of being under
positive selection.
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Table 4.3: Branched site model parameter estimates for HBx sequences across genotypes A-H. In
Model A, ωˆ0 and ωˆ1 are fixed, whereas in model B they are free to vary.
Genotype l Estimates of Parameters Positively Selected Sites
genotype A
Model A
-8754.12 pˆ0 = 0.714, pˆ1 = 0.202, 5V 6C 11P 26G 29L 89F 100P (>0.95)
(pˆ2 + pˆ3 = 0.084), ωˆ2 = 4.736
Model B
-8716.36 pˆ0 = 0.846, pˆ1 = 0.099, (pˆ2 + pˆ3 = 0.055)
ωˆ0=0.310, ωˆ1=2.278, ωˆ2=5.994
genotype B
Model A
-8785.33 pˆ0 = 0.781, pˆ1 = 0.218, 30S 32V 47A 86E 95H 98C (>0.92)
(pˆ2 + pˆ3 = 0.001), ωˆ2 = 999
Model B
-8729.168 pˆ0 = 0.417, pˆ1 = 0.071, (pˆ2 + pˆ3 = 0.513)
ωˆ0=0.335, ωˆ1=2.415, ωˆ2=0.137
genotype C
Model A
-8737.935 pˆ0 = 0.747, pˆ1 = 0.232, 5V 79L (=1)
(pˆ2 + pˆ3 = 0.021), ωˆ2 = 9.608
Model B
-8750.280 pˆ0 = 0.850, pˆ1 = 0.150, (pˆ2 + pˆ3 = 0.000)
ωˆ0=0.295, ωˆ1 = 2.034, ωˆ2 = 3.071
genotype D
Model A
-8785.544 pˆ0 = 0.780, pˆ1 = 0.218, 21R 25V 27F 29L (>0.71)
(pˆ2 + pˆ3 = 0.002), ωˆ2 = 999
Model B
-8737.240 pˆ0 = 0.627, pˆ1 = 0.110, (pˆ2 + pˆ3 = 0.263)
ωˆ0=0.313, ωˆ1=2.087, ωˆ2= 0.00
genotype E
Model A
-8771.196 pˆ0 = 0.688, pˆ1 = 0.203, 25V 31S 42V 72D 84L 99S 102F (>0.89)
(pˆ2 + pˆ3 = 0.110), ωˆ2 = 5.023
Model B
-8748.111 pˆ0 = 0.850, pˆ1 = 0.150, (pˆ2 + pˆ3 = 0.00)
ωˆ0=0.294, ωˆ1=2.025, ωˆ2 = 0.00
genotype F
Model A
-8786.054 pˆ0 = 0.781, pˆ1 = 0.218, 24P 29L 33H 44A 69M (>0.66)
(pˆ2 + pˆ3 = 0.0007), ωˆ2 = 999
Model B
-8748.521 pˆ0 = 0.850, pˆ1 = 0.150, (pˆ2 + pˆ3 = 0.00)
ωˆ0 = 0.294, ωˆ1=2.025, ωˆ2=46.987
genotype G
Model A
-8781.898 pˆ0 = 0.631, pˆ1 = 0.169, 9L 44A 57R 86E (>0.65)
(pˆ2 + pˆ3 = 0.200), ωˆ2 = 1.986
Model B
8743.369 pˆ0 = 0.598, pˆ1 = 0.105, (pˆ2 + pˆ3 = 0.297)
ωˆ0=0.285, ωˆ1=2.035, ωˆ2=1.731
genotype H
Model A
-8793.564 pˆ0 = 0.782, pˆ1 = 0.218, No positive sites
(pˆ2 + pˆ3 = 0.00), ωˆ2 = 999
Model B
-8747.710 pˆ0 = 0.625, pˆ1 = 0.110, (pˆ2 + pˆ3 = 0.265)
ωˆ0=0.294, ωˆ1=2.037, ωˆ2=0.246
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4.3.5 Posterior Probability Estimates of Omega
The parameters estimates described above focussed on specific sites within HBx under positive
selection. The posterior probability estimate from PAML was used to show the proportion of negative
(ω <1), neutral (ω = 1) or positive selection (ω >1) at each nucleotide across HBx. Thus this final
estimate provided a more complete depiction of selection across HBx in different subtypes.
Fig 4.7-A shows the average selection probabilities across all genotypes. Fig 4.7-B and Fig
4.7-C display specific selection probabilities for genotype A and C respectively. Overall the average
data showed that the disordered regions (25-55) as well as a few clusters in the transactivation
domain have a higher probability of being under neutral or positive selection. This is in contrast
to the data for genotypes A and C, where numerous sites have a higher probability of being under
positive selection. Comparisons between the genotypes-specific and averaged datasets highlights
the inherent problem with averaging data.
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Figure 4.7: Posterior probabilities across all nucleotides within HBx displayed as Bayes Empirical
Bayes values per codon. A - mean data across all genotypes, B - data for genotype A, C - data for
genotype C. Sites under positive selection are displayed in green, sites under neutral selection are
displayed in orange and sites under negative selection are displayed as blue.
88
4.4 Discussion
The HBV genome provides an interesting model with which to study the evolution of overlapping
sequences. Studies have previously focussed on the surface and polymerase genes within HBV, as
surface is entirely encoded within the polymerase gene and has a p3/s1 orientation (i.e. the third
nucleotide of each polymerase coding triplet corresponds with the first nucleotide of each surface
triplet, see Fig 4.1). However, the evolution of the HBx gene has not previously been described. As
hbx overlaps with polymerase on its N-terminus and pre-core on its C-terminus, as well as having a
non-overlapping region in the middle of its sequence, it was hypothesised that these three segments
of hbx have different evolutionary constraints.
Entropy Initially, a cumulative entropy value was calculated for each of the three nucleotide posi-
tions of hbx coding triplets. This calculation is simply a measure of the sequence variability in an
alignment at a particular position. The higher the variability, the higher the entropy value; the lower
the entropy value the more certainty in the prediction of which nucleotide or amino acid is present at
a particular position. Substitutions in the 3 different nucleotide positions will have different outcomes
for the sequence concerned, and in overlapping genes the overprinted gene would importantly, be
affected as well.
Evolution in the segment of hbx that overlaps with the polymerase gene, (encompassing 54 %
of HBx protein length or amino acids 1-83) occurs mainly as a result of x1/p3 substitutions. This
mechanism was evident in all the genotypes and importantly was similar to that reported by Zaaijer
et al, where evolution of the surface region was found to occur primarily at s2/p3 sites. This result
means that a nucleotide substitution in the x1 position, which would be non-synonymous in HBx is
likely to be synonymous in P (p3). Additionally, mutations in the x2 and x3 positions were shown to
be less frequent for this domain of HBx (Fig 4.2).
The middle section of hbx, which does not overlap with other HBV genes showed a different
pattern of entropy. Evolution still occurred primarily via substitutions at x1, but there was a marked
increase in substitutions at x2 positions. This is likely to be a result of the relaxation of substitution
constraints compared to segment one which were dictated by the polymerase overlap. Substitutions
at x3 sites were still as rare as in the first segment of hbx.
The last segment of hbx which overlaps with the pre-core section of the core gene did not show
substantial entropy as shown by the low entropy values for these six amino acids. Nonetheless,
evolution in this section was shown to occur primarily in the x2/c3 and x3/c1 positions and is thus
consistent with reports published for the surface and polymerase overlapping domains (200).
Ka/Ks Analyses After determining at which codon positions substitutions were occurring, it was
important to identify whether the evolutionary pressures were under positive selection or whether
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they were merely polymorphisms.
The Ka/Ks ratio, which can be used to identify regions under positive selection was calculated
first. Positive selection was suggested to occur in the following three sections of hbx : in genotypes
A, E and F, there was a distinct spike in positive selection between amino acids 0-40; a cluster
of positive selection within all the genotypes, between amino acids 80-160 (with values between
two and eight) was observed; the trans-activation domain showed 3 spikes around nucleotides 300,
375 and 440 although values were between two and three. A matrix plot of the sliding window
Ka/Ks values indicated that although most of the amino acids are under negative selection and
thus clustered below one, there are distinct amino acid positions within certain genotypes that are
experiencing positive selection, and are unique to that genotype. This may mean that HBx from the
different genotypes is experiencing selection pressure unique to that genotype such as geographic
separation, differences in ethnicity and healthcare disparities.
There are several sites in genotype A under positive selection, which are also under positive
selection in genotypes B, C and E. A comparison of genotypes A, B and C with genotype E shows
that there are sites under positive selection unique to the latter that are not present in the former
three. A clearer illustration that some of the HBV genotypes are under different selective pressures
is shown when comparing genotypes A and D and C and D, where sites showing Ka/Ks ratios
substantially >1 in one genotype, are under negative or neutral selection in another genotype.
Even though the Ka/Ks ratio is a fair indicator of positive selection at the sequence level, it is
unable to measure evolutionary changes brought about by changes to regulatory regions of genes,
making it suitable for protein coding genes only. Ka/Ks also has limited power in determining se-
lection in closely related lineages (such as the sequences used in this study) and cannot consider
balancing selection where a polymorphism is maintained in a population. Many approaches average
the Ka/Ks across the gene however, if a mean Ka/Ks >1 is calculated, regions within the gene may
still be experiencing negative or neutral selection (for example). Thus it is important not to average
when calculating the Ka/Ks values for a gene. Furthermore, as it is more common for transitions (T-C
and A-G) to be favoured over transversions (result of the bias in the frequency at which various nu-
cleotides are swopped (218)), models need to account for non-homogenous rates of exchange (219).
The Nei and Gojobori method used in this chapter overestimates non-synonymous substitutions
and underestimates synonymous substitutions. Despite this, the software package provided a less
complicated result output as compared to other packages. In addition this method included sliding
window analysis which generated a Ka/Ks for HBx without averaging.
The analyses presented in this chapter do not take in account when sequences were initially
described. As it can take several generations for deleterious mutations to be removed from a popu-
lation, it would be useful to include time as a component of the analysis. This would be particularly
challenging as even though there are 350 million chronically infected people with the virus, there are
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just over 2 000 full genomic sequences of HBV in public databases. Many of the entries are not well
annotated which leaves an even smaller dataset with which to work. Despite these limitations, the
results generated by the Ka/Ks sliding window analyses gave broad (gross) information regarding
regions undergoing positive selection within HBx.
PAML Site Selection Analyses To further examine potential sites within HBx under positive se-
lection, a comprehensive set of analyses were applied using other rigorous models. The dataset of
re-genotyped and re-annotated HBV genome sequences was analysed by various models using the
PAML software suite (208). As displayed graphically in Fig 4.5, there are several sites within HBV and
HBx that are specifically under positive selection. Amino acids and probabilities of positive selection
are presented in Appendices A.1, A.2, A.3 and A.4 and only data for HBx is discussed further.
HBx shows an interesting partition of negative selection in the segment of the gene which forms
the boundary between the negative regulatory domain and the trans-activation domain (nucleotides
200-260 in Fig 4.4). The negative selection observed in this region suggests that amino acid
changes in this region are not tolerated thus highlighting the importance of this sequence within
HBx. This approach provided a more accurate description of where mutations in HBx are likely to
occur, and importantly, where in the gene they are likely to become fixed in the population. As with
the calculation of the Ka/Ks, it would also be useful to include the effect of time, as in the analysis
of closely related sequences, it is uncertain if these sites (calculated using PAML) represent fixation
events in different genotypes, or polymorphisms that have segregated within a population (220).
PAML Branched Sites Selection Assuming that two lineages of HBx are evolving under purifying
selection, and that the lineages are periodically subjected to bursts of adaptive change, a compar-
ison of two sequences is unlikely to show a dN/dS ratio significantly greater than 1. Thus positive
selection in one lineage is obscured by the other lineages as a result of the methods used to analyse
the data. Therefore methods have been developed to determine whether there are different sites
under positive selection, in different lineages of a phylogeny. PAML contains such methods which
are based on a maximum likelihood approach and the models were applied to a phylogenetic tree
constructed using all the HBx sequences used in this chapter.
The application of PAML branched site tests (211,221), where each genotype (the foreground) is
compared to all the other genotypes (the background), showed that there are sites in almost all HBV
genotypes that are under positive selection (Fig 4.6 and Table 4.3). This reflects what was observed
in both the Ka/Ks ratio calculations as well as the site models (Table 4.1).
Generally models used in the study of the evolution of sequences are designed for certain cate-
gories of sequences, for example divergent as opposed to closely related sequences. Unfortunately,
PAML suffers from limitations in the analysis of closely related sequences. The calculation of ω
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(dN/dS) by PAML explicitly ignores polymorphisms that segregate within a population and instead
represents each divergent species as a single sequence. Additionally, the package does not con-
sider mechanisms by which a substitution enters a population and eventually becomes fixed. As
stated by Kryazhimskiy and Plotkin, these simplified assumptions are acceptable when analysing
substitution rates between long divergent species (220). Additionally, all amino acid changes are
assumed to be advantageous which is unrealistic, and as substitutions of amino acids are known
to correlate with chemical properties, it is unclear how this information could be incorporated into
current models (222,223).
Despite the limitations of the PAML analysis presented in this work, the results do demonstrate
that there is strong positive selection on the negative regulatory domain which was predicted to
be disordered. This suggests that the segment evolved more recently in a de novo, over-printing
fashion. The evolution of HBx presented in this chapter fits with the three scenarios proposed by
Rogozin et al for the modes of evolution in overlapping genes (224). Firstly, the C-terminus of an
overlapping protein evolves neutrally or almost neutrally. Secondly, the new protein coding region
undergoes positive selection of non-synonymous replacement substitutions, thus altering its phys-
ical properties quite rapidly. Thirdly, the terminal regions of the two overlapping genes experience
different modes of evolution.
The selection factors responsible for differential evolution in hbx could be as a result of stochas-
tic processes in host-pathogen interactions, especially as the different genotypes are geographically
separated. Additional factors could include HBV vaccine coverage, the proportion of the host pop-
ulation infected with HBV, regional differences in health care provision, cultural practises related to
exposure to bodily fluids, or concurrent infections with other pathogens or parasites. The establish-
ment of causality for the differences in positively selected sites between genotypes is not possible,
and is thus open to speculation.
Applications of Evolutionary Patterning Analysis Phylogenomic analysis involves the compari-
son of genes and gene products, generally in the context of a whole genome to determine conserved
functional residues. Such an approach offers insights into the evolutionary process and is frequently
used in the drug design process (225). Current treatment regimens for chronic HBV infection rely
on nucleotide and nucleoside mimics to inhibit viral replication. Therefore, although there are no
peptide inhibitors available for the treatment of HBV, there exists a useful method of determining
the best possible target sites that would be effective across multiple genotypes. The evaluation of a
plot of cumulative probabilities in Fig 4.7 demonstrates quite clearly which sections of HBx are sub-
jected to positive evolutionary pressures and those that are not. This evaluated output, which can be
applied to any sequence of interest, is known as evolutionary patterning, and has been previously
applied to Plasmodium falciparum (226). Sequences under strong negative selection are unlikely to
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undergo substitution and thus present attractive targets. Importantly, different evolutionary pres-
sures in the different genotypes of HBV means that different sections of proteins are more or less
likely to undergo mutation. This is illustrated in Fig 4.7. It is important to consider this information
when designing chemotherapeutic agents, such that the rapid generation of drug resistant mutants
can be mitigated against.
Overall the analysis of evolution across multiple related pathogen sequences such as those in
the HBV family has not been exploited. The power of these approaches is under appreciated, partic-
ularly with regards to human pathogens that cause a high disease burden in Africa. Computational
biology and evolutionary studies will most definitely play a more prominent role moving forward and
should be more readily included in research approaches.
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Chapter 5
General Discussion and Conclusions
HBV has been implicated in disease since 1947, yet despite discovery of the HBx protein in the
early 1980s, controversy remains as to its function in both the viral lifecycle and progression of
HBV-associated HCC. Structural studies of other pathogen-derived proteins have been of benefit to
targeted drug development in diseases such as malaria (caused by Plasmodium falciparum). Con-
versely HBx structural studies have been hampered by expression difficulties and as a result no
X-ray or NMR data are available for HBx. Furthermore, the role that HBx plays in liver disease has
been negatively affected by reliance on transfection-based overexpression systems and physiologi-
cally irrelevant cellular models. These methodologies may have inadvertently introduced numerous
artefactual findings into the field.
The work presented in this thesis adds to the growing body of knowledge and methods used
to study the function/s of HBx, with particular emphasis on the generation of soluble protein within
eukaryotic cells. In addition an extensive evolutionary analysis across hundreds of HBV sequences,
and an in-depth exploration into disordered proteins and antibody problems was conducted. Taken
together these aspects as presented in this thesis provide a solid argument to explain some of the
controversies around HBx and deliver an enlightening explanation of the complex HBx protein.
5.1 Approaches used to Express and Purify HBx
The yeast S. cerevisiae is a well established system that has been used by researchers to express
a multitude of proteins of biomedical and biotechnological importance.
The expression of HBx protein in S. cerevisiae was guided by previous expression studies of the
other major proteins of HBV. The HBV vaccine, derived from the HBs protein, was first produced
using S. cerevisiae in 1982, under the control of an alcohol dehydrogenase (ADH1) promoter (227).
The Core protein, responsible for the core particles, was produced four years later under the control
of a yeast acid phosphatase (APase) promoter (228). The Polymerase protein was also expressed
in yeast for drug testing although not in macro quantities (229). Therefore it was reasoned that S.
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cerevisiae would be a good system in which to express HBx.
In Chapter 2, the expression studies using S. cerevisiae were not initially deemed to be success-
ful as no HBx protein could be detected from any of the vectors used. Two additional mammalian
expression vectors mirrored the results of the yeast vectors i.e. no protein was detected on Western
blots. As full length mRNA was detected for all vectors, an HBx fusion protein was generated to try
and visualise HBx directly within the cells. Fluorescence and immunofluorescence microscopy data
suggested that antibody binding to HBx in Western blotting analysis was the key problem. Overall
this suggested that the denaturation steps required during Western blot analysis were altering the
antigenic sites on HBx and thus negatively affecting antibody binding site recognition. As the HIS
tag was not successfully used nor detected, future work should include multiple affinity tags. A com-
bination of small affinity tags such as 6xHIS, cmyc, haemagluttinin and FLAG would offer a much
higher chance of detecting and purifying recombinant HBx. A detailed critical discussion of antibody
problems is presented later in this chapter (section 5.1.1).
In parallel with the expression of HBx from mammalian vectors, the use of an MBP fusion tag
vector was also explored. This allowed purification of HBx to a high degree as well as major im-
provements in solubility and stability of the protein as compared to non-fusion protein systems.
The MBP-HBX construct was sub-cloned into SFV expression systems to allow for eukaryotic ex-
pression. SFV has been used to express a myriad of proteins, including the structural proteins from
HBV (171), suggesting that it would be suitable for the expression of HBx. Disappointingly only the
pSFV-b12A-ppt-MBP-HBx showed detectable intra- and extracellular HBx protein, albeit with the
continued presence of degradation products. This suggested that the fusion protein was only par-
tially stable in SFV systems, and thus the yield of HBx could be improved with further modifications
to the vector. The scaling up of the SFV expression system was also met with technical hurdles.
SFV has been successfully used in many studies to express a variety of proteins. However,
the limited success in expressing HBx using this system suggests that there are factors influencing
either the intracellular stability of the SFV replicon or that certain proteins (i.e. HBx) are difficult to
express using SFV. It is important to determine whether these factors are general (e.g. an interferon
response that expels the SFV replicon) or specific, such as protein toxicity. A combination of the
cellular toxicity associated with the overexpression of intrinsically disordered proteins (IDPs), the
difficulty in generating high titre virus with pSFV-b12A-ppt-MBP-HBx and the unproductive efforts
in selecting clones of the ncSFV-pac2A-MBP-HBx suggests that it was a combination of general
and specific factors. It would thus be worthwhile to determine the interferon response of BHK-21
cells before investing significant resources and time in trying to express difficult-to-work-with proteins
such as HBx. It would be worthwhile testing other cell lines for the ability to express this construct
as well and/or developing interferon knockout cell lines. Close collaboration with the developers of
the SFV vectors will help ensure that the large-scale expression of eukaroytic HBx is met with future
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success. The minimal expression of soluble HBx remains a significant step in the right direction and
represents a promising point from which further expression studies can continue so that structural
determination of HBx can be achieved.
5.1.1 Problems with Antibodies
The work in Chapter 2 highlighted the limitations in relying on antibodies for detecting recombinant
proteins. Despite antibody detection being a well characterised and successful technology, there are
instances where false positives and false negatives occur as a result of the incomplete characteri-
sation of the antibodies. The frequencies at which these false results occurs is not known, although
The Human Protein Atlas, (an initiative which hopes to create and characterise polyclonal and mon-
oclonal antibodies for every human protein), has noted that only 35 % of commercial antibodies that
have been tested in their strict quality control pipeline actually detect antigens as specified by the
manufacturers (157). This suggests that false results are fairly common and have undoubtedly led to
artefactual findings detrimental to proteomics and many other fields of research.
The protein expression challenges in this project were typified by such misleading antibody activ-
ity. In-house anti-HBx antibodies were developed with the assumption that the structural differences
between prokaryotic and eukaryotic HBx were minimal thus allowing both forms of the protein to be
recognised by the antibodies. This was unfortunately not the case and highlights the major problem
in developing monoclonal antibodies against E. coli derived antigens without adequate characteri-
sation of the binding capacity to eukaryote-derived protein. An assumption such as this is likely to
be correct in many cases, but as HBx is known to have a low antigenicity, there should have been a
larger focus on prokaryotic versus eukaryotic binding validation.
Literature suggests that binding events should be allowed to occur in solution to encourage
interactions between native protein forms and the antibodies (161,162) ans this is recommended for all
future attempts at creating anti-HBx antibodies. Additional specifications should include confirmation
that the antibodies are able to bind to eukaryotic HBx protein, whether by Western blot or ELISA,
and an explicit statement listing which binding capabilities have and have not been tested.
The default use of a multiple antigenic tag (6xHIS, HA, FLAG and/or c-myc) together with a
solubility-enhancing fusion protein (SUMO, NusA or MBP) is likely to ensure that the large scale
reproducible expression of soluble HBx will be achieved.
5.2 Instability, Disorder and Moonlighting in HBx
The evidence of disorder in the secondary structure of HBx was initially shown by Liu et al from re-
sults of CD-spectroscopy using soluble, pure, E. coli derived HBx (128). As CD-spectroscopy cannot
infer where the structural disorder lies in the protein backbone, various predictive models were ap-
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plied to the HBx sequence with results showing the presence of a major disordered region between
amino acids 25-52. These predictions are shown in Fig 2.14 and whilst all four models showed sim-
ilar outputs, PRDOS (Fig 2.14-D) indicated that there may be additional regions of disorder outside
of amino acids 25-52. Based on the presence of multiple disordered regions within the sequence, it
is thus possible to presumptively classify HBx as an Intrinsically Disordered Protein. However as this
prediction is only based on CD-spectroscopy and data modelling, structural determination should be
used to verify the disorder within HBx as it has important implications for HBx-related research.
As IDPs generally have an elevated protease sensitivity and a lower half life (143) this offered
an explanation as to the poor stability and short half-life of HBx. Furthermore these factors could
also have contributed to the technical challenges in working with HBx as detailed in Chapter 2
and 3. Intriguingly the characteristics of IDPs also apply to a specific group of proteins known
as ”moonlighting proteins”. Constance Jeffery coined the term for those proteins with the ability
to perform more than one cellular role (230). Examples include enzymes, chaperones, transcrip-
tion factors, and proteins with additional functions. The characteristics defining moonlighting pro-
teins include one of more of the following: 1) the capacity to bind to different partners, 2) the
performance of different functions in various parts of the cell, 3) the ability to function differently
inside the cell compared to outside, 4) a change in function as a result of a change in tempera-
ture, 5) a change in the redox state of the cell, 6) distinct activities in diverse cell types, 7) the
effect of oligomerisation, i.e. the same protein can have one function in a monomeric state and
another in a multimeric state, 8) the ability to elicit both inhibiting and activating effects on dif-
ferent partners or even the same molecular partner, which may also depend on the concentra-
tion of the substrate, ligand or co-factor available. It is important to note that these character-
istics are not mutually exclusive since a combination might be required for a protein to function.
For example, band 3 of the red blood cell membrane is an anion exchanger but also regulates
the rate of glycolysis in red blood cells (231). There does not seem to be any overlying similar-
ity between moonlighting proteins other than the ability to perform two or more disparate func-
tions. Four examples of proteins that fulfil these criteria are briefly discussed below, and a more
comprehensive list may be found in (Jeffery 1999) (230) and more recently in (Jeffery 2009) (232).
1) E. coli PutA displays proline hydrolase and pyrroline-5-carboxylate dehydrogenase activity when
associated with the plasma membrane, but when the protein is in the cytoplasm it binds DNA and
acts as a transcriptional repressor (233). PutA changes function as a result of substrate concentration
i.e. the protein binds to the membrane when cytoplasmic substrate concentrations of proline are
high, but binds to puta control-region DNA when cytoplasmic substrate concentrations decrease.
2) Neurophilin is a cell surface receptor on endothelial cells that detects endothelial growth factor
and provides an indication of when new blood cells are needed (234). Contrastingly, in nerve axons it
serves as a detector of semaphorin III which helps direct axon growth (235). 3) Thymidine phospho-
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rylase has a different function inside as compared to outside of a cell. In the cytoplasm it catalyses
the dephosphorylation of thymidine and deoxyuridine to their respective analogs. However in the
extracellular milieu, it acts as a platelet-derived endothelial growth factor which is a stimulant of
chemotaxis and endothelial growth. 4) Glyceraldehyde-3-phosphate dehydrogenase is a glycolytic
enzyme that in a tetrameric state converts glyceraldehyde-3-phosphate to 1,3-diphosphoglycerate,
whereas in a monomeric state is a nuclear uracil-DNA glycosylase (236).
Tompa et al suggested that some moonlighting proteins could have disordered structures (143).
The template-induced folding mechanism that many IDPs use to interact with binding partners may
mean that a single disordered region is able to adopt a variety of conformations when it binds to
different proteins. Additionally, activation or inactivation may occur depending on the binding partner,
and the IDP may bind to the same partner at different sites or in different conformations (143).
In addition, IDPs are tightly regulated from transcript synthesis to protein degradation and studies
have shown that most IDPs are present at relatively low levels, for short periods of time as compared
to structured proteins. The short half-life at the transcript and protein levels may facilitate quick ad-
justments of protein concentrations when environmental conditions or signal inputs change. As tight
regulation of IDPs is a conserved mechanism in S. cerevisiae, Schizosaccharomyces pombe and
humans, this suggests that selective forces operate on both IDPs and their transcripts to precisely
regulate abundance and half-life (237). This is likely similar in HBx regulation and there is growing evi-
dence that this tight regulation is exploited by viruses to establish successful infections. It is possible
that exploitation of IDP regulation occurs via the use of mimicry i.e. by viruses encoding host-like
peptide motifs which are able to titrate host cell proteins and thus alter conditions to make infection
more successful (238–242). Related to this, several important viral studies have uncovered a novel
class of compact non-globular protein interaction interfaces (243–246). These are called short linear
motifs, SLiMS, LMs or minimotifs and are ubiquitous in eukaryotic genomes as well (247). The defin-
ing features of short linear motifs include the capacity to encode a functional interaction interface of
only three to ten residues, an enrichment in the intrinsically disordered regions of proteins, the ability
to function independently irrespective of their tertiary structure context, and the tendency to evolve
de novo. Additionally, linear peptide motifs have been shown to be dosage sensitive, and are thus
tightly controlled to prevent toxicity upon overexpression under physiological conditions (247). Vavouri
et al suggests that disordered regions are prone to making promiscuous molecular interactions via
linear motifs when their concentration is increased, and this is the likely cause of toxicity (247).
Linear motif-mediated interactions are abundant in nature, and as the motif binding domains
are present in many families of related proteins with similar binding sequence preferences, there is
a strong possibility that they will bind to each other’s targets if their concentrations are increased
within the cell (248,249). Concomitantly, scaffolding proteins are critical regulators of many key cell
signalling pathways and exhibit one-to-many binding often mediated by short linear motifs (250). As
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scaffolding proteins play a crucial role in coordinating specific interactions, they are required to be
present in cells at a defined concentration range to avoid molecular titration or cooperative binding.
It has also been noted that several of these scaffolding proteins possess disordered domains (251).
The inherent characteristics of moonlighting IDPs and scaffolding proteins offer the clearest ex-
planation of the functions of HBx, provide reasons for contradictions in the literature and elude to its
role in the development of HCC. The disordered region within HBx may be a mechanism used by
the protein to mediate its many functions. As the predicted disordered sequence is only 25 amino
acids in length and is located within a region under positive selection (i.e. prone to mutations), it
provides the protein with a dynamic binding site capable of interacting with multiple partners. The
short predicted disordered region of HBx could encode multiple linear motifs (typically 3-10 amino
acids long) enabling it to bind to multiple protein partners. This has been confirmed as HBx localised
with a cytoplasmic complex containing MEKK1, SEK1, SAPK, and 14-3-3 proteins using antibody
pulldown assays. Mutational analysis of the RXRXXpS phosphorylation motif (amino acids 26–33 of
HBx, pS is phosphoserine) of HBx confirmed that this motif was needed to bind the 14-3-3 scaffold
proteins, which was in turn necessary for the induction of SAPK/JNK activity (252). Separate linear
motif interactions include DDB1 binding (HBx amino acids 84-101) (253), SH3 binding domain PxxxP
starting at amino acid 26 (254) as well as NES binding motifs (amino acids 89-100) (255).
Whilst the presence of linear motifs in HBx have been partially explored, these experiments
regarded the linear motifs as static structures without cognisance of protein disorder. The total
number of potential interactions was not explored. Furthermore the use of overexpression in some
of the studies raises doubt as to the accuracy of the findings. Overexpression constructs specifi-
cally generate protein levels that far exceed physiologically normal concentrations thus encouraging
non-specific interactions. Combined with the promiscuity of disordered proteins and the presence
of linear motifs, overexpression studies of HBx have most likely generated spurious findings and
incorrectly identified artefactual interactions. Nevertheless these studies have provided an initial
indication that interactions between HBx and cellular proteins in part occur via linear motifs.
The disorder and linear motifs of HBx described above may also link to the moonlighting char-
acteristics of this protein. As noted in the introduction of Chapter 2, conclusions regarding the
sub-cellular localisation of HBx remain unresolved. Su et al established that anti-HBx immuno-
cytochemical signals were only located in the cytoplasm of explanted liver cells (256), and this was
also shown using liver cells stably transfected with HBV (82). These bodies of work are important
because naturally infected liver samples i.e. liver cells with no overexpression of HBx were used.
Work by the same lab, but using cultured cells and CMV-driven HBx plasmids, established that HBx
was present in both the cytoplasm and nucleus (84). Conversely Haviv et al, also used cultured cells
and overexpression plasmids and observed that HBx was primarily located within the nucleus (83).
Taken together these datasets highlight the discrepancies produced when disordered proteins such
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as HBx are overexpressed in cell culture models, and argue strongly in favour of abandoning CMV-
driven HBx expression in favour of tuneable or conditional expression systems (e.g. tetracycline or
RNA interference based vectors (257)).
Overexpression studies with HBx have also identified a role for HBx in p53 modulation (258). The
frequency of p53 mutations in HBV-related HCC were lower than the frequency of p53 mutations in
chemical carcinogen-related HCC (259–261). The authors of this study suggested that this was as a
result of HBx counteracting p53 function, thereby influencing cellular death and apoptosis. However
as overexpression was used and some of the studies conducted in physiologically irrelevant mouse
cell lines (NIH3T3) the data should be interpreted with caution. In particular if HBx is indeed an IDP
the high number of interactions observed is not surprising and the relevance and accuracy thereof
is questionable. Indeed in a study conducted with the effects of overexpression in mind and in
relevant cellular models, Terradillos et al found that there was a direct, dose-dependent apoptotic
effect of HBx in transiently transfected, liver-derived cell lines (262). There was also evidence that the
intentional overexpression of HBx induced apoptotic death. Contrary to the authors conclusions this
indicates that these observations were due to the toxic effects of overexpressing a disordered protein
combined with the disorder of p53 and the propensity of IDPs to form non-specific interactions at
elevated levels. In summary, numerous observations suggest that HBx is an IDP that contains linear
motifs capable of binding multiple protein partners, and when overexpressed, particularly in non-
hepatic cells, artefactual interactions abound.
5.3 The Evolution of HBx
The compact nature of the HBV genome provides an interesting model for the study of overlapping
genes and the efficient use of sequence space. This means that the HBV genome can encode
fewer proteins overall but maintain multiple functions and interactions. HBx is particularly interesting
as it overlaps with two other genes, contains intrinsic disorder and may function as a moonlighting
protein. This is unusual as most overlapping proteins have only one overlapping partner. The
measurement of entropy across any gene provides simplified information that is otherwise difficult to
discern from substitutional models. In addition, measurements of entropy reduce the complexity of
models, for example the higher the entropy for a given site within a sequence the greater the number
of substitutions that occur at that site.
Entropy A comparison of the first segment of hbx which overlaps with polymerase (amino acids
1-83 Fig 4.2 Panel A), shows that the first codon position of hbx undergoes the most substitutional
activity. This would result in a change within HBx without a change in Polymerase. However, the en-
tropy in the x2 and x3 positions are generally equal as mutations here are likely to affect polymerase
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and will thus be selected against. Taken as a whole, the pattern of reading frame substitutions is
similar for most of the genotypes, however comparison between individual genotypes reveals many
differences in the preference of one reading frame over another. For example certain genotypes
(E, G and H) show higher activity in the x2 position while others (A and F) show higher activity in
x3. The effect of the genotype-specific substitutions and preferences is suggestive of unique virus
host interactions. Furthermore the effect the reading frame preferences have on the functioning of
the numerous regulatory sequences contained within HBx are not dealt with in this work, and will
provide an important angle for future analysis.
Positive Selection A broad overview of substitution activity using Ka/Ks estimation within hbx
revealed that various sites were under positive selection, predominantly those predicted to be dis-
ordered. Further analysis using the PAML suite of evolutionary models confirmed these data and
suggested that the negative regulatory and transactivation domains were also under positive selec-
tion. The data also showed a notable absence of sites under selection between these two domains.
It is difficult to determine the relevance of these sites of positive and negative selection in the ab-
sence of complete structural data for HBx. However, analysis across all genotypes showed a similar
trend of positive selection within the disordered region (amino acids 25-55). This suggests that the
genotypes are experiencing similar evolutionary pressures within HBx which is interesting given that
the genotypes of HBV are still largely geographically separated. Further analysis to determine if
these positively selected sites are linked to particular linear motifs would be an interesting avenue
of enquiry. This may also be a unique evolutionary strategy for using redundancy to allow multiple
protein expression without an increase in the HBV genome size (263).
5.3.1 Evolutionary Patterning and Drug Targeting (Posterior Probability Estimates
of Omega)
Evolutionary patterning is a tool that can guide the development of chemotherapeutic agents, small
inhibitory molecules and peptides against protein targets of interest. The data generated using this
technique allows one to determine whether amino acid sites are under positive or negative selection,
and thus more or less likely to undergo substitution at some future point. This is especially applicable
to viruses, as their mutation rates are several fold higher than humans or eukaryotes in general. Thus
therapeutics designed against viral proteins are likely to have a shorter therapeutic lifespan.
Sites under negative selection present better targets due to the lower likelihood of resistance
mutations developing. The region between the negative regulatory and transactivation domains of
HBx is under negative selection. As there no sites under positive selection here, it suggests that this
region is important for HBx function and thus substitutions within this region are selected against,
thereby providing a potential drug target site (Fig 4.5). However without adequate structural data,
101
it is not possible to determine whether this would be viable or not. The disordered domain in HBx
would not be a good target as it has numerous sites that are under positive selection and is thus
more likely to undergo substitution.
As HBx interacts with numerous IDPs such as p53, it may be more beneficial to develop drugs
against these targets or the regulatory enzymes that post-translationally modify IDPs instead (264).
IDPs are strictly regulated, but the action of viral infections on these proteins causes their dis-
regulation, resulting in a disease phenotype. A viral protein such as HBx disregulates the human
p53 IDP which is one of the steps involved in the development of HCC. The generation of small
molecules aimed at restoring the levels of host IDPs (e.g. p53) via competitive binding to the af-
fected IDP might be feasible course of treatment in the future. Importantly the propensity of IDPs
to bind to multiple partners would probably be mirrored by the ability of small molecules to bind to
multiple IDPs as well. Thus the spectre of off-target effects would need to be recognised and studied
in detail. Two recent studies using disordered regions of cellular proteins as potential drug targets
illustrate the potential of this approach: 1) the Myc transcriptional regulator is thought to regulate 15
% of genes, and is found in many cancers as a mutated species. Small molecules against Myc were
found to shift the equilibrium of dimerisation of Myc with its binding partner Max (myc-associated
factor X), thus counteracting the effects of Myc overexpression common to many cancers (265). 2)
BRD4 protein which associates with chromosomes during mitosis and to the RING3 serine/threo-
nine kinase was targeted with a cell-permeable compound against its disordered histone tail in the
bromodomain. This event was shown to prevent BRD4 from binding to the chromatin and thus estab-
lished an anti-proliferative effect in human squamus epithelium cells (266). Even though this strategy
would require prior knowledge on the concentrations of cellular IDPs from patient to patient, it may
be more successful long-term as the host target protein is less likely to undergo mutation.
5.4 Future Work and Recommendations
The work in this thesis focussed on the expression and purification of HBx and provides an excel-
lent point from which further studies at improving the results presented, can be attempted. The
difficulties associated with the low antigenicity of HBx should be noted, and only antibodies of high
quality that have been rigorously tested should be used. Ideally, HBx should be expressed with a
solubility-promoting tag (MBP, NusA or SUMO) that has another purification tag such as 6xHIS to
permits rapid purification of the protein and maximum yield. Furthermore, considering the antigenic
differences that were discovered between the E. coli and eukaryotic HBx protein, it is recommended
that structural studies are pursued using eukaryotic HBx.
The presence of disorder in HBx is an important finding as IDPs are known to be difficult to
crystallise and many structural biologists would consider it a waste of time and resources to do so.
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Unless there are a few stable, low energy conformations that HBx can assume, the isomorphous lat-
tice that is needed for X-ray studies will probably not form because of the structural interconversions
of the protein (267). It is thus suggested that structural studies of HBx protein should focus on a wide
array of techniques including: small angle X-ray scattering, paramagnetic spin labelling in combina-
tion with ensemble molecular dynamics and single molecule fluorescence, high-speed atomic force
microscopy, Raman optical activity and NMR (reviewed in (268)).
It is hoped that due to the characteristics of IDPs, the use of overexpression and irrelevant cellu-
lar models is rejected to prevent artefactual research findings from continuing to cloud the functions
of HBx and its contribution to the development of HBV-associated HCC. The use of inducible and tun-
able expression systems but more importantly natural infection conditions is encouraged to ensure
that the levels of HBx, and thus the extent of its interactions with cellular targets is physiologically
relevant. The lack of availability of cell culture and small animal models of HBV infection has been
an important limiting factor. Greater resources should be placed on elucidating the cellular receptor
used by HBV to infect cells. Knowledge of the receptor will aid the development of cell culture and
small animal models.
The evolutionary analysis of HBx provided important insights into the sequence plasticity of hbx
and showed that the main disordered region is under strong positive selection. Whether this is a
result of its de novo creation as discussed in Chapter 4, or interactions with the human immune
system is a topic for future work. It is important to view bioinformatic analysis of hbx and protein
function in general as a tool to improve the design and planning of wet lab experiments. For example,
work in this thesis suggests that the development of inhibitors against HBx should take into account
the presence of disorder and the propensity of substitutions to occur in these regions. It is suggested
that inhibitor development focuses on cellular partners that HBx is known to interact with under
normal physiological conditions.
This work will hopefully result in a re-evaluation of the methodologies used to gather data on the
functions of HBx and other difficult to express proteins. Consideration of the role of IDPs in viral
infection and cancer development will accelerate the description of the role that HBx plays in the
development of HCC and will be useful in the design of inhibitors against HBx ligands. The high
number of publications involving HBx conveys a sense of importance to this protein which may not
a true indication of its biological activity. Upon personal reflection of the first papers linking HBx and
HCC development, I concluded that the field was hungry for a single protein that could be respon-
sible, and HBx became the preferiti. Two decades have followed with little change to the original
methodologies and dogma. Consequently much artefactual data has been generated. Through rig-
orous analysis of all data with particular emphasis on negative results and by not compromising on
methodologies used in this study of HBx, we have illuminated the need for realignment within the
HBx field. It is hoped that this work will contribute to the understanding the role IDPs play in the
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development of cancer. IDPs and linear motifs may provide a novel avenue for the development of
anti-cancer drugs, especially when genes are over-expressed. Furthermore viral exploitation of host
IDPs via linear motifs to establish infection provides targets to develop antiviral therapies. Hopefully
another decade will not lapse before these suggestions are realised.
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Appendix A
Supplementary Data
A.1 Supplementary Data
A.1.1 Testing for overlapping antigenic site reactivity of anti-HBx antibodies
Antibodies that had been generated by Dr Wolfgang Prinz against a urea denatured 6xHIS purified,
bacterial expressed HBx antigen were tested to make sure the antigenic sites did not overlap. It
was simply determined whether the incubation of two different antibodies produced a doubling of
the output reading (no overlapping antigenicity), or a change in the output reading (overlapping
antigenicity). This data is not shown.
A.1.2 Immunofluorescence Microscopy Control Images
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Figure A.1: Immunofluorescence microscopy images of HBx staining in HEK293 cells expressing the HBx negative, pCI-Neo-GFP vector. Antibodies specific to
each figure are shown in the top left corner. Blue indicates DAPI staining and red indicates anti-HBx antibodies bound to a Cy3 conjugated secondary antibody.
Cy3 fluorescence was not detected in any samples. Magnification is 100x and scale bar = 5µm.
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Figure A.2: Immunofluorescence microscopy images of HBx staining in HEK293 cells expressing the HBx negative, pCI-Neo vector. Antibodies specific to each
figure are shown in the top left corner. Blue indicates DAPI staining and red indicates anti-HBx antibodies bound to a Cy3 conjugated secondary antibody. Cy3
fluorescence was not detected in any samples. Magnification is 60x and scale bar = 10µm.
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Figure A.3: Immunofluorescence microscopy images of HBx staining in S. cerevisiae cells expressing the HBx negative, YEp-GFP vector. Antibodies specific to
each figure are shown in the top left corner. Blue indicates DAPI staining and red indicates anti-HBx antibodies bound to a Cy3 conjugated secondary antibody.
Cy3 fluorescence was not detected in samples containing primary or secondary antibody alone. Samples containing both primary and secondary antibodies
showed a low presence of Cy3 fluorescence. Magnification is 100x and scale bar = 5µm.
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Figure A.4: Immunofluorescence microscopy images of HBx staining in S. cerevisiae cells expressing the HBx negative, YEpHF vector. Antibodies specific to
each figure are shown in the top left corner. Blue indicates DAPI staining and red indicates anti-HBx antibodies bound to a Cy3 conjugated secondary antibody.
Cy3 fluorescence was not detected in samples containing either primary or secondary antibody only. Samples containing both primary and secondary antibodies
displayed a low Cy3 fluorescence. Stronger fluorescence is observed in the anti-HIS plus secondary treatment, as the empty vector is expected to express a
short, 6xHIS tagged protein. Magnification is 100x and scale bar = 5µm.
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Figure A.5: Immunofluorescence microscopy images of HBx staining in S. cerevisiae cells expressing the HBx negative, pYES2 vector. Antibodies specific to
each figure are shown in the top left corner. Blue indicates DAPI staining and red indicates anti-HBx antibodies bound to a Cy3 conjugated secondary antibody.
Cy3 fluorescence was not detected in samples only containing primary or secondary antibody. Samples containing both primary and secondary antibodies
displayed a low Cy3 fluorescence. Magnification is 100x and scale bar = 5µm.
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Figure A.6: Immunofluorescence microscopy images of HBx staining in S. cerevisiae cells expressing the HBx negative, pYES2-GFP vector. Antibodies specific
to each figure are shown in the top left corner. Blue indicates DAPI staining and red indicates anti-HBx antibodies bound to a Cy3 conjugated secondary antibody.
A low Cy3 fluorescence was detected in S1,S2, S3 and HIS samples containing both primary and secondary antibody. Magnification is 100x and scale bar =
5µm.
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A.1.3 Box and Whisker Key
Figure A.7: Key to interpret the data presented in a box and whisker plot. Empty circles outside
of the main plot represent outlying data points. The upper bar represents the maximum measured
value in the dataset. The upper edge of the box represents the upper quartile, the line going through
the middle of the box is the median of the dataset. The bottom half of the plot is a mirror of the top.
A.1.4 Sites Under Selection
Table A.1: Sites in HBx under positive selection as determined using the Bayes Empirical Bayes
output of Model 8 from the PAML suite. The probability is listed next to each site.
Genotype Sites Under Selection
genoptye A 5L 0.999, 6Y 0.965, 11S 0.996, 29S 1.000, 30G 1.000, 33L 0.985, 42S 0.898, 83H 0.997, 90P 0.983,
115I 1.000, 118F 0.997, 132S 1.000
genotype B 34L 0.61, 87V 1.000, 90T 0.622, 103T 1.000, 113K 0.675
genotype C 5V 1.000, 86Y 1.000, 107L 1.000, 118I 1.000
genotype D 25C 0.995, 29F 0.998, 32P 0.985, 33L 0.987, 35D 1.000, 36L 0.981, 40S 0.933, 41L 0.987, 42S 0.984,
45T 0.971, 83Q 1.000, 97A 1.000, 115L 0.934
genotype E 29V 1.000, 35D 1.000, 83Q 0.955, 89H 0.962, 117L 0.995, 121T 1.000, 123I 0.988, 138A 0.983
genotype F 12A 0.938, 26R 0.983, 37L 0.991, 40S 0.934, 47D 0.976, 48H 0.999, 97R 0.966, 104E 0.933, 112K
0.967, 121T 0.997, 124K 0.961, 142C 0.977
genotype G 9L 0.584, 12S 0.573, 31P 0.7, 88H 0.689
genotype H 44A 0.815, 87W 0.65
113
Table A.2: Sites in HBc under positive selection as determined using the Bayes Empirical Bayes
output of Model 8 from the PAML suite. The probability is listed next to each site.
Genotype Sites Under Selection
genotype A 96E 1.000
genotype B 39V 0.992, 83L 0.799, 109G 0.621, 119L 0.91, 154Q 0.993, 170R 0.887
genotype C 67S 0.808, 154R 0.946, 179E 0.817
genotype D 27G 0.998, 88D 0.999, 96V 0.972, 102A 0.995
genotype E 5H 0.716, 40T 0.55, 49S 0.509, 88N 0.83, 94A 0.691, 134L 0.796, 148P 0.806
genotype F 11F 0.503, 198S 0.564, 210Q 0.547
genotype G No Sites
genotype H 2Q 0.517, 42V 0.595, 79N 0.81, 95T 0.527, 98S 0.542, 105E 0.931
Table A.3: Sites in HBs gene under positive selection as determined using the Bayes Empirical
Bayes output of Model 8 from the PAML suite. The probability is listed next to each site.
Genotype Sites Under Selection
genoptye A 4W 0.833, 39F 0.899, 44H 0.807, 47Q 0.83, 63V 0.77, 72I 0.751, 76A 0.986
genotype B 49S 0.93, 62T 1.000, 64T 1.000, 95L 0.998, 98Q 0.91, 102L 1.000, 114M 0.960, 115Q 0.997, 134F
1.000, 152S 0.999, 156L 0.993, 157K 1.000, 196N 1.000, 272R 0.982, 275T 0.960, 310Y 1.000, 349F
1.000, 361M 1.000
genotype C 30G 0.988, 48N 1.000, 52V 1.000, 152N 1.000, 154A 0.980, 210I 0.999, 241Q 1.000, 318V 1.000,
329W 0.892
genotype D 27A 0.983, 70Q 0.994, 72A 0.998, 95N 1.000, 134A 0.89, 136H 1.000, 137I 0.998, 146P 0.995, 260T
1.000, 270A 0.905, 276F 0.987
genotype E 13H 1.000, 31R 0.999, 49E 0.992, 76K 0.999, 108M 0.916, 123R 0.994, 125R 1.000, 155P 1.000,
200G 0.977, 201T 0.967, 205L 0.999, 215N 1.000, 266L 0.967, 294S 0.921, 317E 0.991, 353P 0.974
genotype F 135F 0.941, 142E 0.984, 260L 0.906
genotype G 148V 0.997, 149N 0.972, 216V 0.978
genotype H 138F 0.907, 190C 0.754, 201Q 0.767, 333E 0.771, 364I 0.713
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Table A.4: Sites in HBp under positive selection as determined using the Bayes Empirical Bayes
output of Model 8 from the PAML suite. The probability is listed next to each site.
Genotype Sites Under Selection
genoptye A 127H 0.986, 170I 0.956, 171K 0.980, 216T 0.997, 247H 0.952, 248S 0.980, 324A 0.995, 554V 0.977
genotype B 15E 0.982, 69K 1.000, 88K 1.000, 98N 0.933, 223Q 0.946, 312L 0.947, 323E 0.938, 331C 0.975,
657N 0.992, 661N 0.973, 781L 0.998, 813R 0.932
genotype C 206C 0.985, 228K 0.985, 260T 0.954, 285A 0.991, 288L 0.998, 381H 0.999, 525M 0.938, 541S 0.986,
556N 0.994, 584Q 1.000, 587H 0.957, 708K 0.997, 767R 1.000, 791D 0.999, 804R 1.000
genotype D 10R 0.932, 114K 0.998, 201C 0.995, 229V 0.986, 233A 0.916, 257L 0.977, 258Y 0.979, 269S 0.927,
275S 1.000, 285F 0.983, 447F 0.909, 470L 0.934, 538P 0.997, 587R 1.000, 592E 0.999, 683A 0.959,
694S 1.000, 719L 0.994, 772S 1.000
genotype E 162C 1.000, 212P 0.987, 221R 0.993, 231R 0.990, 233G 0.919, 249K 0.982, 282T 0.965, 541S 0.981,
572W 0.968, 580K 0.972, 581L 1.000, 644L 0.968, 677M 0.995, 756I 0.988, 757Y 0.995, 796R 0.970
genotype F 30G 0.914, 121L 0.967, 198T 0.901, 261S 0.955, 301P 0.908, 314F 0.995, 486L 0.915, 579N 0.993,
646T 0.972, 729N 0.924
genotype G 305P 0.895, 329S 0.960, 330R 0.982, 769R 0.981
genotype H 35H 0.918, 100K 0.949, 118V 0.926,3 16F 0.917, 591I 0.984, 671L 0.93, 786Y 0.936
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Appendix B
Standard Laboratory Methods
B.1 Bacterial growth, storage and transformations
B.1.1 Bacterial growth and storage
The host bacterial strain used in normal cloning work was Escherichia coli DH5α (269), whereas
protein expression used the BLR-DE3 strain. Cultures were grown with shaking (350 rpm) in Erlen-
meyer flasks at 37 ◦C in a New Brunswick Series 25 orbital incubator (New Brunswick Scientific Co,
Inc, NJ, USA) in Luria Bertani (LB) broth (B.3.2) or on LB agar (LA) plates supplemented with 200
µg/mL ampicillin antibiotic (Sigma-Aldrich, MO , USA). E.coli DH5α transformants were stored in 33
% glycerol (Merck, Darmstadt, Germany) at −80 ◦C.
B.1.2 Preparation of chemically competent E.coli
E. coli cells were grown overnight in 2 mL of LB, and diluted 1:100 in 100 mL of LB (see B.3.2)
until log phase was reached, as measured by an OD600 of 0.4. Cells were chilled for 20 minutes
on ice, and were pelleted by centrifugation for ten minutes at 4 ◦C and 59.5 x g in a refrigerated
centrifuge (Eppendorf 5415D/R, Eppendorf, Hamburg, Germany). The pellet was resuspended in
10 mL of ice cold, sterile transformation buffer (60 mM CaCl2, 15 % glycerol, 10 mM PIPES pH 7.0
at temperature; Merck, Darmstadt, Germany) and incubated for 20 minutes on ice. The suspension
was then pelleted by centrifugation for 10 minutes at 4 ◦C and 59.5 x g. The pellets was resuspended
in 2 mL of ice cold transformation buffer and 200 µL aliquots were stored at −80 ◦C.
B.1.3 Bacterial transformations
Plasmid DNA (0.5 µg/µL) was added to a 100 µL aliquot of transformation competent cells (thawed
on ice for 5 minutes). This was incubated on ice for 30 minutes before being heat shocked for 90
seconds at 42 ◦C. Following the addition of 1 mL of LB, cells were incubated for 60 minutes at 37 ◦C
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with shaking. This allowed time for the phenotypic expression of antibiotic resistance genes, prior to
plating onto ampicillin LA plates.
B.1.4 Transformation and growth of S. cerevisiae
Transformation of plasmids into S. cerevisiae was done using an adaptation of the method described
in Chen et al (270). Briefly, 800 µL of stationary phase yeast was centrifuged at 16 000 x g, after which
the supernatant was removed. The pellet was resuspended in a mixture that had been preheated to
45 ◦C, comprising 50 ng - 1 µg of plasmid DNA, 5 µL of 10 µg/mL salmon sperm ssDNA that had
been pre-sheared, boiled and chilled. To this, 100 µL of one step buffer [200 mM lithium acetate, 40
% PEG 4000 and 100 mM dithiothreitol (DTT)] was added, and the pellet was vortexed to resuspend
the cells. The transformation mixture was incubated at 45 ◦C for 30 minutes. Cells were pelleted by
centrifugation at 3 500 x g for 3 minutes at room temperature and resuspended in 200 µL of YPD,
and plated on appropriate SC agar plates.
B.2 Plasmid DNA preparation, electrophoresis and extraction
B.2.1 Plasmid DNA preparation
Plasmid DNA was prepared using three commercially available kits (Qiagen, Hilden, Germany) that
differed according to the concentration of DNA required mini-preps (150 ng/µL plasmid DNA), midi-
preps (800 ng/µL of plasmid DNA) and maxi-preps (5 µ/gµL of plasmid DNA). Transformed E.coli
DH5α or BLR-DE3 cultures (two mL for mini-preps, 100 mL for midi-preps and 250 mL for maxi-
preps) were grown in LB overnight. Cells were pelleted by centrifugation for 5 minutes at 4000 x g
(midi and maxi preps) or 16 000 x g for one minute (mini preps). Pellets were resuspended in 300
µL (mini prep), 10 mL (midi prep) or 15 mL (maxi prep) of Buffer P1 (50 mM Tris-HCl pH 8.0, 10
mM EDTA and 100 µg/ml RNAse A). An equal volume of Buffer P2 [200 mM NaOH, 1 % SDS (w/v)]
was added and mixed by inversion for one minute. An equal volume of pre-chilled Buffer P3 (3.0 M
potassium acetate pH 5.5) was added (for midi and maxi preps; 300 µL for mini preps) and mixed
by inversion for one minute prior to centrifugation for 20 minutes at 4000 x g for midi and maxi preps
or 16 000 x g for mini preps.
For mini preps, the supernatant was pipetted into a new 2 mL tube, and an equal volume (900
µL) of isopropanol was added. The samples were vortexed for 5 seconds, and chilled for 20 minutes
at−20 ◦C, after which they were centrifuged for 10 minutes. The supernatant was discarded, and the
pellet was washed in 250 µL of 70 % ethanol, and centrifuged again for 5 minutes. The supernatant
was discarded, and the pellets left to air dry for 10 minutes.
For midi and maxi preps, the supernatant was poured into a QIAtip binding column that had
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been equilibrated with 4 mL (midi prep) or 10 mL (maxi prep) of Buffer QBT [750 mM NaCl, 50 mM
MOPS pH 7.0, 15 % isopropanol (v/v), 0.15 % Triton R© X-100 (v/v)] using gravity flow. The column
was washed with 10 mL (midi prep) or 30 mL (maxi prep) of Buffer QC [1.0 M NaCl, 50 mM MOPS
pH 7.0, 15 % isopropanol (v/v)]. Plasmid DNA was eluted into a new 50 mL tube using 9 mL (midi
prep) or 15 mL (maxi prep) of Buffer QF [1.25 M NaCl, 50 mM Tris-HCl pH 8.5, 15 % isopropanol
(v/v)] followed by the addition of 6.3 mL (midi prep) or 10.5 mL (maxi prep) of isopropanol (Merck,
Darmstadt, Germany). Samples were chilled for 2 hours at -20 ◦C and centrifuged for 30 minutes
at 4 ◦C and 8000 x g. Pellets were air-dried and resuspended in 250 µL or 500 µL of Buffer TE
(10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0). Plasmid DNA was subjected to spectrophotometry
using a NanoDrop Spectrophotometer (Thermo Fisher Scientific, Inc, MA, USA) to determine the
concentration (at a wavelength of 260 nm, 1 absorbance unit at A260 = 50 µg/mL dsDNA and purity
ratio A260/A280 >1.8).
B.2.2 Phenol/chloroform extraction of DNA
The phenol:chloroform:isoamyl alcohol method of nucleic extraction was used to recover DNA for lig-
ation or sequencing analysis following enzymatic digestion or PCR. The recipe for SS-phenol used in
this method was taken from (271). DNA solutions were brought to a volume of 100 µL with nuclease-
free TE buffer (Qiagen, Hilden, Germany). A 100 µL volume of 25:24:1 phenol:chloroform:isoamyl
alcohol mixture added to the samples which were briefly mixed to form an emulsion. The emulsion
was centrifuged for 2 minutes at 12 000 x g. Approximately 100 µL of the aqueous phase was trans-
ferred to a new microfuge tube followed by the addition of one volume of chloroform. The samples
were briefly mixed and centrifuged for 2 minutes at 12000 x g. The aqueous phase was removed and
0.1 volumes of 3 M sodium acetate pH 5.2 and 2.5 volumes of 100 % ethanol were added. Samples
were chilled at −70 ◦C for 15 minutes followed by centrifugation for 15 minutes at 13 000 x g and
4 ◦C. The pellet was washed with 70 % ethanol, re-centrifuged for 10 minutes, after which samples
were air-dried for 10 minutes at 37 ◦C to remove residual ethanol. Pellets were resuspended in an
appropriate volume of nuclease-free water. All DNA extracted from PCRs or agarose gels was quan-
tified using comparative densitometry with 0.5 µg of DNA ladder (O‘GeneRuler TM Mix, Fermentas,
WI, USA).
B.2.3 Agarose gel electrophoresis
To make a 0.8 % agarose gel, 0.8 g of agarose powder (Sigma-Aldrich, MO, USA) was dissolved
in 100 mL of 1 x TAE buffer (Tris base 40 mM, 20 mM Na-acetate, 1 mM EDTA) and heated until
the agarose had dissolved. Prior to pouring, one µL per 50 mL gel of ethidium bromide (10mg/mL
- Sigma, Germany) was added. DNA samples were mixed with 0.2 volume of loading dye (1.67
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mM Tris-HCl pH 7.6, 0.005 % bromophenol blue, 0.005 % xylene cyanol FF, 10 % glycerol, 10 mM
EDTA, Fermentas, WI, USA) and electrophoresed parallel to 5 µL of a DNA molecular weight marker
(O‘GeneRuler TM Mix, Fermentas, WI, USA) that had been loaded into the wells of a set agarose
gel. Gels were subjected to electrophoresis at 100 volts.
B.2.4 DNA purification from agarose gels
DNA fragments were purified from agarose gels by placing the excised gel fragment inside a 0.5 mL
PCR tube that had been punctured at the bottom using a hot 22G needle. Nylon fishtank wool was
placed inside the 0.5 mL PCR tube to act as a sieve. The gel fragment was placed inside the 0.5
mL PCR tube, which was placed inside a 2.0 mL microfuge tube and centrifuged at 12 000 x g for 2
minutes. DNA purification proceeded as described under phenol/chloroform extraction.
B.2.5 RNA extraction from adherent mammalian cells seeded in 10 cm dishes
Forty eight hours post-transfection mammalian HEK293 or Huh7 cells that had been cultured in 10
cm dishes (NuncTM, AEC-Amersham (Pty) Ltd, South Africa) were washed in PBS (Gibco, UK),
resuspended in one mL of TriReagent R© (Sigma, Germany) and transferred to a microfuge tube
with 300 µL of chloroform (Merck, Germany) followed by ten seconds of vortexing. Samples were
centrifuged for 30 minutes at 16 000 x g and 4 ◦C in a refrigerated centrifuge (Eppendorf 5415D/R;
Eppendorf, Germany). The upper aqueous phase was carefully transferred to a new microfuge
tube, an equal volume (∼ 300 µL) of isopropanol (Merck, Germany) was added and samples were
centrifuged for 30 minutes at 16 000 x g and 4 ◦C. The supernatant was discarded and the pellets air
dried before being resuspended in 50 µL formamide (Sigma-Aldrich, MO , USA). RNA was subjected
to spectrophotometry using a NanoDrop Spectrophotometer to determine the concentration (at a
wavelength of 260 nm, 1 absorbance unit (A260) = 40 µg/mL RNA) and purity (A260/A280 >2).
B.2.6 S. cerevisiae RNA extraction
RNA was extracted from yeast cultures by resuspending centrifuged pellets in 400 µL of 1x TES
buffer (10 mM, Tris-HCI pH 7.5 10 mM EDTA, 0.5% SDS) and adding an equal volume of acid
phenol. The cells were vortexed for 10 seconds, and incubated for 1 hour at 65 ◦C, with occasional
vortexing. The samples were centrifuged at maximum speed in a 4 ◦C microfuge for 5 minutes. The
upper phase was transferred into a new tube, and the sample re-extracted with an equal volume
of acid phenol. The sample was treated in the same way as mentioned in B.2.2. Samples were
resuspended in formamide (Sigma-Aldrich, MO , USA) and stored at −20 ◦C.
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B.2.7 DNA Sequencing
Plasmids or PCR products were sequenced using the BigDye R© Terminator Kit 3.1 (Applied Biosys-
tems, CA, USA). The protocol of the manufacturer was followed, except that a half volume reaction
was used. The cleaning reaction was performed as per manufacturers instructions, except that the
volume of the sequencing reaction was made up to 100 µL with dH2O before cleaning.
B.3 Cloning Protocols
Cloning conditions for the myriad of constructs made were standardised, as they were found to
work in almost every case. Backbone DNA was prepared from bulk preparations (B.2) and 20 µg of
backbone plasmid DNA was used in each digestion. 2 units of appropriate restriction enzyme per
reaction were used as restriction digests were done overnight at 37 ◦C.
If restriction digests used 2 different enzymes and the cleavage sites showed ligation compati-
bility or the restriction digest used only 1 restriction enzyme, the DNA backbone would be dephos-
phorylated using 1 unit FastAP (Fermentas, WI, USA) per µg of DNA for 10 minutes at 37 ◦C. If the
cleavage sites showed no ligation potential, or blunt end cloning was involved, the backbone DNA
was not dephosphorylated to increase the likelihood of cloning of desired fragments. All DNA was
cleaned using the phenol:chloroform method (B.2.2) after the correct DNA bands had been excised
from an agarose gel (B.2.4. Following comparative densitometry to determine the concentration of
purified DNA, a ligation reaction would bet set up as described in the main body of text.
B.3.1 pTZ57R/T TA Cloning Protocol
PCR products for cloning into a TA vector, were inserted into pTZ57R/T of the InsTAclone
TM
kit
(Fermentas, WI, USA). Briefly, a 20 µL ligation reaction comprised the following - 1 µL pTZ57R/T
(55ng), 1 µL T4 DNA Ligase (5 units), 2 µL 10X Ligation Buffer, 1 µL PCR product, and 15 µL
nuclease free water. The ligation mixture was incubated at 6 ◦C overnight, after which 10 µL was
transformed into competent E. coli as described B.1.3.
B.3.2 Preparations for Bacterial Cultures
B.3.2.1 ZYM-5052 Media
1 % g Tryptone (Oxoid, U.K.), 0.5 % Yeast Extract (Oxoid), 25 mM Na2HPO4, 25 mM KH2PO4, 50
mM NH4Cl, 5mM Na2SO4, 2 mM MgSO4, 1mM FeCl3, 0.5 % glycerol and 0.05 % glucose. For
bacterial protein induction, 0.5 % Lactose was added, this media is ZYM-505. Media was made up
to a total volume of 1 litre with pure H2O. Medium was sterilized by autoclaving for 20 minutes on a
liquid cycle and stored at room temperature.
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B.3.2.2 Luria-Bertani Broth (LB)
B.3.2.3 Agar Media
Bacterial plates contained 1.5 % (w/v) Agar (Oxoid) in LB medium, whereas yeast plates contained
2.0 % (w/v) agar.
B.3.2.4 Antibiotic Stock Solutions
100 mg/ml of ampicillin (Roche, Germany) in 50 % ethanol; 35 mg/ml of chloramphenicol in iso-
propanol. Both antibiotic solutions were stored at −20 ◦C.
B.3.2.5 IPTG and X-galactosidase
For induction of T7 protein expression and blue-white colony screening, IPTG (Roche, Germany) so-
lutions were stored at −20 ◦C. 200 mg of X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside)
was dissolved in 10 mL of N,N-dimethylformamide and stored at −20 ◦C in foil. 40 µL of X-gal and
4 µL of IPTG (200 mg/ml aqueous solution, Roche, Basel, Switzerland) were spread on Ampicillin
positive LB agar plates and left to air dry for 15 minutes at 37 ◦C prior to plating.
B.4 Preparations for Eukaryotic Cell Cultures
B.4.1 Maintenance and Transfection of plasmid DNA into mammalian cells
The human embryonic kidney (HEK293) cell line was maintained using Dulbecco’s Modified Eagle’s
Medium (DMEM, Lorenza Biosciences, Basel, Switzerland) supplemented with heat-inactivated 10%
fetal calf serum (FCS, Invitrogen, CA, USA) at 37 ◦C and 5% CO2 in a Forma Series II 3110 Water
Jacketed CO2 incubator (Thermo Fisher Scientific, Inc, MA, USA).
Transfection of plasmid DNA into HEK293 cells was performed by either the Calcium-Phosphate
method for 10cm tissue culture dishes, or Lipofectamine2000 (Invitrogen, CA, USA), if 12-48 well
tissue culture plates were used. The Lipofectamine2000 to plasmid DNA ratio was maintained at
1:1, and the maximum quantity of DNA recommended was used for each transfection. There were
no other modifications to this protocol.
B.4.1.1 Antibiotic Solutions for tissue culture
Penicillin in pure H2O (100 000 U/ml, Invitrogen-Gibco-BRL, CA USA) Streptomycin in pure H2O
(100 mg/ml, Invitrogen-Gibco-BRL, CA USA) The antibiotic solutions were filter-sterilized using 0.2
µm filters and stored in 500µL aliquots at −20 ◦C.
121
B.5 General Solutions
B.5.1 DNA/RNA Electrophoresis Buffers
B.5.1.1 (50x) Tris-acetate- EDTA (TAE):
2 M Tris-acetate (pH 8.0), 50 mM EDTA. To prepare 500 ml of a 50 x stock, 121g Tris base, 28.5 ml
glacial acetic acid and 50 ml 0.5 M EDTA (pH 8.0) were mixed in 400 ml of pure H2O. The solution
was made up to 500 ml with pure H20 and stored at room temperature.
B.5.1.2 (10x) Tris-borate-EDTA (TBE):
0.9 M Tris-borate (pH 8.0), 200 mM EDTA A 10 x stock of TBE (1 litre) was prepared by mixing 54
g, 27.5 g Boric acid and 20 ml 0.5 M EDTA (pH 8.0) in 900 ml of pure H2O. The solution was made
up to 1 litre with pure H2O and stored at room temperature.
B.5.1.3 DNA loading Buffer
6 x DNA loading buffer contained 3 ml of glycerol and 25 mg of bromophenol blue (Merck, Germany)
made up to 10 ml with pure H2O. DNA loading buffer was stored at room temperature.
B.5.1.4 RNA Loading Buffer
A 2 x RNA loading buffer was made up by mixing 990 µL of deionized formamide (Saarchem, South
Africa), 2 µL of 500 mM EDTA (pH 8.0), 2.5 mg of bromophenol blue and 2.5 mg of Xylene Cyanol
FF (Merck, Germany). RNA loading buffer was stored at −20 ◦C in 100 µL aliquots.
B.5.2 SDS-PAGE and Western blotting
SDS-PAGE and Western blotting protocols were performed as described in Unit 10.8.1 in Current
Protocols in Molecular Biology (272).
Immunoblot Buffers
1. (5x) SDS-PAGE Tank Buffer: (125 mM Tris (pH 8.3), 0.958 M Glycine, 0.5 % SDS).
2. A 10 x stock of tank buffer was prepared by dissolving 30 g Tris base, 144 g Glycine (BDH,
Germany) and 10 g SDS in 1.5 litres of pure H2O. The solution was made up to 2 litres with
pure H2O and stored at room temperature.
3. A-3.5 SDS-PAGE Loading Buffer: 125 mM Tris (pH 6.8), 4 % SDS, 20 % glycerol, 200 mM
DTT, 0.02 % Bromophenol Blue).
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4. A 2 x Loading buffer was prepared by mixing the following components in a total volume of 10
ml of pure H2O: 0.15 g Tris base, 4.0 ml of 10 % SDS, 2.0 ml Glycerol, 2.0 mg Bromophenol
Blue (Merck, Germany) and 0.31 g Dithiothreitol (DTT, Roche, Germany). 500 µL aliquots
were stored at −20 ◦C.
5. Transfer Buffer: 125 mM Tris (pH 8.3), 0.958 M glycine, 0.5 % SDS, 20 % methanol.
6. Tris-Buffered Saline (TBS): 25 mM Tris (pH 7.4), 150 mM NaCl, TBS (1 litre) was prepared
by dissolving 3.0 g Tris base, 0.2 g KCl and 9.0 g NaCl in 900 ml of pure H2O. The pH of the
solution was adjusted to 7.4 with HCl and made up to 1 liter with pure H2O. TBS-T consisted
of TBS with 0.1 % Tween-20 (Saarchem, South Africa).
7. Blocking buffer consisted of T-TBS with 5 % fat-free milk powder.
B.5.2.1 Staining solution
1. Coomassie Brilliant Blue: 0.025% Coomassie Blue, 40 % methanol, 7 % acetic acid.
2. Staining solution contained 0.5 g Coomassie Brilliant Blue R250 (Merck, Germany), 800 ml
methanol and 140 ml glacial acetic acid made up to a total volume of 2 litres with pure H2O,
and was stored at room temperature.
3. Destaining Solution contained 10 % methanol and 10 % acetic acid.
B.6 General ELISA Protocol
1. The antigen is diluted to a final concentration between 5 and 10 µg/ml in Coating Buffer (alt.
PBS). Coating buffer comprises (50 m M carbonate/bicarbonate buffer, pH 9.6) made up as
follows: 15 mM Na2CO3, 35 mM NaHCO3, 0.05 % azide, 0.05 % Tween 20.
2. Dispense 100 µl into each Elisa plate well. Incubate at 37 ◦C for 2 hrs or in the fridge overnight.
3. Discard coating solution. Wash 3x with washing solution (0.9% NaCl + 0.05% Tween 20;
alternate. PBS). Dry plate by inversion and tapping onto towel paper.
4. Block possible remaining binding sites in wells with 150µl per well of Dilution Buffer : 50mM
Tris, pH 7.4 (alternate PBS) 2% BSA or non-fat milk powder, 0.05% Tween 20, 0.02% Na-
azide. Incubate at room temperature 30 – 40 minutes.
5. Discard solution and dry as before. Add 100µl clonal supernatant and 50µl Dilution Buffer to
each corresponding well. Incubate for 30 minutes at room temperature.
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6. Discard solution; wash 3x with Washing Solution; dry as before. Add 100µl peroxidase con-
jugated anti-mouse Ig at the appropriate dilution in PBS. Incubate at room temperature for 30
minutes.
7. Discard solution; wash 3x with Washing Solution and 1X with 100mM Citrate Buffer, pH 5.0
made up as follows: citric acid.H2O 46mM, Na2HPO4 67mM. Discard and dry as before.
8. Add 10µl freshly prepared Substrate Solution : 20mg OPD.2HCl in 30ml 100mM citrate buffer
+ 20µl 30% H2O2. Check for colour development. The reaction may be stopped by the addition
of 150µl 1M H2SO4. Colour intensity was read at 496nm.
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Appendix C
Python Computer Code
An example of the Python code used to extract genotype specific gene sequences from a database
of re-genotyped and re-annotated HBV sequences. Additional scripts were written for a variety of
purposes but have not been shown for the sake of brevity.
## Impor t the Sequence f u n c t i o n o f BioPython
from Bio impor t SeqIO
s u b t y p e l i s t = ( ( [ ] , [ ] , [ ] , [ ] ) , ( [ ] , [ ] , [ ] , [ ] ) ,
( [ ] , [ ] , [ ] , [ ] ) , ( [ ] , [ ] , [ ] , [ ] ) ,
( [ ] , [ ] , [ ] , [ ] ) , ( [ ] , [ ] , [ ] , [ ] ) ,
( [ ] , [ ] , [ ] , [ ] ) , ( [ ] , [ ] , [ ] , [ ] ) )
## s u b t y p e l i s t i s a l i s t w i t h i n a l i s t and i s meant to hold the var ious records
## from the the inpu t f i l e below which conta ins a mix ture o f genes and genotypes .
## The order o f the l i s t i s based on the o r f d i c and subtype d ic d i r e c t l y below .
## i . e . The f i r s t p o s i t i o n w i l l be subtype A records , and the f i r s t en t r y i s the
## polymerase , fo l l owed by X, sur face and precore−core etc .
o r f d i c = ( [ ’ polymerase ’ ] , [ ’ x ’ ] , [ ’ sur face ’ ] , [ ’ precore−core ’ ] )
sub type d ic = ( [ ’A ’ ] , [ ’B ’ ] , [ ’C ’ ] , [ ’D ’ ] , [ ’E ’ ] , [ ’F ’ ] , [ ’G ’ ] , [ ’H ’ ] )
sequence = ” ”
from Bio . SeqRecord impor t SeqRecord
## o p t i o n a l f u n c t i o n to t r a n s l a t e the DNA sequence i n t o p r o t e i n
def make pro te in record ( nuc record ) :
” ” ” Returns a new SeqRecord w i th the t r a n s l a t e d sequence ( d e f a u l t t ab l e ) . ” ” ”
r e t u r n SeqRecord ( seq = nuc record . seq . t r a n s l a t e ( t o s t op =False , stop symbol= ”∗ ” ) , \
i d = ” t r a n s ” + nuc record . id , \
d e s c r i p t i o n = ” t r a n s l a t i o n o f CDS, using d e f a u l t t ab l e ” )
## f u n c t i o n to w r i t e records to f i l e − using genotype and gene as a f i lename
def w r i t e r e c o r d s ( rece ive ) :
f o r i , v i n enumerate ( subtype d ic ) :
f o r x , y i n enumerate ( o r f d i c ) :
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f i lename = ” genotye ” + s t r ( v [ 0 ] ) + ” ” + s t r ( y [ 0 ] ) + ” . f as ta ”
handle = open ( f i lename , ’w ’ )
f o r e n t r i e s i n rece ive [ i ] [ x ] :
ou tput = s t r ( e n t r i e s )
handle . w r i t e ( output )
handle . c lose ( )
p ro te i ns = ( make pro te in record ( nuc rec ) f o r nuc rec i n \
SeqIO . parse ( f i lename , ” f as ta ” ) )
f i lename = ” genotye ” + s t r ( v [ 0 ] ) + ” ” + s t r ( y [ 0 ] ) + ” t r a n s l a t i o n s . f as ta ”
SeqIO . w r i t e ( p ro te ins , f i lename , ” f as ta ” )
f o r records i n SeqIO . parse ( ” c t s . gb ” , ” gb ” ) :
p r i n t records . name
#gives p o s i t i o n ( i ) and value ( v ) o f each en t ry i n sub type d ic
f o r i , v i n enumerate ( subtype d ic ) :
i f records . fea tu res [ 0 ] . q u a l i f i e r s [ ’ genotype ’ ] == v :
f o r o r f s i n records . fea tu res :
i f o r f s . type == ”CDS” :
f o r x , y i n enumerate ( o r f d i c ) :
#g ives p o s i t i o n ( x ) and value ( y ) o f each en t ry i n o r f d i c
i f o r f s . q u a l i f i e r s [ ’ product ’ ] == y :
i f len ( o r f s . sub fea tu res ) == 2:
f o r sub f i n o r f s . sub fea tu res :
sequence = sequence + \
records . seq [ sub f . l o c a t i o n . n o f u z z y s t a r t : sub f . l o c a t i o n . nofuzzy end ]
i f len ( o r f s . sub fea tu res ) == 0:
sequence = records . seq [ o r f s . l o c a t i o n . n o f u z z y s t a r t : o r f s . l o c a t i o n .←↩
nofuzzy end ]
sequence = ”>” + s t r ( records . annota t ions [ ’ accessions ’ ] [ 0 ] ) + ”\n ” + ←↩
sequence + ”\n ”
s u b t y p e l i s t [ i ] [ x ] . append ( sequence )
sequence = ” ”
w r i t e r e c o r d s ( s u b t y p e l i s t )
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